[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 744
1. Sales KJ, Grant V, Jabbour HN: Prostaglandin E2 and F2alpha activate the FP receptor and up-regulate cyclooxygenase-2 expression via the cyclic AMP response element. Mol Cell Endocrinol; 2008 Mar 26;285(1-2):51-61
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In endometrial adenocarcinomas COX-2 and F-series prostanoid (FP) receptor expression and prostanoid biosynthesis (PGE(2) and PGF(2alpha)) are elevated.
  • In the present study, we investigated the effect of PGE(2) and PGF(2alpha) on the expression of COX-2 via the FP receptor in endometrial adenocarcinoma cells stably expressing the FP receptor (FPS cells).
  • These data indicate that PGE(2) and PGF(2alpha) biosynthesized locally within endometrial adenocarcinomas can regulate tumor cell function in an autocrine/paracrine manner via the FP receptor.
  • [MeSH-minor] Adenocarcinoma / metabolism. Cell Line, Tumor. Endometrial Neoplasms / metabolism. Enzyme Activation. Enzyme Inhibitors / metabolism. Extracellular Signal-Regulated MAP Kinases / metabolism. Female. Genes, Reporter. Humans. Inositol 1,4,5-Trisphosphate / metabolism. Promoter Regions, Genetic. Prostaglandin Antagonists / metabolism. Receptors, Prostaglandin / antagonists & inhibitors. Receptors, Prostaglandin / genetics. Receptors, Prostaglandin / metabolism. Receptors, Prostaglandin E / metabolism. Xanthones / metabolism

  • Hazardous Substances Data Bank. PROSTAGLANDIN F2ALPHA .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 2003 Dec 12;278(50):49954-64 [14517215.001]
  • [Cites] Cancer Res. 2002 Jan 15;62(2):506-11 [11809702.001]
  • [Cites] Mol Endocrinol. 2004 Jun;18(6):1533-45 [15044590.001]
  • [Cites] Trends Endocrinol Metab. 2004 Oct;15(8):398-404 [15380812.001]
  • [Cites] Am J Obstet Gynecol. 1978 Mar 15;130(6):640-6 [637076.001]
  • [Cites] Br J Obstet Gynaecol. 1981 Apr;88(4):434-42 [7225303.001]
  • [Cites] Br J Obstet Gynaecol. 1983 Dec;90(12):1135-40 [6580910.001]
  • [Cites] Br J Obstet Gynaecol. 1984 Jul;91(7):673-80 [6589016.001]
  • [Cites] Br J Obstet Gynaecol. 1988 Feb;95(2):162-5 [2894838.001]
  • [Cites] J Pharmacol Exp Ther. 1990 Nov;255(2):756-68 [2147038.001]
  • [Cites] Cancer Res. 2002 May 1;62(9):2522-30 [11980644.001]
  • [Cites] J Biol Chem. 2002 May 24;277(21):18649-57 [11901151.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Oct 15;99(21):13926-31 [12242329.001]
  • [Cites] J Biol Chem. 2003 Apr 4;278(14):12151-6 [12566441.001]
  • [Cites] J Biol Chem. 2003 Sep 12;278(37):35451-7 [12824187.001]
  • [Cites] Life Sci. 2003 Dec 5;74(2-3):143-53 [14607241.001]
  • [Cites] Reproduction. 2003 Nov;126(5):559-67 [14611628.001]
  • [Cites] J Biol Chem. 1991 Aug 25;266(24):15771-81 [1874734.001]
  • [Cites] J Biol Chem. 1993 Feb 5;268(4):2712-8 [8381413.001]
  • [Cites] Prostaglandins. 1993 May;45(5):413-26 [8321911.001]
  • [Cites] J Biol Chem. 1994 Jul 1;269(26):17619-25 [8021271.001]
  • [Cites] Mol Pharmacol. 1994 Sep;46(3):477-84 [7935328.001]
  • [Cites] J Biol Chem. 1995 Nov 17;270(46):27489-94 [7499206.001]
  • [Cites] Biochem Pharmacol. 1995 Nov 9;50(10):1731-3 [7503778.001]
  • [Cites] Biol Chem Hoppe Seyler. 1996 Jun;377(6):373-84 [8839983.001]
  • [Cites] Gastroenterol Clin North Am. 1996 Dec;25(4):773-91 [8960892.001]
  • [Cites] J Histochem Cytochem. 1998 Jan;46(1):77-84 [9405496.001]
  • [Cites] J Natl Cancer Inst. 1998 Mar 18;90(6):455-60 [9521170.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Mar 31;95(7):3914-9 [9520467.001]
  • [Cites] J Biol Chem. 1998 Apr 10;273(15):8890-6 [9535870.001]
  • [Cites] Adv Cancer Res. 1998;74:49-139 [9561267.001]
  • [Cites] Int J Tissue React. 1998;20(1):3-15 [9561441.001]
  • [Cites] Annu Rev Pharmacol Toxicol. 1998;38:97-120 [9597150.001]
  • [Cites] J Biol Chem. 1999 Aug 13;274(33):22903-6 [10438452.001]
  • [Cites] J Pharmacol Exp Ther. 1999 Sep;290(3):1278-84 [10454504.001]
  • [Cites] Physiol Rev. 1999 Oct;79(4):1193-226 [10508233.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Dec;89(12):6112-8 [15579767.001]
  • [Cites] Cancer Res. 2005 Sep 1;65(17):7707-16 [16140938.001]
  • [Cites] Endocrinology. 2005 Nov;146(11):4657-64 [16081631.001]
  • [Cites] Curr Pharm Des. 2006;12(8):943-54 [16533161.001]
  • [Cites] Endocrinology. 2006 Apr;147(4):1697-705 [16373414.001]
  • [Cites] J Clin Invest. 2006 May;116(5):1391-9 [16614756.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Sep 26;103(39):14507-12 [16973753.001]
  • [Cites] Curr Opin Investig Drugs. 2007 May;8(5):411-5 [17520870.001]
  • [Cites] Endocrinology. 2007 Aug;148(8):3635-44 [17478553.001]
  • [Cites] Biochim Biophys Acta. 2000 Jan 17;1483(2):285-93 [10634944.001]
  • [Cites] Carcinogenesis. 2000 Apr;21(4):543-50 [10753183.001]
  • [Cites] Cancer Lett. 2000 Aug 1;156(1):57-61 [10840160.001]
  • [Cites] Annu Rev Biochem. 2000;69:145-82 [10966456.001]
  • [Cites] Urology. 2000 Oct 1;56(4):671-6 [11018637.001]
  • [Cites] Trends Endocrinol Metab. 2000 Apr;11(3):91-9 [10707049.001]
  • [Cites] Neoplasia. 2000 Nov-Dec;2(6):483-90 [11228540.001]
  • [Cites] J Clin Endocrinol Metab. 2001 May;86(5):2243-9 [11344234.001]
  • [Cites] J Biol Chem. 2001 May 25;276(21):18075-81 [11278548.001]
  • [Cites] Nat Med. 2001 Sep;7(9):1048-51 [11533709.001]
  • [Cites] Br J Cancer. 2001 Sep 28;85(7):1023-31 [11592775.001]
  • [Cites] Cancer Res. 2002 Jan 1;62(1):28-32 [11782353.001]
  • [Cites] Cancer Res. 2002 Jan 15;62(2):424-32 [11809691.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Feb;89(2):986-93 [14764825.001]
  • (PMID = 18316157.001).
  • [ISSN] 0303-7207
  • [Journal-full-title] Molecular and cellular endocrinology
  • [ISO-abbreviation] Mol. Cell. Endocrinol.
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / MC/ U127684438; United Kingdom / Medical Research Council / / U.1276.00.004.00002.01/2(61014)
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / AL 8810; 0 / Enzyme Inhibitors; 0 / Prostaglandin Antagonists; 0 / Receptors, Prostaglandin; 0 / Receptors, Prostaglandin E; 0 / Xanthones; 0 / prostaglandin F2alpha receptor; 33458-93-4 / 6-isopropoxy-9-oxoxanthene-2-carboxylic acid; 85166-31-0 / Inositol 1,4,5-Trisphosphate; B7IN85G1HY / Dinoprost; EC 1.14.99.1 / Cyclooxygenase 2; EC 1.14.99.1 / PTGS2 protein, human; EC 2.7.11.24 / Extracellular Signal-Regulated MAP Kinases; K7Q1JQR04M / Dinoprostone
  • [Other-IDs] NLM/ PMC2694994; NLM/ UKMS2447
  •  go-up   go-down


2. van der Horst C, Evans AJ: Peritoneal keratin granulomas complicating endometrial carcinoma: a report of two cases and review of the literature. Int J Gynecol Cancer; 2008 May-Jun;18(3):549-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Peritoneal keratin granulomas complicating endometrial carcinoma: a report of two cases and review of the literature.
  • Squamous differentiation in endometrial adenocarcinoma is common.
  • Keratin granulomas accompanied by viable adenocarcinoma cells are regarded as conventional metastatic foci.
  • However, the significance of keratin granulomas without accompanying viable adenocarcinoma cells is difficult to ascertain.
  • [MeSH-major] Adenocarcinoma / pathology. Endometrial Neoplasms / pathology. Granuloma / pathology. Keratins / metabolism. Peritoneal Diseases / pathology

  • MedlinePlus Health Information. consumer health - Peritoneal Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17645505.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 68238-35-7 / Keratins
  • [Number-of-references] 8
  •  go-up   go-down


3. Carlsson J, Helenius G, Karlsson M, Klinga-Levan K: Loss of glutathione peroxidase 3 expression is correlated with epigenetic mechanisms in endometrial adenocarcinoma. Cancer Cell Int; 2010 Nov 24;10:46
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Loss of glutathione peroxidase 3 expression is correlated with epigenetic mechanisms in endometrial adenocarcinoma.
  • In a previous microarray study performed by our group, Gpx3 was identified as a potential biomarker for rat endometrial adenocarcinoma (EAC), since the expression was highly downregulated in rat EAC tumors.
  • In addition we have examined the expression of GPX3 and MET in 30 human EACs of different FIGO grades and 20 benign endometrial tissues.
  • Preliminary results also suggest that the production of H2O2 is higher in rat endometrial tumors with down-regulated Gpx3 expression.
  • A likely consequence of loss of GPX3 protein function would be a higher amount of ROS in the cancer cell environment.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biol Neonate. 1990;57(6):343-8 [2164849.001]
  • [Cites] Cancer Metastasis Rev. 2008 Mar;27(1):85-94 [18175071.001]
  • [Cites] Bioinformatics. 2002 Nov;18(11):1427-31 [12424112.001]
  • [Cites] Hum Pathol. 2004 Jun;35(6):649-62 [15188130.001]
  • [Cites] Cancer Res. 2005 May 15;65(10):4218-27 [15899813.001]
  • [Cites] Cancer Res. 1991 Feb 1;51(3):794-8 [1846317.001]
  • [Cites] Z Versuchstierkd. 1987;30(5-6):209-16 [3445711.001]
  • [Cites] Cancer Cell Int. 2009;9:12 [19426485.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Sep 29;95(20):11715-20 [9751731.001]
  • [Cites] Int J Cancer. 2007 Apr 1;120(7):1472-81 [17245700.001]
  • [Cites] Nat Rev Mol Cell Biol. 2003 Dec;4(12):915-25 [14685170.001]
  • [Cites] Oncogene. 1999 Apr 8;18(14):2343-50 [10327054.001]
  • [Cites] Cancer Res. 2007 Mar 1;67(5):2081-8 [17332337.001]
  • [Cites] Cancer Genet Cytogenet. 2001 Jun;127(2):118-27 [11425450.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 May 24;91(11):4731-5 [8197126.001]
  • [Cites] J Natl Cancer Inst. 1987 Jun;78(6):1245-51 [3473261.001]
  • [Cites] Curr Probl Cancer. 1997 Mar-Apr;21(2):65-127 [9128804.001]
  • [Cites] Science. 1991 Feb 15;251(4995):802-4 [1846706.001]
  • [Cites] Gynecol Oncol. 1983 Feb;15(1):10-7 [6822361.001]
  • [Cites] Cancer Res. 2007 Sep 1;67(17):8043-50 [17804715.001]
  • [Cites] J Cell Biol. 2001 May 28;153(5):1023-34 [11381087.001]
  • [Cites] Oncol Rep. 2008 Dec;20(6):1299-303 [19020706.001]
  • [Cites] Eur J Cancer. 2009 May;45(7):1282-93 [19195878.001]
  • [Cites] Cancer Detect Prev. 1987;10(3-4):237-46 [3568022.001]
  • [Cites] Int J Oncol. 2010 Feb;36(2):405-14 [20043075.001]
  • [Cites] Verh Dtsch Ges Pathol. 1997;81:228-32 [9474874.001]
  • [Cites] Neoplasia. 2005 Sep;7(9):854-61 [16229808.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Jan 21;94(2):701-6 [9012848.001]
  • [Cites] Endocr Relat Cancer. 2003 Mar;10(1):23-42 [12653669.001]
  • [Cites] Cancer Res. 2006 May 1;66(9):4742-9 [16651427.001]
  • (PMID = 21106063.001).
  • [ISSN] 1475-2867
  • [Journal-full-title] Cancer cell international
  • [ISO-abbreviation] Cancer Cell Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC3014921
  •  go-up   go-down


Advertisement
4. Zhu LC, Yim J, Chiriboga L, Cassai ND, Sidhu GS, Moreira AL: DC-LAMP stains pulmonary adenocarcinoma with bronchiolar Clara cell differentiation. Hum Pathol; 2007 Feb;38(2):260-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] DC-LAMP stains pulmonary adenocarcinoma with bronchiolar Clara cell differentiation.
  • DC-LAMP marks pulmonary adenocarcinomas that show Clara cell characteristics by electron microscopy.
  • DC-LAMP staining was lost in solid type adenocarcinomas but persisted in well-differentiated areas.
  • DC-LAMP and CC-10 reactivity was also observed in endometrial adenocarcinomas but not in other tumor types.
  • [MeSH-major] Adenocarcinoma / pathology. Bronchi / pathology. Lung Neoplasms / pathology. Lysosome-Associated Membrane Glycoproteins / analysis
  • [MeSH-minor] Aged. Aged, 80 and over. Antibodies, Monoclonal / immunology. Carcinoma, Small Cell / metabolism. Carcinoma, Small Cell / pathology. Carcinoma, Squamous Cell / metabolism. Carcinoma, Squamous Cell / pathology. Cell Differentiation. Endometrial Neoplasms / metabolism. Endometrial Neoplasms / pathology. Female. Humans. Immunohistochemistry. Lung / chemistry. Lung / pathology. Lung / ultrastructure. Male. Microscopy, Electron. Middle Aged. Nuclear Proteins / analysis. Prognosis. Pulmonary Surfactants / analysis. Survival Rate. Transcription Factors / analysis

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17056097.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Lysosome-Associated Membrane Glycoproteins; 0 / Nuclear Proteins; 0 / Pulmonary Surfactants; 0 / Transcription Factors; 0 / thyroid nuclear factor 1
  •  go-up   go-down


5. Hu K, Zhong G, He F: Expression of estrogen receptors ERalpha and ERbeta in endometrial hyperplasia and adenocarcinoma. Int J Gynecol Cancer; 2005 May-Jun;15(3):537-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of estrogen receptors ERalpha and ERbeta in endometrial hyperplasia and adenocarcinoma.
  • We assessed the expression of estrogen receptors (ER)alpha and ERbeta in 114 human endometrial hyperplasia and adenocarcinomas.
  • The aim of this study was to determine the expression of both ER isoforms in human endometrial tissue by immunohistochemistry.
  • In atypia hyperplasia and adenocarcinoma, both ERalpha and ERbeta were decreased significantly (P < 0.05).
  • Most endometrial adenocarcinomas expressed ERalpha, either alone or in combination with ERbeta, and the ERbeta/ERalpha ratio was decreased when compared to normal proliferation (P < 0.05).
  • Also, we found that the expression of ERalpha and ERbeta has no relationship with the status of lymph node of adenocarcinoma (P > 0.05).
  • Both ERalpha and ERbeta play an important role in endometrial hyperplasia and carcinomas, the levels of ERalpha and ERbeta appear be used as prognostic indicators.
  • [MeSH-major] Adenocarcinoma / genetics. Adenocarcinoma / pathology. Endometrial Hyperplasia / genetics. Endometrial Hyperplasia / pathology. Endometrial Neoplasms / genetics. Endometrial Neoplasms / pathology. Estrogen Receptor alpha / biosynthesis. Estrogen Receptor beta / biosynthesis. Gene Expression Profiling

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15882182.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Estrogen Receptor alpha; 0 / Estrogen Receptor beta; 0 / Protein Isoforms
  •  go-up   go-down


6. Jeong JW, Lee HS, Lee KY, White LD, Broaddus RR, Zhang YW, Vande Woude GF, Giudice LC, Young SL, Lessey BA, Tsai SY, Lydon JP, DeMayo FJ: Mig-6 modulates uterine steroid hormone responsiveness and exhibits altered expression in endometrial disease. Proc Natl Acad Sci U S A; 2009 May 26;106(21):8677-82
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mig-6 modulates uterine steroid hormone responsiveness and exhibits altered expression in endometrial disease.
  • Normal endometrial function requires a balance of progesterone (P4) and estrogen (E2) effects.
  • An imbalance caused by increased E2 action and/or decreased P4 action can result in abnormal endometrial proliferation and, ultimately, endometrial adenocarcinoma, the fourth most common cancer in women.
  • We have identified mitogen-inducible gene 6 (Mig-6) as a downstream target of progesterone receptor (PR) and steroid receptor coactivator (SRC-1) action in the uterus.
  • Here, we demonstrate that absence of Mig-6 in mice results in the inability of P4 to inhibit E2-induced uterine weight gain and E2-responsive target genes expression.
  • At 5 months of age, the absence of Mig-6 results in endometrial hyperplasia.
  • Ovariectomized Mig-6(d/d) mice treated with E2 developed invasive endometrioid-type endometrial adenocarcinoma.
  • Importantly, the observation that endometrial carcinomas from women have a significant reduction in MIG-6 expression provides compelling support for an important growth regulatory role for Mig-6 in the uterus of both humans and mice.
  • This demonstrates the Mig-6 is a critical regulator of the response of the endometrium to E2 in regulating tissue homeostasis.
  • Since Mig-6 is regulated by both PR and SRC-1, this identifies a PR, SRC-1, Mig-6 regulatory pathway that is critical in the suppression of endometrial cancer.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. PROGESTERONE .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 2000 Jun 9;275(23):17838-47 [10749885.001]
  • [Cites] Genesis. 2007 Nov;45(11):716-21 [17987665.001]
  • [Cites] Cancer Res. 2000 Sep 1;60(17):4894-906 [10987304.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Jan 2;98(1):31-6 [11134512.001]
  • [Cites] Biochemistry. 2001 Jun 12;40(23):6756-65 [11389589.001]
  • [Cites] Trends Genet. 2001 Jul;17(7):370-3 [11418196.001]
  • [Cites] Mol Cell Endocrinol. 2001 Jun 20;179(1-2):97-103 [11420134.001]
  • [Cites] Mol Carcinog. 2001 Jun;31(2):63-7 [11429782.001]
  • [Cites] Cell. 2002 Feb 22;108(4):465-74 [11909518.001]
  • [Cites] Nat Genet. 2002 May;31(1):19-20 [11984561.001]
  • [Cites] Recent Prog Horm Res. 2002;57:339-55 [12017551.001]
  • [Cites] FEBS Lett. 2002 Oct 23;530(1-3):186-90 [12387890.001]
  • [Cites] Endocrinology. 2003 Jul;144(7):2870-81 [12810542.001]
  • [Cites] Cancer Res. 2004 Feb 1;64(3):844-56 [14871811.001]
  • [Cites] Am J Obstet Gynecol. 1975 May;122(2):262-3 [1155504.001]
  • [Cites] N Engl J Med. 1975 Dec 4;293(23):1167-70 [171569.001]
  • [Cites] Endocrinology. 1989 Sep;125(3):1683-90 [2667965.001]
  • [Cites] Endocr Rev. 1990 May;11(2):266-301 [2114281.001]
  • [Cites] Obstet Gynecol. 1990 Nov;76(5 Pt 1):792-7 [2216226.001]
  • [Cites] Curr Opin Obstet Gynecol. 1991 Dec;3(6):853-8 [1818724.001]
  • [Cites] Epidemiology. 1993 Jan;4(1):20-4 [8380547.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Dec 1;90(23):11162-6 [8248223.001]
  • [Cites] Baillieres Clin Obstet Gynaecol. 1993 Dec;7(4):701-13 [8131311.001]
  • [Cites] Exp Cell Res. 1995 Aug;219(2):527-35 [7641805.001]
  • [Cites] Genes Dev. 1995 Sep 15;9(18):2266-78 [7557380.001]
  • [Cites] Science. 1995 Nov 24;270(5240):1354-7 [7481822.001]
  • [Cites] J Biol Chem. 1995 Dec 8;270(49):29071-4 [7493928.001]
  • [Cites] EMBO J. 1996 Jul 15;15(14):3667-75 [8670870.001]
  • [Cites] Science. 1997 Aug 15;277(5328):965-8 [9252329.001]
  • [Cites] Science. 1998 Mar 20;279(5358):1922-5 [9506940.001]
  • [Cites] Cancer Res. 1998 Apr 1;58(7):1380-3 [9537234.001]
  • [Cites] Mol Cell Biochem. 1998 Mar;180(1-2):59-64 [9546631.001]
  • [Cites] Int J Fertil Womens Med. 1998 Mar-Apr;43(2):73-83 [9609206.001]
  • [Cites] Biol Reprod. 1998 Nov;59(5):1143-52 [9780321.001]
  • [Cites] Mech Ageing Dev. 2004 Oct-Nov;125(10-11):669-78 [15541762.001]
  • [Cites] Genesis. 2005 Feb;41(2):58-66 [15682389.001]
  • [Cites] Arch Histol Cytol. 2004 Dec;67(5):417-34 [15781983.001]
  • [Cites] Oncogene. 2005 Jun 30;24(28):4540-8 [15856022.001]
  • [Cites] Endocrinology. 2005 Aug;146(8):3490-505 [15845616.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Aug 16;102(33):11740-5 [16087873.001]
  • [Cites] Mol Cell Biol. 2005 Sep;25(18):8150-65 [16135805.001]
  • [Cites] CA Cancer J Clin. 2006 Mar-Apr;56(2):106-30 [16514137.001]
  • [Cites] Mol Endocrinol. 2006 May;20(5):1138-52 [16423883.001]
  • [Cites] Nat Med. 2006 May;12(5):568-73 [16648858.001]
  • [Cites] Oncogene. 2007 Jan 11;26(2):269-76 [16819504.001]
  • [Cites] Cell Cycle. 2007 Mar 1;6(5):507-13 [17351343.001]
  • [Cites] Endocrinology. 2007 Aug;148(8):3814-26 [17510236.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Jun 6;97(12):6379-84 [10823921.001]
  • (PMID = 19439667.001).
  • [ISSN] 1091-6490
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] ENG
  • [Grant] United States / NICHD NIH HHS / HD / R01HD057873; United States / NCI NIH HHS / CA / 1P50CA098258-01; United States / NICHD NIH HHS / HD / R03 HD077495; United States / NCI NIH HHS / CA / P50 CA098258; United States / NICHD NIH HHS / HD / U54HD0077495; United States / NICHD NIH HHS / HD / U01 HD042311; United States / NCI NIH HHS / CA / R01 CA077530; United States / NCI NIH HHS / CA / R29 CA077530; United States / NICHD NIH HHS / HD / U01HD042311; United States / NICHD NIH HHS / HD / R01 HD057873; United States / NICHD NIH HHS / HD / U54 HD035041; United States / NICHD NIH HHS / HD / 2U54HD035041-11; United States / NCI NIH HHS / CA / R01-CA7753
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / Errfi1 protein, mouse; 0 / Estrogens; 0 / Intracellular Signaling Peptides and Proteins; 0 / MIG-6 protein, human; 0 / Ncoa1 protein, mouse; 0 / Transcription Factors; 0 / Tumor Suppressor Proteins; 4G7DS2Q64Y / Progesterone; EC 2.3.1.48 / Histone Acetyltransferases; EC 2.3.1.48 / NCOA1 protein, human; EC 2.3.1.48 / Nuclear Receptor Coactivator 1
  • [Other-IDs] NLM/ PMC2681319
  •  go-up   go-down


7. Liao CL, Lee MY, Tyan YS, Kok LF, Wu TS, Koo CL, Wang PH, Chao KC, Han CP: Progesterone receptor does not improve the performance and test effectiveness of the conventional 3-marker panel, consisting of estrogen receptor, vimentin and carcinoembryonic antigen in distinguishing between primary endocervical and endometrial adenocarcinomas in a tissue microarray extension study. J Transl Med; 2009;7:37
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Progesterone receptor does not improve the performance and test effectiveness of the conventional 3-marker panel, consisting of estrogen receptor, vimentin and carcinoembryonic antigen in distinguishing between primary endocervical and endometrial adenocarcinomas in a tissue microarray extension study.
  • OBJECTIVE: Endocervical adenocarcinomas (ECA) and endometrial adenocarcinomas (EMA) are uterine malignancies that have differing biological behaviors.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Carcinoembryonic Antigen / metabolism. Endometrial Neoplasms / metabolism. Receptors, Estrogen / metabolism. Receptors, Progesterone / metabolism. Uterine Cervical Neoplasms / metabolism. Vimentin / metabolism
  • [MeSH-minor] Diagnosis, Differential. Female. Humans. Immunohistochemistry. Sensitivity and Specificity. Tissue Array Analysis


8. Srikantia N, B R, A G R, Kalyan SN: Endometrioid endometrial adenocarcinoma in a premenopausal woman with multiple organ metastases. Indian J Med Paediatr Oncol; 2009 Apr;30(2):80-3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endometrioid endometrial adenocarcinoma in a premenopausal woman with multiple organ metastases.
  • Endometrial adenocarcinoma is the third common malignancy of the female genital tract occurring most often in the postmenopausal age group.
  • We present an unusual case of endometrial adenocarcinoma in a premenopausal woman with simultaneous metastases in brain, liver, skin and skeletal system, within one month of completion of treatment.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gynecol Oncol. 1997 Jun;65(3):530-3 [9190989.001]
  • [Cites] Int J Gynecol Pathol. 2002 Jul;21(3):281-4 [12068176.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 May 1;59(1):168-73 [15093913.001]
  • [Cites] Gynecol Oncol. 2004 May;93(2):524-8 [15099973.001]
  • [Cites] Expert Rev Anticancer Ther. 2004 Aug;4(4):679-89 [15270671.001]
  • [Cites] Gynecol Oncol. 2004 Aug;94(2):333-9 [15297170.001]
  • [Cites] Gan To Kagaku Ryoho. 2008 Sep;35(9):1488-94 [18799902.001]
  • [Cites] Anticancer Res. 2009 May;29(5):1715-20 [19443392.001]
  • (PMID = 20596308.001).
  • [ISSN] 0975-2129
  • [Journal-full-title] Indian journal of medical and paediatric oncology : official journal of Indian Society of Medical & Paediatric Oncology
  • [ISO-abbreviation] Indian J Med Paediatr Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC2885881
  • [Keywords] NOTNLM ; Adjuvant chemotherapy / endometrial carcinoma / multiple organ metastases
  •  go-up   go-down


9. Hoekstra AV, Kim JJ, Keh P, Schink JC: Absence of progesterone receptors in a failed case of fertility-sparing treatment in early endometrial cancer: a case report. J Reprod Med; 2008 Nov;53(11):869-73
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Absence of progesterone receptors in a failed case of fertility-sparing treatment in early endometrial cancer: a case report.
  • BACKGROUND: Fertility-sparing treatment may be offered as an alternative to standard surgical management of early-stage, well-differentiated endometrial cancer in young women.
  • CASE: We describe a 29-year-old woman who used oral contraceptive pills on a long-term basis in whom early-stage, well-differentiated endometrial cancer was diagnosed.
  • CONCLUSION: Combination oral contraceptive pills may stimulate clonal expansion of endometrial cells that lack PR, leading to endometrial adenocarcinoma unresponsive to progestin therapy.

  • Genetic Alliance. consumer health - Endometrial cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. MEGESTROL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19097521.001).
  • [ISSN] 0024-7758
  • [Journal-full-title] The Journal of reproductive medicine
  • [ISO-abbreviation] J Reprod Med
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA127674-02; United States / NCI NIH HHS / CA / R21 CA127674; United States / NCI NIH HHS / CA / R21 CA127674-02
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Contraceptives, Oral, Hormonal; 0 / Progesterone Congeners; 0 / Receptors, Progesterone; EA6LD1M70M / Megestrol
  • [Other-IDs] NLM/ NIHMS282703; NLM/ PMC4780569
  •  go-up   go-down


10. van de Poll-Franse LV, Mols F, Essink-Bot ML, Haartsen JE, Vingerhoets AJ, Lybeert ML, van den Berg HA, Coebergh JW: Impact of external beam adjuvant radiotherapy on health-related quality of life for long-term survivors of endometrial adenocarcinoma: a population-based study. Int J Radiat Oncol Biol Phys; 2007 Sep 1;69(1):125-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of external beam adjuvant radiotherapy on health-related quality of life for long-term survivors of endometrial adenocarcinoma: a population-based study.
  • PURPOSE: To compare the health-related quality of life (HRQOL) among 5-10-year survivors of Stage I-II endometrial (adeno-)carcinoma (EC) treated with surgery alone or surgery with external beam adjuvant radiotherapy (EBRT) and an age-matched norm population.
  • METHODS AND MATERIALS: A population-based, cross-sectional survey was conducted by the Eindhoven Cancer Registry.
  • Information from the questionnaires returned was linked to data from the Eindhoven Cancer Registry on patient, tumor, and treatment characteristics.
  • The analyses were restricted to women with Stage I-II disease at diagnosis, treated with either surgery alone or surgery with adjuvant EBRT, and without recurrent disease or new primary malignancies (n = 264).
  • The patients who had received adjuvant EBRT (n = 80) had had a significantly higher tumor stage and grade at diagnosis (p < 0.0001) and a longer mean time since diagnosis (p = 0.04).
  • [MeSH-major] Adenocarcinoma / radiotherapy. Endometrial Neoplasms / radiotherapy. Health Status. Quality of Life

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17544600.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


11. Zergeroğlu S, Ozdemir HB, Ozel M, Kuzey GM, Mollamahmutoğlu L: The prognostic importance of proliferative activity and oestrogen receptor expression in stage I endometrial carcinomas. J Obstet Gynaecol; 2006 Nov;26(8):798-801
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The prognostic importance of proliferative activity and oestrogen receptor expression in stage I endometrial carcinomas.
  • The purpose of this study was to evaluate the prognostic significance of steroid hormone receptor proliferation index in endometrial adenocarcinoma.
  • In this study, the correlation between oestrogen receptor expression, proliferation index and FIGO grade, age, myometrial invasion, tumour size and menopause status was evaluated in 40 patients with endometrial carcinoma.
  • Quantitative assessment of tumour proliferation and expression of oestrogen receptor were found to be important prognostic indicators in endometrial adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / pathology. Endometrial Neoplasms / pathology. Receptors, Estrogen / analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17130035.001).
  • [ISSN] 0144-3615
  • [Journal-full-title] Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology
  • [ISO-abbreviation] J Obstet Gynaecol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Ki-67 Antigen; 0 / Receptors, Estrogen
  •  go-up   go-down


12. Homesley HD: Present status and future direction of clinical trials in advanced endometrial carcinoma. J Gynecol Oncol; 2008 Sep;19(3):157-61
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Present status and future direction of clinical trials in advanced endometrial carcinoma.
  • Endometrial adenocarcinoma is staged surgically, and advanced endometrial carcinoma is considered to be FIGO stage III and IV.
  • The Gynecologic Oncology Group (GOG) has come a long way in developing new strategies in the management of advanced endometrial carcinoma.
  • Combining surgery, radiation, and chemotherapy, the 5-year survival has improved to between 40-60% in newly diagnosed advanced endometrial carcinoma.
  • Recent findings in GOG184 indicate that multiple risk factors noted at the time of surgical staging could lead to concurrent clinical trials that could be completed expeditiously rather than a subsequent ten year long phase III trial including all the various risk subgroups of patients.
  • This review is a focus on the accomplishments of the GOG in advanced endometrial carcinoma with an emphasis on future challenges.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gynecol Oncol. 1996 Dec;63(3):299-303 [8946862.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1991 Sep;21(4):1019-25 [1917597.001]
  • [Cites] J Clin Oncol. 2004 Oct 1;22(19):3902-8 [15459211.001]
  • [Cites] Gynecol Oncol. 2004 Oct;95(1):95-100 [15385116.001]
  • [Cites] J Clin Oncol. 2004 Jun 1;22(11):2159-66 [15169803.001]
  • [Cites] Gynecol Oncol. 2003 Mar;88(3):277-81 [12648575.001]
  • [Cites] Gynecol Oncol. 2006 Feb;100(2):349-54 [16213007.001]
  • [Cites] J Clin Oncol. 2006 Jan 1;24(1):36-44 [16330675.001]
  • (PMID = 19471566.001).
  • [ISSN] 2005-0380
  • [Journal-full-title] Journal of gynecologic oncology
  • [ISO-abbreviation] J Gynecol Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2676463
  • [Keywords] NOTNLM ; Chemotherapy / Clinical trial / Endometrial cancer / Radiotherapy / Therapy
  •  go-up   go-down


13. Soeda S, Nakamura N, Ozeki T, Nishiyama H, Hojo H, Yamada H, Abe M, Sato A: Tumor-associated macrophages correlate with vascular space invasion and myometrial invasion in endometrial carcinoma. Gynecol Oncol; 2008 Apr;109(1):122-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor-associated macrophages correlate with vascular space invasion and myometrial invasion in endometrial carcinoma.
  • OBJECTIVE: This study was conducted to determine whether tumor-associated macrophages (TAMs) correlate with clinicopathological features in endometrioid adenocarcinoma.
  • METHODS: 76 cases of endometrioid adenocarcinoma treated initially by hysterectomy with pelvic lymphadenectomy were retrospectively retrieved, and their histological features were evaluated.
  • TAMs may play a significant role in the biology of tumor progression of endometrial adenocarcinoma, but do not appear to be independent prognostic indicators of patient's survival.
  • [MeSH-major] Carcinoma, Endometrioid / pathology. Endometrial Neoplasms / pathology. Macrophages / pathology. Myometrium / pathology

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18289648.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Ki-67 Antigen
  •  go-up   go-down


14. Willis SF, Barton D, Ind TE: Laparoscopic hysterectomy with or without pelvic lymphadenectomy or sampling in a high-risk series of patients with endometrial cancer. Int Semin Surg Oncol; 2006;3:28
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laparoscopic hysterectomy with or without pelvic lymphadenectomy or sampling in a high-risk series of patients with endometrial cancer.
  • BACKGROUND: The purpose of the study was to determine the outcome of all patients with endometrial adenocarcinoma cancer treated by laparoscopic hysterectomy at our institution, many of whom were high-risk for surgery.
  • METHODS: Data was collected by a retrospective search of the case notes and Electronic Patient Records of the thirty eight patients who underwent laparoscopic hysterectomy for endometrial cancer at our institutions.
  • Comorbidities were present in 76% (29 patients); 40% (15 patients) had a single comorbid condition, whilst 18% (7 patients) had two, and a further 18% (7 patients) had more than two.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Gynecol Cancer. 2005 Sep-Oct;15(5):932-7 [16174248.001]
  • [Cites] Int J Gynaecol Obstet. 2003 Oct;83 Suppl 1:79-118 [14763170.001]
  • [Cites] Arch Gynecol Obstet. 2004 Jul;270(1):25-30 [12728326.001]
  • [Cites] Eur J Gynaecol Oncol. 2002;23(4):305-10 [12214729.001]
  • [Cites] Curr Opin Obstet Gynecol. 2005 Feb;17(1):77-82 [15711416.001]
  • [Cites] Gynecol Oncol. 2000 Sep;78(3 Pt 1):329-35 [10985889.001]
  • [Cites] Gynecol Oncol. 2001 Feb;80(2):239-44 [11161866.001]
  • [Cites] Cancer. 2001 Jan 15;91(2):378-87 [11180085.001]
  • [Cites] Gynecol Oncol. 1990 Nov;39(2):171-4 [2227591.001]
  • [Cites] Int J Gynecol Cancer. 2005 Sep-Oct;15(5):946-51 [16174250.001]
  • [Cites] Gynecol Oncol. 2004 Mar;92(3):789-93 [14984942.001]
  • [Cites] J Minim Invasive Gynecol. 2005 Mar-Apr;12(2):130-6 [15904616.001]
  • [Cites] Gynecol Oncol. 2005 Apr;97(1):4-9 [15790430.001]
  • [Cites] BJOG. 2005 Jan;112(1):115-7 [15663410.001]
  • (PMID = 16968556.001).
  • [ISSN] 1477-7800
  • [Journal-full-title] International seminars in surgical oncology : ISSO
  • [ISO-abbreviation] Int Semin Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1586010
  •  go-up   go-down


15. Cannon GM, Geye H, Terakedis BE, Kushner DM, Connor JP, Hartenbach EM, Bradley KA: Outcomes following surgery and adjuvant radiation in stage II endometrial adenocarcinoma. Gynecol Oncol; 2009 May;113(2):176-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcomes following surgery and adjuvant radiation in stage II endometrial adenocarcinoma.
  • PURPOSE: To evaluate locoregional control, disease free survival, and overall survival in patients treated with surgery and adjuvant radiation for stage II adenocarcinoma of the endometrium.
  • MATERIALS AND METHODS: All patients receiving adjuvant radiation at the University of Wisconsin following surgery for FIGO stage II adenocarcinoma of the endometrium between January 1991 and December 2006 were retrospectively reviewed.
  • RESULTS: Between January 1991 and December 2006, 71 patients with FIGO stage II adenocarcinoma of the endometrium (23 stage IIA, 48 stage IIB) received adjuvant radiation at the University of Wisconsin.
  • DISCUSSION: Local recurrence rates remain low after surgery and adjuvant radiation therapy for stage II endometrial cancer using a combination of VB and EXT tailored to the surgical and pathologic features.
  • [MeSH-major] Adenocarcinoma / radiotherapy. Adenocarcinoma / surgery. Endometrial Neoplasms / radiotherapy. Endometrial Neoplasms / surgery

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19217147.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / U10 CA180799
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Wilson M, Hermes R, Bainbridge J, Bassett H: A case of metastatic uterine adenocarcinoma in a southern white rhinoceros (Ceratotherium simum simum). J Zoo Wildl Med; 2010 Mar;41(1):111-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of metastatic uterine adenocarcinoma in a southern white rhinoceros (Ceratotherium simum simum).
  • The rhinoceros' uterus had previously been evaluated by ultrasound and diffuse endometrial hyperplasia and two benign uterine leiomyomas had been diagnosed.
  • At necropsy examination, a large, infiltrative, metastatic uterine adenocarcinoma was found multifocally throughout the uterus, scattered within the peritoneal cavity, on the diaphragm, the splenic capsule, the pleural surface of the lung and mesenteric lymph nodes.
  • [MeSH-major] Adenocarcinoma / veterinary. Lung Neoplasms / veterinary. Perissodactyla. Peritoneal Neoplasms / veterinary. Splenic Neoplasms / veterinary. Uterine Neoplasms / veterinary

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20722262.001).
  • [ISSN] 1042-7260
  • [Journal-full-title] Journal of zoo and wildlife medicine : official publication of the American Association of Zoo Veterinarians
  • [ISO-abbreviation] J. Zoo Wildl. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Koistinen H, Seppälä M, Knuutila S, Koistinen R: Extracellular matrix-induced changes in expression of cell cycle-related proteins and proteasome components in endometrial adenocarcinoma cells. Gynecol Oncol; 2006 Sep;102(3):546-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extracellular matrix-induced changes in expression of cell cycle-related proteins and proteasome components in endometrial adenocarcinoma cells.
  • Whereas ECM has been shown to alter cellular morphology and reduce proliferation of HEC-1B endometrial adenocarcinoma cells, little is known about the underlying changes in gene expression.
  • METHODS: We studied by cDNA array the effects of ECM components, as present in Matrigel basement membrane cell culture matrix, on gene expression in HEC-1B endometrial adenocarcinoma cells in respect of the same cells cultured on conventional plastic surface.
  • RESULTS: As expected, several growth-promoting genes were downregulated, while many genes associated with growth restriction were upregulated in Matrigel-grown carcinoma cells.
  • The observed changes point to a less malignant phenotype of Matrigel-grown tumor cells, supported by reduced growth characteristics and morphology.
  • [MeSH-major] Adenocarcinoma / metabolism. Cell Cycle Proteins / metabolism. Endometrial Neoplasms / metabolism. Extracellular Matrix / physiology. Proteasome Endopeptidase Complex / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16497364.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cell Cycle Proteins; 0 / Drug Combinations; 0 / Laminin; 0 / Proteoglycans; 119978-18-6 / matrigel; 9007-34-5 / Collagen; EC 3.4.25.1 / Proteasome Endopeptidase Complex
  •  go-up   go-down


18. Viswanathan AN, Feskanich D, Schernhammer ES, Hankinson SE: Aspirin, NSAID, and acetaminophen use and the risk of endometrial cancer. Cancer Res; 2008 Apr 1;68(7):2507-13
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aspirin, NSAID, and acetaminophen use and the risk of endometrial cancer.
  • To date, no prospective studies have explored the relationship between the use of aspirin, other nonsteroidal anti-inflammatory medications (NSAID), and acetaminophen and endometrial adenocarcinoma.
  • Of the 82,971 women enrolled in a prospective cohort study, 747 developed medical record-confirmed invasive endometrial cancer over a 24-year period.
  • Cox regression models calculated multivariate relative risks (MV RR), controlling for body mass index (BMI), postmenopausal hormone (PMH) use, and other endometrial cancer risk factors.
  • Currency, duration, and quantity of aspirin were not associated with endometrial cancer risk overall [current use: MV RR, 1.03; 95% confidence interval (CI) 0.83-1.27; >10 years of use: MV RR, 1.01; 95% CI, 0.78-1.30; and cumulative average >7 tablets per week: (MV RR, 1.10; 95% CI, 0.84-1.44)].
  • However, stratified analyses showed that a lower risk of endometrial cancer among obese (BMI, >or=30 kg/m(2)) women was seen with current aspirin use (MV RR, 0.66; 95% CI, 0.46-0.95).
  • The use of other NSAIDs or acetaminophen was not associated with endometrial cancer.
  • Our data suggest that use of aspirin or other NSAIDs does not play an important role in endometrial cancer risk overall.

  • Genetic Alliance. consumer health - Endometrial cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ACETAMINOPHEN .
  • Hazardous Substances Data Bank. ACETYLSALICYLIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Obstet Gynecol. 2000 Jan;182(1 Pt 1):23-9 [10649152.001]
  • [Cites] Int J Gynecol Cancer. 2007 Mar-Apr;17(2):447-54 [17316360.001]
  • [Cites] Epidemiology. 2001 Jan;12(1):88-93 [11138826.001]
  • [Cites] Lancet. 2001 Feb 17;357(9255):539-45 [11229684.001]
  • [Cites] Obstet Gynecol. 2001 Mar;97(3):423-7 [11239649.001]
  • [Cites] J Exp Med. 2001 Mar 19;193(6):F23-6 [11257144.001]
  • [Cites] Br J Cancer. 2001 Sep 28;85(7):1023-31 [11592775.001]
  • [Cites] J Biol Chem. 2002 Jul 19;277(29):26208-16 [12006564.001]
  • [Cites] Cancer. 2002 Aug 15;95(4):801-7 [12209724.001]
  • [Cites] J Reprod Immunol. 2002 Oct-Nov;57(1-2):81-93 [12385835.001]
  • [Cites] Nature. 2002 Dec 19-26;420(6917):860-7 [12490959.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2002 Dec;11(12):1531-43 [12496040.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2002 Dec;11(12):1586-91 [12496048.001]
  • [Cites] Ann Med. 2002;34(6):428-33 [12523498.001]
  • [Cites] Cancer Res. 2003 Sep 15;63(18):6096-101 [14522941.001]
  • [Cites] J Steroid Biochem Mol Biol. 2003 Sep;86(3-5):501-7 [14623550.001]
  • [Cites] J Natl Cancer Inst. 2004 Jan 7;96(1):22-8 [14709735.001]
  • [Cites] J Natl Cancer Inst. 2004 Apr 7;96(7):524-8 [15069114.001]
  • [Cites] Br J Cancer. 2004 Aug 2;91(3):525-9 [15226764.001]
  • [Cites] Am J Epidemiol. 1982 Aug;116(2):333-42 [7114042.001]
  • [Cites] Biol Rev Camb Philos Soc. 1986 Nov;61(4):313-28 [3542071.001]
  • [Cites] Am J Epidemiol. 1987 Aug;126(2):319-25 [3605058.001]
  • [Cites] Contraception. 1987 Jul;36(1):23-35 [3311624.001]
  • [Cites] Cancer Res. 1988 Aug 1;48(15):4399-404 [3390835.001]
  • [Cites] Int J Cancer. 1989 May 15;43(5):795-9 [2714884.001]
  • [Cites] Epidemiology. 1990 Nov;1(6):466-73 [2090285.001]
  • [Cites] Int J Cancer. 1991 Aug 19;49(1):38-43 [1874568.001]
  • [Cites] Int J Cancer. 1992 Feb 20;50(4):567-71 [1537622.001]
  • [Cites] J Natl Cancer Inst. 1993 Aug 4;85(15):1220-4 [8331682.001]
  • [Cites] N Engl J Med. 1995 Sep 7;333(10):609-14 [7637720.001]
  • [Cites] N Engl J Med. 2003 Mar 6;348(10):891-9 [12621133.001]
  • [Cites] Am J Obstet Gynecol. 2003 May;188(5):1174-6 [12748469.001]
  • [Cites] Prog Exp Tumor Res. 2003;37:1-24 [12795046.001]
  • [Cites] Endocrinology. 1996 Dec;137(12):5739-42 [8940410.001]
  • [Cites] J Womens Health. 1997 Feb;6(1):49-62 [9065374.001]
  • [Cites] Fertil Steril. 1998 Aug;70(2):371-3 [9696240.001]
  • [Cites] Lancet. 1999 May 29;353(9167):1824-8 [10359406.001]
  • [Cites] Int J Cancer. 1999 Jul 2;82(1):38-42 [10360818.001]
  • [Cites] J Natl Cancer Inst. 1999 Jul 7;91(13):1131-7 [10393721.001]
  • [Cites] Contraception. 2004 Dec;70(6):451-62 [15541406.001]
  • [Cites] Cancer Sci. 2004 Nov;95(11):901-7 [15546508.001]
  • [Cites] Prostaglandins Leukot Essent Fatty Acids. 2005 Feb;72(2):85-7 [15626590.001]
  • [Cites] Int J Cancer. 2005 May 10;114(6):996-1001 [15645490.001]
  • [Cites] Am J Obstet Gynecol. 2005 Apr;192(4):1262-71; discussion 1271-3 [15846217.001]
  • [Cites] JAMA. 2005 Jul 6;294(1):47-55 [15998890.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Dec;14(12):2840-7 [16364998.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Dec;14(12):2923-8 [16365011.001]
  • [Cites] Ann Intern Med. 2007 Mar 6;146(5):365-75 [17339622.001]
  • [Cites] J Clin Epidemiol. 2000 Apr;53(4):385-91 [10785569.001]
  • (PMID = 18381460.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P01 CA087969; United States / NCI NIH HHS / CA / CA117979-04; United States / NCI NIH HHS / CA / K07 CA117979-04; United States / NCI NIH HHS / CA / CA87969; United States / NCI NIH HHS / CA / K07 CA117979-01; United States / NCI NIH HHS / CA / CA117979-02; United States / NCI NIH HHS / CA / CA117979-01; United States / NCI NIH HHS / CA / K07 CA117979; United States / NCI NIH HHS / CA / K07 CA117979-02; United States / NCI NIH HHS / CA / K07 CA117979-03; United States / NCI NIH HHS / CA / CA117979-03; United States / NCI NIH HHS / CA / 5K07 CA117979-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal; 362O9ITL9D / Acetaminophen; R16CO5Y76E / Aspirin
  • [Other-IDs] NLM/ NIHMS191688; NLM/ PMC2857531
  •  go-up   go-down


19. Wang C, Norton JT, Ghosh S, Kim J, Fushimi K, Wu JY, Stack MS, Huang S: Polypyrimidine tract-binding protein (PTB) differentially affects malignancy in a cell line-dependent manner. J Biol Chem; 2008 Jul 18;283(29):20277-87
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RNA processing is altered during malignant transformation, and expression of the polypyrimidine tract-binding protein (PTB) is often increased in cancer cells.
  • Although some data support that PTB promotes cancer, the functional contribution of PTB to the malignant phenotype remains to be clarified.
  • Here we report that although PTB levels are generally increased in cancer cell lines from multiple origins and in endometrial adenocarcinoma tumors, there appears to be no correlation between PTB levels and disease severity or metastatic capacity.
  • Reduction of PTB inhibits the invasive behavior of two cancer cell lines in Matrigel invasion assays but enhances the invasive behavior of another.
  • These data demonstrate that PTB is not oncogenic and can either promote or antagonize a malignant trait dependent upon the specific intra-cellular environment.

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 2006 Jan 13;281(2):800-6 [16282332.001]
  • [Cites] Nat Rev Mol Cell Biol. 2005 May;6(5):386-98 [15956978.001]
  • [Cites] Bioessays. 2006 Apr;28(4):378-86 [16547952.001]
  • [Cites] Nat Struct Mol Biol. 2006 Sep;13(9):839-48 [16936729.001]
  • [Cites] Mol Cell Biol. 2006 Dec;26(23):8755-69 [16982681.001]
  • [Cites] Oncogene. 2007 Jul 26;26(34):4961-8 [17310993.001]
  • [Cites] Cancer Res. 2000 Mar 1;60(5):1221-4 [10728679.001]
  • [Cites] J Biol Chem. 2000 Aug 4;275(31):23869-76 [10791952.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Jan 30;98(3):938-43 [11158574.001]
  • [Cites] Mol Cell Biol. 2001 May;21(10):3281-8 [11313454.001]
  • [Cites] J Biol Chem. 2001 Mar 16;276(11):8535-43 [11116151.001]
  • [Cites] RNA. 2001 Jun;7(6):819-32 [11421360.001]
  • [Cites] Mol Cell Biol. 2001 Dec;21(23):8238-46 [11710333.001]
  • [Cites] Mol Biol Cell. 2001 Dec;12(12):3808-20 [11739782.001]
  • [Cites] Mol Cell. 2002 Oct;10(4):943-9 [12419237.001]
  • [Cites] Cancer. 2002 Dec 15;95(12):2524-33 [12467066.001]
  • [Cites] Nucleic Acids Res. 2003 Jan 15;31(2):639-46 [12527772.001]
  • [Cites] Genes Dev. 2003 Feb 15;17(4):419-37 [12600935.001]
  • [Cites] RNA. 2003 Apr;9(4):443-56 [12649496.001]
  • [Cites] Mol Biol Cell. 2003 Jun;14(6):2425-35 [12808040.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jul 22;100(15):8776-81 [12851456.001]
  • [Cites] Annu Rev Biochem. 2003;72:291-336 [12626338.001]
  • [Cites] Cancer Res. 2003 Oct 1;63(19):6154-7 [14559795.001]
  • [Cites] Neuro Oncol. 2004 Jan;6(1):9-14 [14769134.001]
  • [Cites] Mol Cell Biol. 2004 May;24(10):4174-83 [15121839.001]
  • [Cites] Clin Cancer Res. 2004 Jul 15;10(14):4652-60 [15269137.001]
  • [Cites] Cancer Res. 1984 Aug;44(8):3522-9 [6744277.001]
  • [Cites] Biochemistry. 1990 May 22;29(20):4966-70 [2114170.001]
  • [Cites] Cell. 1991 Apr 5;65(1):13-24 [1707342.001]
  • [Cites] Genes Dev. 1991 Jul;5(7):1224-36 [1906035.001]
  • [Cites] Genes Dev. 1991 Jul;5(7):1237-51 [1906036.001]
  • [Cites] Nucleic Acids Res. 1992 Jul 25;20(14):3671-8 [1641332.001]
  • [Cites] Mol Cell Biol. 1993 May;13(5):2993-3001 [8474457.001]
  • [Cites] J Virol. 1994 Feb;68(2):941-50 [8289396.001]
  • [Cites] Cell. 1994 Sep 9;78(5):739-50 [8087842.001]
  • [Cites] Virology. 1995 Dec 20;214(2):660-3 [8553572.001]
  • [Cites] RNA. 1995 Nov;1(9):924-38 [8548657.001]
  • [Cites] Genes Dev. 1996 Jan 15;10(2):208-19 [8566754.001]
  • [Cites] Mol Cell Biol. 1996 Oct;16(10):5400-8 [8816452.001]
  • [Cites] J Cell Biol. 1997 Jun 2;137(5):965-74 [9166399.001]
  • [Cites] RNA. 1997 Jul;3(7):764-78 [9214659.001]
  • [Cites] Biochemistry. 1997 Sep 30;36(39):11881-90 [9305981.001]
  • [Cites] Curr Biol. 1997 Nov 1;7(11):R705-8 [9382788.001]
  • [Cites] Biochem J. 1998 Apr 1;331 ( Pt 1):169-75 [9512476.001]
  • [Cites] Clin Cancer Res. 1996 Sep;2(9):1627-36 [9816342.001]
  • [Cites] Mol Cell Biol. 1999 Jan;19(1):78-85 [9858533.001]
  • [Cites] Electrophoresis. 1999 Apr-May;20(4-5):1082-6 [10344288.001]
  • [Cites] Gene. 2005 Jan 3;344:1-20 [15656968.001]
  • [Cites] J Cell Biochem. 2005 May 15;95(2):217-25 [15770648.001]
  • [Cites] Thromb Haemost. 2005 Apr;93(4):676-81 [15841311.001]
  • [Cites] Nat Methods. 2004 Dec;1(3):233-9 [15782199.001]
  • [Cites] Trends Biochem Sci. 2006 Feb;31(2):73-6 [16403634.001]
  • (PMID = 18499661.001).
  • [ISSN] 0021-9258
  • [Journal-full-title] The Journal of biological chemistry
  • [ISO-abbreviation] J. Biol. Chem.
  • [Language] ENG
  • [Grant] United States / NIGMS NIH HHS / GM / GM 078555-01; United States / NIGMS NIH HHS / GM / GM 070967; United States / NCI NIH HHS / CA / R21 CA127674-01A2; United States / NCI NIH HHS / CA / CA127674-01A2; United States / NCI NIH HHS / CA / R21 CA127674; United States / NCI NIH HHS / CA / CA 097761
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Protein Isoforms; 0 / RNA, Small Interfering; 139076-35-0 / Polypyrimidine Tract-Binding Protein; EC 3.4.22.- / Caspase 2
  • [Other-IDs] NLM/ PMC2459264
  •  go-up   go-down


20. Erkanli S, Bolat F, Kayaselcuk F, Demirhan B, Kuscu E: COX-2 and survivin are overexpressed and positively correlated in endometrial carcinoma. Gynecol Oncol; 2007 Feb;104(2):320-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] COX-2 and survivin are overexpressed and positively correlated in endometrial carcinoma.
  • OBJECTIVES: To investigate the expressions of survivin and Cyclooxygenase-2 (COX-2), and their possible correlations in the development of endometrial adenocarcinoma (EC).
  • METHODS: Archived tissue samples of 50 EC, 30 endometrial hyperplasia and 20 proliferative endometrium were selected and immunohistochemically analyzed for survivin and COX-2 expression.
  • RESULTS: Both survivin and COX-2 were overexpressed in hyperplasia and endometrial adenocarcinoma cases compared to proliferative endometrium, which was statistically significant (p=0.01, p=0.02, respectively).
  • Neither survivin nor COX-2 expression was correlated with classical prognostic factors of endometrial carcinoma such as myometrial invasion, grade or lymph node metastasis (p>0.05).
  • Molecular basis of such a relationship should be further investigated in endometrial carcinogenesis.
  • [MeSH-major] Biomarkers, Tumor / biosynthesis. Carcinoma, Endometrioid / metabolism. Cyclooxygenase 2 / biosynthesis. Endometrial Neoplasms / metabolism. Microtubule-Associated Proteins / biosynthesis. Neoplasm Proteins / biosynthesis
  • [MeSH-minor] Endometrial Hyperplasia / enzymology. Endometrial Hyperplasia / metabolism. Endometrial Hyperplasia / pathology. Female. Humans. Immunohistochemistry. Inhibitor of Apoptosis Proteins. Middle Aged. Neoplasm Staging. Prognosis. Survival Rate

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17030351.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BIRC5 protein, human; 0 / Biomarkers, Tumor; 0 / Inhibitor of Apoptosis Proteins; 0 / Microtubule-Associated Proteins; 0 / Neoplasm Proteins; EC 1.14.99.1 / Cyclooxygenase 2
  •  go-up   go-down


21. Roncati L, Barbolini G, Ghirardini G, Rivasi F: Mature solid teratoma of the fallopian tube mimicking metastasis of endometrial adenocarcinoma: a case report. Int J Surg Pathol; 2010 Dec;18(6):561-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mature solid teratoma of the fallopian tube mimicking metastasis of endometrial adenocarcinoma: a case report.
  • This mass was noted on CT scan and considered metastatic in nature since following a bioptical diagnosis of endometrial adenocarcinoma.
  • Hysterectomy and bilateral salpingectomy and ovariectomy were performed and a second minor mature solid teratoma was discovered inside the right ovary.
  • [MeSH-major] Adenocarcinoma / pathology. Endometrial Neoplasms / pathology. Fallopian Tube Neoplasms / pathology. Neoplasms, Multiple Primary / pathology. Teratoma / pathology
  • [MeSH-minor] Aged. Diagnosis, Differential. Female. Humans

  • Genetic Alliance. consumer health - Teratoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19282291.001).
  • [ISSN] 1940-2465
  • [Journal-full-title] International journal of surgical pathology
  • [ISO-abbreviation] Int. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Horn LC, Hänel C, Bartholdt E, Dietel J: Mixed serous carcinoma of the endometrium with trophoblastic differentiation: analysis of the p53 tumor suppressor gene suggests stem cell origin. Ann Diagn Pathol; 2008 Feb;12(1):1-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mixed serous carcinoma of the endometrium with trophoblastic differentiation: analysis of the p53 tumor suppressor gene suggests stem cell origin.
  • The pathogenesis of mixed endometrial adenocarcinoma with trophoblastic differentiation is quite unclear at times.
  • The present study examines a serous carcinoma with choriocarcinomatous differentiation. p53 staining was seen in the serous component and the cytotrophoblastic cells of the choriocarcinomatous component, but not in the syncytiotrophoblastic cells. p53 mutational analysis showed a heterozygotic mutation at exon 8 for the choriocarcinomatous component and a homozygote deletion at exon 7 for the serous component.
  • [MeSH-major] Adenocarcinoma / genetics. Choriocarcinoma / genetics. Endometrial Neoplasms / genetics. Neoplasms, Multiple Primary / genetics. Trophoblastic Neoplasms / genetics. Tumor Suppressor Protein p53 / genetics

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18164407.001).
  • [ISSN] 1092-9134
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


23. Zhang Y, Zhang Y, Lin QH: [Progesterone-modulated proteins in human endometrial cancer cell line Ishikawa]. Nan Fang Yi Ke Da Xue Xue Bao; 2006 Aug;26(8):1110-3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Progesterone-modulated proteins in human endometrial cancer cell line Ishikawa].
  • OBJECTIVE: To identify proteins associated with growth inhibitory effects of progesterone in Ishikawa endometrial adenocarcinoma cell line (Ishikawa).
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Cell Line, Tumor. Down-Regulation / drug effects. Electrophoresis, Gel, Two-Dimensional. Endometrial Neoplasms / metabolism. Endometrial Neoplasms / pathology. Female. Humans. Mass Spectrometry. Megestrol Acetate / pharmacology. Up-Regulation / drug effects

  • Genetic Alliance. consumer health - Endometrial cancer.
  • Hazardous Substances Data Bank. PROGESTERONE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16939895.001).
  • [ISSN] 1673-4254
  • [Journal-full-title] Nan fang yi ke da xue xue bao = Journal of Southern Medical University
  • [ISO-abbreviation] Nan Fang Yi Ke Da Xue Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Proteins; 0 / Proteome; 4G7DS2Q64Y / Progesterone; TJ2M0FR8ES / Megestrol Acetate
  •  go-up   go-down


24. Graziani G, Tentori L, Muzi A, Vergati M, Tringali G, Pozzoli G, Navarra P: Evidence that corticotropin-releasing hormone inhibits cell growth of human breast cancer cells via the activation of CRH-R1 receptor subtype. Mol Cell Endocrinol; 2007 Jan 29;264(1-2):44-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evidence that corticotropin-releasing hormone inhibits cell growth of human breast cancer cells via the activation of CRH-R1 receptor subtype.
  • It has been previously shown that corticotropin-releasing hormone (CRH) exerts antiproliferative activity on an estrogen-dependent tumor cell line, i.e. human endometrial adenocarcinoma Ishikawa (IK) cells.
  • Here we have investigated the effects of CRH on another estrogen-dependent tumor cell line, human breast cancer MCF7 cells.
  • We have also investigated the putative source of CRH acting on breast cancer cells; we found that MCF7 cells express CRH mRNA under basal conditions and secrete sizable amounts of immunoreactive CRH, which leads to postulate the existence of paracrine-autocrine inhibitory mechanism operated by CRH in breast cancer cells.

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Hormones.
  • Hazardous Substances Data Bank. ESTRADIOL .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17097220.001).
  • [ISSN] 0303-7207
  • [Journal-full-title] Molecular and cellular endocrinology
  • [ISO-abbreviation] Mol. Cell. Endocrinol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / CRF receptor type 1; 0 / Hormones; 0 / Pyrimidines; 0 / Pyrroles; 0 / Receptors, Corticotropin-Releasing Hormone; 0 / antalarmin; 4TI98Z838E / Estradiol; 9015-71-8 / Corticotropin-Releasing Hormone
  •  go-up   go-down


25. Trimble EL, Harlan LC, Clegg LX, Stevens JL: Pre-operative imaging, surgery and adjuvant therapy for women diagnosed with cancer of the corpus uteri in community practice in the United States. Gynecol Oncol; 2005 Mar;96(3):741-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pre-operative imaging, surgery and adjuvant therapy for women diagnosed with cancer of the corpus uteri in community practice in the United States.
  • INTRODUCTION: Non-Hispanic black women are less often diagnosed with endometrial cancer than are non-Hispanic white women, but are more likely to die of their disease.
  • METHODS: The Surveillance, Epidemiology, and End-Results Program data were used to sample women newly diagnosed in 1998 with cancer of the corpus uteri.
  • A total of 711 women with no previous diagnosis of cancer were selected.
  • CONCLUSIONS: Our study did not show any difference in recommended therapy for women with uterine adenocarcinoma among NH black women, NH white women, and Hispanic women.
  • We must look for other factors, therefore, to explain the disparities in cancer outcome observed among NH black women with endometrial cancer.
  • [MeSH-major] Adenocarcinoma / therapy. Endometrial Neoplasms / therapy

  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15721420.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


26. Ditto A, Martinelli F, Carcangiu ML, Hanozet F, Solima E, Barisella M, Cerrotta A, Raspagliesi F: Incidental diagnosis of primary vaginal adenocarcinoma of intestinal type: a case report and review of the literature. Int J Gynecol Pathol; 2007 Oct;26(4):490-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incidental diagnosis of primary vaginal adenocarcinoma of intestinal type: a case report and review of the literature.
  • Primary vaginal adenocarcinoma of intestinal type is a rare malignant gynecologic disease.
  • A 53-year-old woman was admitted to our institution with a diagnosis of endometrial adenocarcinoma.
  • The patient underwent surgery for endometrial cancer and wedge resection of the vaginal lesion.
  • The diagnosis of primary vaginal adenocarcinoma of intestinal type was obtained after standard and immunohistochemical analyses of the specimen.
  • No endometrial cancer was detected in the specimen.
  • Extensive radiological investigations and careful immunohistochemical analysis of the specimen are needed for a correct diagnosis of vaginal adenocarcinoma of intestinal type.
  • [MeSH-major] Adenocarcinoma / pathology. Vaginal Neoplasms / pathology
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Cisplatin / therapeutic use. Combined Modality Therapy. Diagnosis, Differential. Endometrial Neoplasms / pathology. Female. Gynecologic Surgical Procedures. Humans. Immunohistochemistry. Incidental Findings. Intestinal Neoplasms / pathology. Middle Aged. Neoplasm Staging. Positron-Emission Tomography. Radiotherapy

  • MedlinePlus Health Information. consumer health - Vaginal Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17885503.001).
  • [ISSN] 0277-1691
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


27. Gien LT, Barbera L, Kupets R, Saskin R, Paszat L: Utilization of preoperative imaging in uterine cancer patients. Gynecol Oncol; 2009 Nov;115(2):226-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Utilization of preoperative imaging in uterine cancer patients.
  • This study evaluates patterns of preoperative ultrasound, CT and MRI use among uterine cancer patients in Ontario.
  • METHODS: This population-based study identified women diagnosed with uterine malignancy from 1995-2005 in the Ontario Cancer Registry.
  • Record linkages were made to other healthcare databases to characterize residence, socioeconomic status, comorbidities, and timing of investigations surrounding diagnosis.
  • RESULTS: We identified 12,522 women who received surgery for uterine adenocarcinoma or sarcoma, of which 9145 (73%) had a preoperative ultrasound, and 1148 (9.2%) had a preoperative CT and/or MRI.
  • Higher rates of CT/MRI use were associated with non-endometrioid high-risk histology (33.5% vs 14.6%, p<0.0001).
  • Time from diagnosis to surgery was 2 weeks longer if a preoperative CT/MRI was done.
  • CONCLUSIONS: The rate of preoperative CT and MRI use in patients with uterine cancer has increased twice as much as the reported rate in cancer patients overall.
  • Given the questionable utility of preoperative CT/MRI in this disease, guidelines should be developed for use of these imaging tests in uterine cancer, especially when use is associated with a delay in surgery.
  • [MeSH-major] Adenocarcinoma / diagnosis. Sarcoma / diagnosis. Uterine Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19683807.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


28. Sales KJ, Grant V, Cook IH, Maldonado-Pérez D, Anderson RA, Williams AR, Jabbour HN: Interleukin-11 in endometrial adenocarcinoma is regulated by prostaglandin F2alpha-F-prostanoid receptor interaction via the calcium-calcineurin-nuclear factor of activated T cells pathway and negatively regulated by the regulator of calcineurin-1. Am J Pathol; 2010 Jan;176(1):435-45
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Interleukin-11 in endometrial adenocarcinoma is regulated by prostaglandin F2alpha-F-prostanoid receptor interaction via the calcium-calcineurin-nuclear factor of activated T cells pathway and negatively regulated by the regulator of calcineurin-1.
  • This study investigated the expression of IL-11 and role of prostaglandin F(2alpha)-F-prostanoid receptor (FP receptor) signaling in the modulation of IL-11 expression in endometrial adenocarcinoma cells.
  • IL-11 and regulator of calcineurin 1 isoform 4 (RCAN1-4) mRNA and protein expression were determined by real-time RT-PCR and/or enzyme-linked immunosorbent assay/Western blot analysis using Ishikawa endometrial adenocarcinoma cells stably expressing the FP receptor (FPS cells) and endometrial adenocarcinoma explants.
  • IL-11 mRNA expression was significantly elevated in endometrial adenocarcinoma samples compared with normal endometrium and increased with tumor grade.
  • IL-11 protein expression localized with FP receptor, IL-11Ralpha, and GP130 in the neoplastic glandular epithelium of endometrial adenocarcinomas.
  • Indeed, RCAN1-4 expression was significantly elevated in well-differentiated endometrial adenocarcinoma compared with normal endometrium and was found to decrease with tumor grade and negatively regulate IL-11 expression in vitro.
  • This study has highlighted a new mechanism regulating IL-11 expression in endometrial adenocarcinoma cells by the FP receptor via the calcium-calcineurin-nuclear factor of activated T cells pathway.
  • [MeSH-major] Calcineurin / metabolism. Calcium / metabolism. Endometrial Neoplasms / genetics. Interleukin-11 / genetics. Intracellular Signaling Peptides and Proteins / metabolism. Muscle Proteins / metabolism. NFATC Transcription Factors / metabolism. Receptors, Prostaglandin / metabolism
  • [MeSH-minor] Aged. Cell Differentiation. Cell Proliferation. Cytokine Receptor gp130 / genetics. Cytokine Receptor gp130 / metabolism. Endometrium / metabolism. Endometrium / pathology. Female. Gene Expression Regulation, Neoplastic. Humans. Middle Aged. Models, Biological. RNA, Messenger / genetics. RNA, Messenger / metabolism. Receptors, Interleukin-11 / genetics. Receptors, Interleukin-11 / metabolism

  • Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hum Mol Genet. 2000 Jul 1;9(11):1681-90 [10861295.001]
  • [Cites] Biochim Biophys Acta. 2009 Jul;1793(7):1315-24 [19348862.001]
  • [Cites] Mol Hum Reprod. 2000 Oct;6(10):907-14 [11006319.001]
  • [Cites] Am J Pathol. 2001 Jan;158(1):25-32 [11141475.001]
  • [Cites] J Steroid Biochem Mol Biol. 2000 Nov 30;74(5):357-64 [11162945.001]
  • [Cites] Gynecol Oncol. 2001 Feb;80(2):121-7 [11161848.001]
  • [Cites] Neoplasia. 2000 Nov-Dec;2(6):483-90 [11228540.001]
  • [Cites] Br J Cancer. 2001 Sep 28;85(7):1023-31 [11592775.001]
  • [Cites] J Biol Chem. 2001 Oct 19;276(42):38787-94 [11483593.001]
  • [Cites] J Pharmacol Exp Ther. 2002 Jul;302(1):219-24 [12065720.001]
  • [Cites] Cancer Genet Cytogenet. 2002 Oct 15;138(2):165-8 [12505265.001]
  • [Cites] Mol Hum Reprod. 2003 Feb;9(2):75-80 [12569176.001]
  • [Cites] Eur J Pharmacol. 2003 Mar 28;465(1-2):39-41 [12650831.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Apr;88(4):1825-32 [12679480.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Feb;89(2):986-93 [14764825.001]
  • [Cites] Gynecol Oncol. 1983 Feb;15(1):10-7 [6822361.001]
  • [Cites] Gynecol Oncol. 1991 Apr;41(1):1-16 [2026352.001]
  • [Cites] Nucleic Acids Res. 1992 May 11;20(9):2233-9 [1317548.001]
  • [Cites] Cancer Surv. 1994;19-20:287-307 [7895220.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Apr 2;93(7):3115-20 [8610178.001]
  • [Cites] Biochem J. 1998 Sep 1;334 ( Pt 2):297-314 [9716487.001]
  • [Cites] J Biol Chem. 2004 Nov 26;279(48):50537-54 [15448146.001]
  • [Cites] J Reprod Immunol. 2004 Dec;64(1-2):145-55 [15596233.001]
  • [Cites] Cancer Res. 2005 Sep 1;65(17):7707-16 [16140938.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Sep 13;102(37):13075-80 [16131541.001]
  • [Cites] Endocrinology. 2005 Nov;146(11):4657-64 [16081631.001]
  • [Cites] Hum Reprod Update. 2005 Nov-Dec;11(6):613-30 [16006437.001]
  • [Cites] Cell Tissue Res. 2005 Oct;322(1):53-61 [15947972.001]
  • [Cites] J Reprod Immunol. 2006 Feb;69(1):53-64 [16310857.001]
  • [Cites] World J Gastroenterol. 2006 Jan 14;12(2):317-21 [16482637.001]
  • [Cites] J Surg Res. 2006 Apr;131(2):267-75 [16457848.001]
  • [Cites] J Exp Med. 2006 Apr 17;203(4):941-51 [16567391.001]
  • [Cites] Ann Surg Oncol. 2006 Jun;13(6):802-8 [16614887.001]
  • [Cites] Int J Oncol. 2006 Oct;29(4):869-76 [16964382.001]
  • [Cites] Mol Cancer Res. 2006 Nov;4(11):811-20 [17114339.001]
  • [Cites] Int J Mol Med. 2007 Feb;19(2):273-8 [17203201.001]
  • [Cites] Int J Oncol. 2007 Apr;30(4):825-33 [17332920.001]
  • [Cites] Endocrinology. 2007 Aug;148(8):3635-44 [17478553.001]
  • [Cites] FASEB J. 2007 Oct;21(12):3023-8 [17595344.001]
  • [Cites] Endocrinology. 2007 Nov;148(11):5566-72 [17702845.001]
  • [Cites] Mol Cell Endocrinol. 2008 Mar 26;285(1-2):51-61 [18316157.001]
  • [Cites] Oncogene. 2008 Apr 10;27(17):2466-77 [17968320.001]
  • [Cites] J Biol Chem. 2000 Sep 22;275(38):29907-14 [10893233.001]
  • (PMID = 20008143.001).
  • [ISSN] 1525-2191
  • [Journal-full-title] The American journal of pathology
  • [ISO-abbreviation] Am. J. Pathol.
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / MC/ U127684438
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Interleukin-11; 0 / Intracellular Signaling Peptides and Proteins; 0 / Muscle Proteins; 0 / NFATC Transcription Factors; 0 / RCAN1 protein, human; 0 / RNA, Messenger; 0 / Receptors, Interleukin-11; 0 / Receptors, Prostaglandin; 0 / prostaglandin F2alpha receptor; 133483-10-0 / Cytokine Receptor gp130; EC 3.1.3.16 / Calcineurin; SY7Q814VUP / Calcium
  • [Other-IDs] NLM/ PMC2797902
  •  go-up   go-down


29. Buchynska LG, Nesina IP, Kashuba EV: Different trends of p53, MDM2 and p14 ARF expression patterns in endometrial adenocarcinomas versus hyperplasia. Exp Oncol; 2007 Dec;29(4):287-94
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Different trends of p53, MDM2 and p14 ARF expression patterns in endometrial adenocarcinomas versus hyperplasia.
  • AIM: To study the expression of p53, MDM2, and p14 ARF in the highly, moderately and low differentiated endometrial adenocarcinomas, compared to hyperplasia.
  • MATERIAL AND METHODS: Surgical material and the scrapes of endometrial cancer, glandular and atypical hyperplasia patients.
  • RESULTS: High p53 expression level is accompanied by decreased level of MDM2 expression in endometrial cancers.
  • On contrary, in endometrial hyperplasia, there was clear connection between the expression levels of p53 and MDM2.
  • We hypothesize that the high p53 and low MDM2 levels in endometrial cancers could arise due to the inhibition of transcriptional activity of p53 by its binding to estrogen receptors.
  • CONCLUSION: High p53 expression level with low MDM2 and p14 ARF levels may be the characteristic features of low differentiated endometrial carcinoma.
  • [MeSH-major] Adenocarcinoma / metabolism. Endometrial Hyperplasia / metabolism. Endometrial Neoplasms / metabolism. Proto-Oncogene Proteins c-mdm2 / biosynthesis. Tumor Suppressor Protein p14ARF / biosynthesis. Tumor Suppressor Protein p53 / biosynthesis

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18199985.001).
  • [ISSN] 1812-9269
  • [Journal-full-title] Experimental oncology
  • [ISO-abbreviation] Exp. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ukraine
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Tumor Suppressor Protein p14ARF; 0 / Tumor Suppressor Protein p53; EC 6.3.2.19 / MDM2 protein, human; EC 6.3.2.19 / Proto-Oncogene Proteins c-mdm2
  •  go-up   go-down


30. Siami K, McCluggage WG, Ordonez NG, Euscher ED, Malpica A, Sneige N, Silva EG, Deavers MT: Thyroid transcription factor-1 expression in endometrial and endocervical adenocarcinomas. Am J Surg Pathol; 2007 Nov;31(11):1759-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thyroid transcription factor-1 expression in endometrial and endocervical adenocarcinomas.
  • Thyroid transcription factor-1 (TTF-1) is widely used in the diagnosis of lung and thyroid carcinomas.
  • Although there have been reports of TTF-1 immunoreactivity in tumors other than those originating in the lung or thyroid, endocervical and endometrial adenocarcinomas have not been studied in large numbers.
  • Twenty-eight endocervical (9 well, 12 moderately, and 7 poorly differentiated), 32 endometrioid endometrial adenocarcinomas (11 grade I, 8 grade II, and 13 grade III), and 13 uterine serous carcinomas were retrieved and stained with TTF-1.
  • TTF-1 expression was seen in 1 of 28 (4%) of the endocervical adenocarcinomas and this was 4+ in distribution.
  • The positive endocervical carcinoma was poorly differentiated.
  • TTF-1 expression was present in 6 of 32 (19%) of the endometrioid adenocarcinomas (1 grade I, 2 grade II, and 3 grade III) and varied from 1+ to 4+ in distribution.
  • Only 2 of 32 (6%) of the endometrioid adenocarcinomas stained diffusely (4+).
  • There was no apparent correlation between the degree of differentiation and TTF-1 positivity in the adenocarcinomas.
  • Three of 13 (23%) serous carcinomas were also positive (1 case 5+ and 2 cases 1+).
  • Although TTF-1 is generally considered to be a relatively specific marker for lung and thyroid neoplasms, the occasional expression of endometrial and endocervical carcinomas should be kept in mind when evaluating neoplasms of uncertain origin.
  • It should also be taken into consideration in the evaluation of adenocarcinomas involving the lung in patients with a history of a gynecologic malignancy.
  • [MeSH-major] Adenocarcinoma / chemistry. Biomarkers, Tumor / analysis. Carcinoma, Endometrioid / chemistry. Cystadenocarcinoma, Serous / chemistry. Endometrial Neoplasms / chemistry. Nuclear Proteins / analysis. Transcription Factors / analysis. Uterine Cervical Neoplasms / chemistry. Uterine Neoplasms / chemistry


31. Pozharisskiĭ KM, Vinokurov VL, Zharinov GM, Bolbarian NA, Kuznetsova ME, Gasparian NA, Samsonova EA: [Immunohistochemical markers as prognosticators in gynecologic oncology]. Vopr Onkol; 2008;54(4):463-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cyclooxygenase and particularly COX-2 expression impaired survival in patients operated on for endometrial adenocarcinoma of the uterus: 5-year overall and relapse-free survival in absence of expression was 92% and 88%, respectively, while in cases of distinct expression, it fell down to 52% and 48%, respectively (p = 0.0004; 0.0005).
  • The end-results of radiotherapy were associated with proliferative levels of squamous cell cervical carcinoma: for Ki-67--below median of < or = 50%, 5-year survival rate was 77%, mean survival--80 months; for Ki-67 above median of > or = 50%, the indices were 47% and 47 months, respectively, (p = 0.002).
  • [MeSH-major] Biomarkers, Tumor / analysis. Genital Neoplasms, Female / chemistry. Genital Neoplasms, Female / diagnosis. Immunohistochemistry
  • [MeSH-minor] Adenocarcinoma / chemistry. Adenocarcinoma / diagnosis. Adult. Aged. Cyclooxygenase 1 / analysis. Cyclooxygenase 2 / analysis. Disease-Free Survival. Endometrial Neoplasms / chemistry. Endometrial Neoplasms / diagnosis. Female. Gene Expression Regulation, Developmental. Gene Expression Regulation, Neoplastic. Humans. Kaplan-Meier Estimate. Ki-67 Antigen / analysis. Middle Aged. Neoplasm Staging. Predictive Value of Tests. Prognosis. Tumor Suppressor Protein p53 / analysis

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18942401.001).
  • [ISSN] 0507-3758
  • [Journal-full-title] Voprosy onkologii
  • [ISO-abbreviation] Vopr Onkol
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; 0 / Tumor Suppressor Protein p53; EC 1.14.99.1 / Cyclooxygenase 1; EC 1.14.99.1 / Cyclooxygenase 2
  •  go-up   go-down


32. Juretzka MM, O'Hanlan KA, Katz SL, El-Danasouri I, Westphal LM: Embryo cryopreservation after diagnosis of stage IIB endometrial cancer and subsequent pregnancy in a gestational carrier. Fertil Steril; 2005 Apr;83(4):1041
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Embryo cryopreservation after diagnosis of stage IIB endometrial cancer and subsequent pregnancy in a gestational carrier.
  • OBJECTIVE: To describe a case of embryo cryopreservation before hysterectomy and bilateral salpingo-oophorectomy for endometrial cancer.
  • PATIENT(S): An infertile woman with endometrial biopsy demonstrating grade II/III moderately differentiated endometrial adenocarcinoma.
  • INTERVENTION(S): A Progestasert intrauterine device (IUD) was inserted into the uterine cavity to potentially reduce tumor proliferation during the stimulation cycle followed by oocyte retrieval and cryopreservation of 14 embryos.
  • CONCLUSION(S): Embryo cryopreservation and use of a gestational carrier may offer a fertility option for patients with endometrial malignancies without substantially delaying treatment.
  • [MeSH-major] Adenocarcinoma / surgery. Cryopreservation / methods. Embryo Transfer. Embryo, Mammalian / physiology. Endometrial Neoplasms / surgery. Infertility, Female / therapy. Pregnancy Outcome. Surrogate Mothers


33. Oshiro H, Miyagi Y, Kawaguchi Y, Rino Y, Arai H, Asai-Sato M, Nakayama H, Yamanaka S, Inayama Y, Fukushima N: Endometrial adenocarcinoma without myometrial invasion metastasizing to the pancreas and masquerading as primary pancreatic neoplasm. Pathol Int; 2008 Jul;58(7):456-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endometrial adenocarcinoma without myometrial invasion metastasizing to the pancreas and masquerading as primary pancreatic neoplasm.
  • Reported herein is a case of endometrial adenocarcinoma without myometrial invasion that metastasized to the pancreas in a 69-year-old Japanese woman who had a history of hysterectomy.
  • Excised in distal pancreatectomy, the tumor was diagnosed as a pancreatic primary, an invasive papillary adenocarcinoma at first, but both the endometrial tumor and the pancreatic tumor demonstrated similar morphology and immunohistochemistry.
  • Furthermore, the identical nucleotide mutation of TP53 gene was observed from both the endometrial and pancreatic tumors.
  • The pancreatic tumor was therefore confirmed to be a metastasis from the primary endometrial adenocarcinoma.
  • Metastasis to the pancreas from endometrial carcinoma is extremely rare but must be considered even if the previous cancer was treated at an early stage.
  • Histopathological comparison study and genetic analysis are important for the correct diagnosis of metastasis.
  • [MeSH-major] Adenocarcinoma / secondary. Endometrial Neoplasms / pathology. Pancreatic Neoplasms / secondary
  • [MeSH-minor] Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Papillary / pathology. Aged. Base Sequence. Diagnosis, Differential. Female. Genes, p53. Humans. Hysterectomy. Immunohistochemistry. Molecular Sequence Data. Mutation

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18577117.001).
  • [ISSN] 1440-1827
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


34. Risse EK, Ouwerkerk-Noordam E, Meijer-Marres EM, Boon ME: Exploiting the residual of cervical thin layer brush samples through cytohistology in cases with invasive carcinoma with application of antibodies. Acta Cytol; 2010 Mar-Apr;54(2):175-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Exploiting the residual of cervical thin layer brush samples through cytohistology in cases with invasive carcinoma with application of antibodies.
  • OBJECTIVE: To exploit cervical thin layer brush samples through cytohistology in cases with invasive carcinoma with application of antibodies.
  • STUDY DESIGN: Fourteen cases from women with carcinoma diagnosed in 2006 were selected out of 29 invasive carcinomas.
  • Eight women had squamous cell carcinoma, 4 endocervical adenocarcinoma, 1 endometrial adenocarcinoma and 1 ovarian adenocarcinoma.
  • These were stained with the Papanicolaou method and for the biomarkers Ki-67 and p16 and, if desired, for differentiation markers, including carcinoembryonic antigen, vimentin, cytokeratin 7 and cytokeratin 20 to establish the immunoprofile of the carcinoma.
  • RESULTS: The morphologic details in the cancer nuclei in the paraffin sections were excellent, while in all cases the thin layer cytology slide contained thick epithelial fragments with blurred nuclei.
  • In 5 of the 6 adenocarcinomas, the glandular architecture diagnostic of adenocarcinoma was visible in the cytohistology, which was highlighted in the biomarker stainings, particularly so in the Ki-67 sections.
  • With the exception of endometrial adenocarcinoma, all p16(INK4a) stainings were positive, as they were in the ovarian adenocarcinoma case.
  • CONCLUSION: Cytohistology is an adjunct to routine cervical cytologic examination of thin layer samples, allowing an unequivocal and refined diagnosis.
  • [MeSH-major] Cytodiagnosis / methods. Immunohistochemistry / methods. Neoplasm, Residual / diagnosis. Uterine Cervical Neoplasms / diagnosis


35. Macdonald OK, Sause WT, Lee RJ, Dodson MK, Zempolich K, Gaffney DK: Does oncologic specialization influence outcomes following surgery in early stage adenocarcinoma of the endometrium? Gynecol Oncol; 2005 Dec;99(3):730-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Does oncologic specialization influence outcomes following surgery in early stage adenocarcinoma of the endometrium?
  • OBJECTIVE: To evaluate treatment outcomes in women with early-stage endometrial cancer (FIGO IA, IB, IC, or IIA) surgically managed by a general gynecologist (GYN) or a gynecologic oncologist (GYO).
  • [MeSH-major] Adenocarcinoma / surgery. Endometrial Neoplasms / surgery

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16139348.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


36. Zhou J, Shen K, Zeng JF, Yang JX, Cao DY, Cui QC: [Differential expression of microRNAs associated with estrogen receptor alpha and progesterone receptor in typeIand typeII endometrial adenocarcinomas.]. Zhonghua Fu Chan Ke Za Zhi; 2009 Oct;44(10):765-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Differential expression of microRNAs associated with estrogen receptor alpha and progesterone receptor in typeIand typeII endometrial adenocarcinomas.].
  • OBJECTIVE: To identify differentially expression of microRNAs associated with expression of estrogen receptor alpha (ERalpha) and progesterone receptor (PR) between type I and type II endometrial adenocarcinoma.
  • METHODS: Two kinds of endometrial adenocarcinoma cell lines, Ishikawa and KLE, was transplanted into nude mice and biopsied to identify the expression of ERalpha, PR and p53, and test their response to estrogen and progesterone.
  • RESULTS: Ishikawa cell line was confirmed from type I endometrial adenocarcinoma, KLE cell line was confirmed from type II endometrial adenocarcinoma.
  • CONCLUSION: Hsa-miR-100 is significantly down-expressed in type I endometrial adenocarcinoma compared to type II, which may be a great potential to target ESR1.
  • [MeSH-minor] Adenocarcinoma / genetics. Animals. Endometrial Neoplasms. Estrogen Receptor alpha / metabolism. Gene Expression Regulation, Neoplastic. Humans. Mice, Nude

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20078964.001).
  • [ISSN] 0529-567X
  • [Journal-full-title] Zhonghua fu chan ke za zhi
  • [ISO-abbreviation] Zhonghua Fu Chan Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Estrogen Receptor alpha; 0 / MicroRNAs; 0 / Receptors, Progesterone
  •  go-up   go-down


37. Sales KJ, Maldonado-Pérez D, Grant V, Catalano RD, Wilson MR, Brown P, Williams AR, Anderson RA, Thompson EA, Jabbour HN: Prostaglandin F(2alpha)-F-prostanoid receptor regulates CXCL8 expression in endometrial adenocarcinoma cells via the calcium-calcineurin-NFAT pathway. Biochim Biophys Acta; 2009 Dec;1793(12):1917-28
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prostaglandin F(2alpha)-F-prostanoid receptor regulates CXCL8 expression in endometrial adenocarcinoma cells via the calcium-calcineurin-NFAT pathway.
  • Recently we showed elevated expression of the chemokine (C-X-C motif) receptor 2 (CXCR2) in endometrial adenocarcinomas localized to neutrophils and neoplastic epithelial and vascular cells.
  • Furthermore we found that PGF(2alpha)-F-prostanoid (FP) receptor regulates the expression of the CXCR2 ligand CXCL1, to promote neutrophil chemotaxis in endometrial adenocarcinomas.
  • In the present study we identified another CXCR2 ligand, CXCL8 as a target for PGF(2alpha)-FP receptor signalling which enhances epithelial cell proliferation in endometrial adenocarcinoma cells in vitro and in nude mice in vivo.
  • We found that PGF(2alpha)-FP receptor interaction induces CXCL8 expression in endometrial adenocarcinoma cells via the protein kinase C-calcium-calcineurin-NFAT signaling pathway.
  • Using an adenovirus to overexpress RCAN1-4, we found that RCAN1-4 is a negative regulator of CXCL8 expression in endometrial adenocarcinoma cells.
  • Taken together our data have elucidated the molecular and cellular mechanism whereby PGF(2alpha) regulates CXCL8 expression via the FP receptor in endometrial adenocarcinomas and have highlighted RCAN1-4 as a negative regulator of CXCL8 expression which may be exploited therapeutically to inhibit CXCL8-mediated tumour development.
  • [MeSH-major] Adenocarcinoma / metabolism. Calcineurin / metabolism. Calcium / metabolism. Endometrial Neoplasms / metabolism. Gene Expression Regulation, Neoplastic. Interleukin-8 / biosynthesis. NFATC Transcription Factors / metabolism. Neoplasm Proteins / metabolism. Receptors, Prostaglandin / metabolism. Signal Transduction

  • Hazardous Substances Data Bank. PROSTAGLANDIN F2ALPHA .
  • Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Cancer. 2007 Dec 1;121(11):2373-80 [17893866.001]
  • [Cites] FASEB J. 2007 Oct;21(12):3023-8 [17595344.001]
  • [Cites] Cytokine. 2008 Mar;41(3):232-9 [18182303.001]
  • [Cites] Mol Cell Endocrinol. 2008 Mar 26;285(1-2):51-61 [18316157.001]
  • [Cites] Oral Oncol. 2008 Oct;44(10):920-6 [18282785.001]
  • [Cites] Biochim Biophys Acta. 2009 Jul;1793(7):1315-24 [19348862.001]
  • [Cites] Cancer Res. 2009 Jul 15;69(14):5726-33 [19549892.001]
  • [Cites] Int J Biochem Cell Biol. 1999 Oct;31(10):1221-36 [10582349.001]
  • [Cites] J Immunol. 2000 Jun 1;164(11):5944-51 [10820277.001]
  • [Cites] J Steroid Biochem Mol Biol. 2000 Nov 30;74(5):357-64 [11162945.001]
  • [Cites] Neoplasia. 2000 Nov-Dec;2(6):483-90 [11228540.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Apr 24;98(9):4893-8 [11320240.001]
  • [Cites] J Biol Chem. 2001 Jun 15;276(24):21797-808 [11259418.001]
  • [Cites] Oncogene. 2001 Apr 30;20(19):2476-89 [11402342.001]
  • [Cites] Oncogene. 2001 May 17;20(22):2771-80 [11420689.001]
  • [Cites] Br J Cancer. 2001 Sep 28;85(7):1023-31 [11592775.001]
  • [Cites] Am J Reprod Immunol. 2002 Apr;47(4):213-21 [12069388.001]
  • [Cites] Am J Pathol. 2002 Jul;161(1):125-34 [12107097.001]
  • [Cites] Nature. 2002 Dec 19-26;420(6917):860-7 [12490959.001]
  • [Cites] Reproduction. 2003 Nov;126(5):559-67 [14611628.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Feb;89(2):986-93 [14764825.001]
  • [Cites] Gastroenterology. 2004 Apr;126(4):1030-43 [15057743.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 May 18;101(20):7554-9 [15131267.001]
  • [Cites] Bioorg Med Chem. 2004 Jun 15;12(12):3125-33 [15158780.001]
  • [Cites] Trends Endocrinol Metab. 2004 Oct;15(8):398-404 [15380812.001]
  • [Cites] J Cell Physiol. 1986 Dec;129(3):375-84 [3465735.001]
  • [Cites] J Pharmacol Exp Ther. 1990 Nov;255(2):756-68 [2147038.001]
  • [Cites] Gynecol Oncol. 1991 Apr;41(1):1-16 [2026352.001]
  • [Cites] Cancer Surv. 1994;19-20:287-307 [7895220.001]
  • [Cites] J Biol Chem. 1995 Jun 16;270(24):14255-8 [7782278.001]
  • [Cites] Biol Chem Hoppe Seyler. 1996 Jun;377(6):373-84 [8839983.001]
  • [Cites] J Biol Chem. 1996 Oct 25;271(43):27018-24 [8900190.001]
  • [Cites] Chem Biol. 1996 Dec;3(12):981-91 [9000009.001]
  • [Cites] Eur J Obstet Gynecol Reprod Biol. 1996 Dec;70(1):15-7 [9031912.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 May 13;94(10):4919-24 [9144165.001]
  • [Cites] J Clin Endocrinol Metab. 1998 Apr;83(4):1201-5 [9543141.001]
  • [Cites] J Biol Chem. 1998 Apr 24;273(17):10095-8 [9553055.001]
  • [Cites] J Clin Endocrinol Metab. 1998 May;83(5):1783-7 [9589693.001]
  • [Cites] Hum Reprod. 1998 Aug;13(8):2292-5 [9756313.001]
  • [Cites] Mol Endocrinol. 1999 Feb;13(2):276-85 [9973257.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Mar 2;96(5):2435-8 [10051660.001]
  • [Cites] Gastroenterol Clin North Am. 1999 Jun;28(2):459-77, x [10372277.001]
  • [Cites] J Pharmacol Exp Ther. 1999 Sep;290(3):1278-84 [10454504.001]
  • [Cites] J Biol Chem. 2004 Nov 12;279(46):47438-45 [15339913.001]
  • [Cites] J Biol Chem. 2004 Nov 26;279(48):50537-54 [15448146.001]
  • [Cites] Hum Reprod. 2005 Mar;20(3):794-801 [15618253.001]
  • [Cites] Cancer Res. 2005 Sep 1;65(17):7707-16 [16140938.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Sep 13;102(37):13075-80 [16131541.001]
  • [Cites] Cancer Res. 2006 Apr 15;66(8):4198-207 [16618742.001]
  • [Cites] J Exp Med. 2006 Apr 17;203(4):941-51 [16567391.001]
  • [Cites] Endocrinology. 2007 Aug;148(8):3635-44 [17478553.001]
  • [Cites] Endocr Relat Cancer. 2007 Dec;14(4):1039-52 [18045955.001]
  • (PMID = 19819266.001).
  • [ISSN] 0006-3002
  • [Journal-full-title] Biochimica et biophysica acta
  • [ISO-abbreviation] Biochim. Biophys. Acta
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / MC/ U127684438; United Kingdom / Medical Research Council / / U.1276.00.004.00002.01
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / IL8 protein, human; 0 / Interleukin-8; 0 / NFATC Transcription Factors; 0 / Neoplasm Proteins; 0 / Receptors, Prostaglandin; 0 / prostaglandin F2alpha receptor; B7IN85G1HY / Dinoprost; EC 2.7.11.13 / Protein Kinase C; EC 3.1.3.16 / Calcineurin; SY7Q814VUP / Calcium
  • [Other-IDs] NLM/ PMC2806519
  •  go-up   go-down


38. Koshiba H, Hosokawa K, Kubo A, Tokumitsu N, Watanabe A, Honjo H: Junctional adhesion molecule A [corrected] expression in human endometrial carcinoma. Int J Gynecol Cancer; 2009 Feb;19(2):208-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Junctional adhesion molecule A [corrected] expression in human endometrial carcinoma.
  • Loss of cell adhesion molecules may be associated with high histologic grade and invasiveness of endometrial carcinoma.
  • We attempted to determine JAM-A expression in human endometrial carcinoma and its correlations with pathologic features, stage, and survival.
  • Junctional adhesion molecule A expression in human endometrial carcinoma was evaluated by immunohistochemistry.
  • In addition, we cultured human well and poorly differentiated endometrial adenocarcinoma cell lines, Ishikawa cells, and KLE in 3-dimensional basement membrane preparation, and JAM-A expression in these cells was assessed by real-time reverse transcription-polymerase chain reaction and immunohistochemistry.
  • Additionally, in our 3-dimensional epithelial cell culture, JAM-A expression in poorly differentiated adenocarcinoma was significantly lower than that in well-differentiated adenocarcinoma (P < 0.001).
  • Junctional adhesion molecule A expression seems to be reduced in high-grade or advanced endometrial carcinoma and may be a prognostic factor.
  • [MeSH-major] Adenocarcinoma / metabolism. Cell Adhesion Molecules / biosynthesis. Endometrial Neoplasms / metabolism. Immunoglobulins / biosynthesis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Int J Gynecol Cancer. 2009 Aug;19(6):1153
  • (PMID = 19395995.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cell Adhesion Molecules; 0 / F11R protein, human; 0 / Immunoglobulins; 0 / Receptors, Cell Surface
  •  go-up   go-down


39. Bharwani N, Newland A, Tunariu N, Babar S, Sahdev A, Rockall AG, Reznek RH: MRI appearances of uterine malignant mixed müllerian tumors. AJR Am J Roentgenol; 2010 Nov;195(5):1268-75
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MRI appearances of uterine malignant mixed müllerian tumors.
  • OBJECTIVE: Uterine malignant mixed müllerian tumors (MMMTs) are rare aggressive tumors with a high incidence of lymphatic, peritoneal, and pulmonary metastases.
  • Preoperative differentiation from endometrial adenocarcinoma would be beneficial because their prognoses differ.
  • Data were compared with MRI appearances of 73 endometrial adenocarcinomas.
  • RESULTS: On T1-weighted images, MMMTs were predominantly isointense to myometrium (76%) and endometrium (71%), with heterogeneous texture in 33% of cases and hyperintense foci in 27% of cases.
  • On T2-weighted images, 92% of MMMTs were hyperintense to myometrium and either hypointense (55%) or isointense (41%) to endometrium.
  • In 12% of cases, large heterogeneous MMMTs obliterated uterine architecture and were aggressive in appearance, whereas in 88% of cases, the appearances were indistinguishable from those of endometrial adenocarcinoma.
  • Significantly more MMMTs than endometrial adenocarcinomas had cervical invasion (p = 0.008) and nodal enlargement (p = 0.00008).
  • This finding is significantly different from that for endometrial adenocarcinoma, where enhancement is less than that of myometrium in 90% of cases (p = 4 × 10⁻⁸).
  • [MeSH-major] Magnetic Resonance Imaging / methods. Mixed Tumor, Mullerian / pathology. Uterine Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma / pathology. Aged. Aged, 80 and over. Chi-Square Distribution. Contrast Media. Endometrial Neoplasms / pathology. Female. Humans. Meglumine. Middle Aged. Organometallic Compounds. Retrospective Studies

  • MedlinePlus Health Information. consumer health - MRI Scans.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20966339.001).
  • [ISSN] 1546-3141
  • [Journal-full-title] AJR. American journal of roentgenology
  • [ISO-abbreviation] AJR Am J Roentgenol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media; 0 / Organometallic Compounds; 0 / gadoterate meglumine; 6HG8UB2MUY / Meglumine
  •  go-up   go-down


41. Yang X, Dong Y, Zhao J, Sun H, Deng Y, Fan J, Yan Q: Increased expression of human macrophage metalloelastase (MMP-12) is associated with the invasion of endometrial adenocarcinoma. Pathol Res Pract; 2007;203(7):499-505
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increased expression of human macrophage metalloelastase (MMP-12) is associated with the invasion of endometrial adenocarcinoma.
  • To evaluate the association between the expression of human macrophage metalloelastase (matrix metalloproteinase-12, MMP-12) with cancer invasion and differentiation of endometrial adenocarcinoma, specimens from endometrial adenocarcinoma (n=61) of diverse stages and histologic types were collected from patients having undergone hysterectomy, and specimens from normal endometrium (n=38) were obtained from patients with benign diseases.
  • The positive rate of MMP-12 was significantly increased in endometrial adenocarcinoma (81.97%) as compared with that in normal endometrium (13.16%).
  • The results showed that expression of MMP-12 correlated with stage (p=0.022) and grade (p=0.018) of endometrial cancer.
  • MMP-12 immunoreactive proteins were found mainly on the glandular epithelial cells of endometrial adenocarcinoma.
  • The macrophage infiltration detected by CD68 immunohistochemical staining in endometrial adenocarcinoma was also higher than that in normal endometrium.
  • In this study, we show that in addition to macrophages, endometrial adenocarcinoma cells are able to express MMP-12.
  • Increased MMP-12 expression tended to be associated with the extent of adenocarcinoma invasion accompanied by marked macrophage infiltration.
  • Our results suggest that MMP-12 is an important oncogene in high-stage and high-grade endometrial adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / metabolism. Endometrial Neoplasms / metabolism. Matrix Metalloproteinase 12 / biosynthesis. Neoplasm Invasiveness / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17574772.001).
  • [ISSN] 0344-0338
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, Differentiation, Myelomonocytic; 0 / CD68 antigen, human; EC 3.4.24.65 / Matrix Metalloproteinase 12
  •  go-up   go-down


42. Hanley KZ, Tadros TS, Briones AJ, Birdsong GG, Mosunjac MB: Hematologic malignancies of the female genital tract diagnosed on liquid-based Pap test: Cytomorphologic features and review of differential diagnoses. Diagn Cytopathol; 2009 Jan;37(1):61-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Clinical symptoms are often nonspecific and mimic other more common gynecologic malignancies such as squamous cell carcinoma of the cervix or endometrial adenocarcinoma.
  • Although cervico-vaginal (Pap) smear is the primary screening method for cervical squamous cell carcinoma and its precursors, it is far less sensitive for detection of other primary or metastatic malignancies.
  • In this review, we present three cases of hematologic gynecologic malignancies, two cases of primary NHL, and a case of acute myeloid leukemia with relapse as a pelvic mass, all of which were diagnosed on a liquid-based Pap test.
  • In addition, we discuss the morphologic features of differential diagnostic entities of these rare tumors on conventional and liquid-based preparations.
  • [MeSH-major] Leukemia, Myeloid, Acute / diagnosis. Lymphoma, Non-Hodgkin / diagnosis. Uterine Cervical Neoplasms / diagnosis. Vaginal Neoplasms / diagnosis
  • [MeSH-minor] Aged, 80 and over. Diagnosis, Differential. Female. Humans. Middle Aged. Papanicolaou Test. Vaginal Smears


43. Lehmann L, Wagner J, Metzler M: Estrogenic and clastogenic potential of the mycotoxin alternariol in cultured mammalian cells. Food Chem Toxicol; 2006 Mar;44(3):398-408
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AOH replaced E2 from isolated human estrogen receptors alpha and beta and increased the level of alkaline phosphatase (ALP) mRNA and the enzymatic activity of ALP in a human endometrial adenocarcinoma cell line (Ishikawa cells).
  • [MeSH-minor] Adenocarcinoma / enzymology. Adenocarcinoma / metabolism. Alternaria / metabolism. Animals. Cell Line, Tumor. Chromosome Aberrations. Cricetinae. Cricetulus. Dose-Response Relationship, Drug. Endometrial Neoplasms / enzymology. Endometrial Neoplasms / metabolism. Enzyme Induction. Esophageal Neoplasms / chemically induced. Estrogen Receptor alpha / metabolism. Estrogen Receptor beta / metabolism. Female. Flow Cytometry. Food Contamination. Humans. Male. Micronucleus Tests. RNA, Messenger / metabolism

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16194592.001).
  • [ISSN] 0278-6915
  • [Journal-full-title] Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association
  • [ISO-abbreviation] Food Chem. Toxicol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cholinesterase Inhibitors; 0 / Estrogen Receptor alpha; 0 / Estrogen Receptor beta; 0 / Estrogens; 0 / Lactones; 0 / Mutagens; 0 / RNA, Messenger; EC 3.1.3.1 / Alkaline Phosphatase; KN9L4260JW / alternariol
  •  go-up   go-down


44. Li ZL, Morishima S, Tang JT, Otsuki Y: Apoptotic effects of Tian-Long compound on endometrial adenocarcinoma cells in vitro. Med Mol Morphol; 2009 Mar;42(1):32-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Apoptotic effects of Tian-Long compound on endometrial adenocarcinoma cells in vitro.
  • To explore its antitumor properties and the mechanism for activity in gynecological malignancies, the present studies were carried out using Ishikawa cells derived from uterine endometrial adenocarcinoma.
  • The present results indicate that the ingredients of TL compound are very promising for use in the treatment of endometrial adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Agents, Phytogenic / pharmacology. Apoptosis / drug effects. Drugs, Chinese Herbal / pharmacology. Endometrial Neoplasms / drug therapy. Phytotherapy

  • MedlinePlus Health Information. consumer health - Herbal Medicine.
  • Hazardous Substances Data Bank. ESTRADIOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int Rev Cytol. 1980;68:251-306 [7014501.001]
  • [Cites] J Histochem Cytochem. 2003 Dec;51(12):1601-9 [14623928.001]
  • [Cites] J Nat Prod. 2001 Mar;64(3):286-8 [11277740.001]
  • [Cites] Med Mol Morphol. 2008 Mar;41(1):34-43 [18470679.001]
  • [Cites] Cell Stress Chaperones. 1998 Dec;3(4):213-20 [9880233.001]
  • [Cites] Cancer Res. 1993 May 1;53(9):2133-9 [8481916.001]
  • [Cites] Am J Chin Med. 1994;22(2):137-45 [7992813.001]
  • [Cites] Food Chem Toxicol. 2003 Oct;41(10 ):1421-8 [12909277.001]
  • [Cites] Pathol Annu. 1982;17 Pt 2:229-59 [7182752.001]
  • [Cites] Curr Opin Pharmacol. 2004 Aug;4(4):327-32 [15251124.001]
  • [Cites] Science. 1995 Mar 10;267(5203):1456-62 [7878464.001]
  • [Cites] Med Mol Morphol. 2008 Sep;41(3):132-8 [18807138.001]
  • [Cites] Cancer Res. 1989 Nov 1;49(21):5870-8 [2790800.001]
  • [Cites] Lancet. 1994 Jul 2;344(8914):28-9 [7912299.001]
  • [Cites] Ann N Y Acad Sci. 2004 Dec;1028:150-6 [15650241.001]
  • [Cites] J Leukoc Biol. 1993 Nov;54(5):407-13 [8228619.001]
  • [Cites] Biochem Syst Ecol. 2000 Jun 1;28(5):403-419 [10725598.001]
  • [Cites] J Ethnopharmacol. 1999 Nov 1;67(2):163-9 [10619380.001]
  • [Cites] World J Gastroenterol. 2003 Sep;9(9):1963-7 [12970885.001]
  • [Cites] Toxicol Appl Pharmacol. 1994 Oct;128(2):169-81 [7940532.001]
  • [Cites] J Pharmacobiodyn. 1990 Jul;13(7):426-31 [2290126.001]
  • [Cites] Hum Cell. 2002 Sep;15(3):104-17 [12703541.001]
  • (PMID = 19294490.001).
  • [ISSN] 1860-1480
  • [Journal-full-title] Medical molecular morphology
  • [ISO-abbreviation] Med Mol Morphol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / DNA, Neoplasm; 0 / Drugs, Chinese Herbal; 0 / Phosphatidylserines; 0 / Proto-Oncogene Proteins c-bcl-2; 4TI98Z838E / Estradiol; EC 3.4.22.- / CASP3 protein, human; EC 3.4.22.- / CASP9 protein, human; EC 3.4.22.- / Caspase 3; EC 3.4.22.- / Caspase 9
  •  go-up   go-down


45. Nishimura S, Ito YM, Tsuda H, Ohnishi Y, Kataoka F, Nomura H, Chiyoda T, Suzuki A, Susumu N, Aoki D, Hatae M: The sensitivity and specificity of a new formula to distinguish endometrioid type endometrial carcinoma from ovarian endometrial carcinoma. Eur J Obstet Gynecol Reprod Biol; 2010 Jan;148(1):67-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The sensitivity and specificity of a new formula to distinguish endometrioid type endometrial carcinoma from ovarian endometrial carcinoma.
  • OBJECTIVES: Endometrioid type adenocarcinoma sometimes occupies both endometrium and ovary and in some cases the origin cannot be determined.
  • STUDY DESIGN: In this study, we established a formula to distinguish ovarian endometrioid cancer (EOC) from endometrioid type endometrial cancer (EEC), based on our previous report of cyclin and KI67 expression pattern by immunohistochemistry of 36 EECc and 37 OECc by the logistic regression.
  • We calculated the diagnostic accuracy using 92 test samples retrospectively and finally could diagnose the origin of 16 cases in whom endometrioid type adenocarcinoma arose in both ovary and endometrium and could be determined by Scully's criteria, and 15 cases in whom endometrioid type adenocarcinoma arose in both ovary and endometrium and Scully's criteria were not useful retrospectively.
  • If Prob(EOC) is larger than 0.5, the diagnosis is ovarian cancer; if less than 0.5 it is endometrial cancer.
  • In the other 15 cases, 12 cases were judged as ovary/ovary, 2 cases were judged as uterus/uterus and 1 case was judged as uterus/ovary.
  • CONCLUSION: The formula we established was thought to be useful to distinguish the origin of the cases in whom endometrioid type adenocarcinoma arises in both ovary and endometrium.
  • [MeSH-major] Carcinoma, Endometrioid / pathology. Endometrial Neoplasms / pathology. Ovarian Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Cyclin A / biosynthesis. Cyclin B1 / biosynthesis. Cyclin D1 / biosynthesis. Cyclin E / biosynthesis. Cyclins / biosynthesis. Endometrium / pathology. Female. Humans. Ki-67 Antigen / biosynthesis. Middle Aged. Retrospective Studies. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19815329.001).
  • [ISSN] 1872-7654
  • [Journal-full-title] European journal of obstetrics, gynecology, and reproductive biology
  • [ISO-abbreviation] Eur. J. Obstet. Gynecol. Reprod. Biol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / CCNB1 protein, human; 0 / CCNF protein, human; 0 / Cyclin A; 0 / Cyclin B1; 0 / Cyclin E; 0 / Cyclins; 0 / Ki-67 Antigen; 136601-57-5 / Cyclin D1
  •  go-up   go-down


46. Fuentes Dehesa M, Arteaga Gómez AC, Moreno Verduzco E, Aranda Flores CE: [Pregnancy after conservative management of endometrial cancer]. Ginecol Obstet Mex; 2009 Sep;77(9):419-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Pregnancy after conservative management of endometrial cancer].
  • [Transliterated title] Embarazo después del tratamiento conservador de cáncer de endometrio.
  • OBJECTIVE: To show the reproductive future of a case of endometrial cancer with conservative management.
  • 31 years old woman, with a history of infertility of three years and abnormal uterine bleeding of one year, diagnosed with well differentiated endometrial adenocarcinoma IA GI.
  • Treatment was initiated with 500 mg of progesterone three times a week for 6 months, after an endometrial curettage reporting healthy endometrium, pregnancy was achieved with homologous artificial insemination after hysteroscopy and directed biopsy with laparoscopic control by assisted reproduction service.
  • CONCLUSIONS: Endometrial cancer is common in adult women and is increasingly affecting young women, associated with infertility, obesity and nulliparity.
  • [MeSH-major] Adenocarcinoma / therapy. Endometrial Neoplasms / therapy. Pregnancy Outcome

  • Genetic Alliance. consumer health - Pregnancy.
  • Genetic Alliance. consumer health - Endometrial cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19899431.001).
  • [ISSN] 0300-9041
  • [Journal-full-title] Ginecología y obstetricia de México
  • [ISO-abbreviation] Ginecol Obstet Mex
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Mexico
  • [Number-of-references] 6
  •  go-up   go-down


47. Chen F, Shen K, Lang JH, Huang HF, Wu M: [Clinical features and prognostic of double primary carcinoma of uterine corpus and the ovary]. Zhonghua Yi Xue Za Zhi; 2005 May 18;85(18):1257-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical features and prognostic of double primary carcinoma of uterine corpus and the ovary].
  • OBJECTIVE: To investigate the clinical features, treatment and prognosis of patients with double primary carcinoma of uterine corpus and ovary.
  • METHODS: The clinical features, operation findings, treatment and prognosis of 36 patients with double primary carcinoma of uterine corpus diagnosed and treated in the last 20 years, 25 with typical endometrial adenocarcinoma and endometrioid carcinoma of the ovary (group A) 11 with non-endometrioid carcinoma in uterine corpus and/or ovary (group B) were respectively analyzed.
  • RESULTS: There was no significant difference in survival rate between the group A and group B.
  • The 1, 3, and 5-year survival rates of these 36 patients were 89%, 83%, and 75% respectively, all equal to those of the patients with stage I ovarian cancer.
  • CONCLUSION: The prognosis of double primary carcinoma of uterine corpus and ovary is rather good.
  • It is necessary to distinguish double primary carcinoma of uterine corpus and ovary from stage II ovarian cancer and stage III endometrial carcinoma.
  • [MeSH-major] Carcinoma, Endometrioid / pathology. Endometrial Neoplasms / pathology. Neoplasms, Multiple Primary / pathology. Ovarian Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16029611.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


48. Wu HM, Lai CH, Huang HY, Wang HS, Soong YK: A successful live twin birth by in vitro fertilization after conservative treatment of recurrent endometrial cancer. Chang Gung Med J; 2008 Jan-Feb;31(1):102-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A successful live twin birth by in vitro fertilization after conservative treatment of recurrent endometrial cancer.
  • Endometrial cancer is predominately a postmenopausal disease.
  • Endometrial cancer in women of childbearing age is relatively unusual.
  • Endometrial cancer is typically treated with hysterectomy.
  • After the development of endometrial cancer, successful pregnancy is rare.
  • We present a case of recurrent stage I endometrial adenocarcinoma in a 35-year-old woman.
  • Magnetic resonance imaging (MRI) revealed endometrial lesions without myometrium invasion and no pelvic lymph node enlargement.
  • On the basis of these observations and the low malignant potential of well-differentiated endometrial carcinoma, fertility-preserving treatment using Megace therapy was suggested.
  • Recurrent endometrial adenocarcinoma was documented using hysteroscopy and direct endometrial biopsy.
  • [MeSH-major] Adenocarcinoma / drug therapy. Endometrial Neoplasms / drug therapy. Fertilization in Vitro. Megestrol Acetate / therapeutic use. Neoplasm Recurrence, Local / drug therapy. Pregnancy Complications, Neoplastic / drug therapy. Twins

  • Genetic Alliance. consumer health - Endometrial cancer.
  • MedlinePlus Health Information. consumer health - Tumors and Pregnancy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18419059.001).
  • [ISSN] 2072-0939
  • [Journal-full-title] Chang Gung medical journal
  • [ISO-abbreviation] Chang Gung Med J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China (Republic : 1949- )
  • [Chemical-registry-number] TJ2M0FR8ES / Megestrol Acetate
  •  go-up   go-down


49. Indraccolo U, Cingolani N, Indraccolo SR: Bilateral Brenner tumor with endometrial adenocarcinoma in a postmenopausal woman. Eur J Gynaecol Oncol; 2007;28(3):233-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bilateral Brenner tumor with endometrial adenocarcinoma in a postmenopausal woman.
  • Brenner tumor is a rare ovarian neoplasm which is generally monolateral, more rarely bilateral, and often associated with endometrial disorders related to oestrogenic production.
  • However, there is no considerable evidence that the possible oestrogenic production of this tumor may be the cause of endometrial disorders.
  • A case of bilateral Brenner tumor with endometrial adenocarcinoma in a postmenopausal woman is presented and the features are briefly discussed, with the conclusion that hormone-producing Brenner tumors may exert their promoter effect on the development of endometrial carcinoma causing an imbalance in the oestrogen and progesterone ratio rather than producing a large amount of oestrogen.
  • [MeSH-major] Brenner Tumor / pathology. Carcinoma, Endometrioid / pathology. Endometrial Stromal Tumors / pathology. Neoplasms, Second Primary / pathology. Ovarian Neoplasms / pathology. Postmenopause

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17624095.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


51. Maxwell GL, Tian C, Risinger J, Brown CL, Rose GS, Thigpen JT, Fleming GF, Gallion HH, Brewster WR, Gynecologic Oncology Group study: Racial disparity in survival among patients with advanced/recurrent endometrial adenocarcinoma: a Gynecologic Oncology Group study. Cancer; 2006 Nov 1;107(9):2197-205
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Racial disparity in survival among patients with advanced/recurrent endometrial adenocarcinoma: a Gynecologic Oncology Group study.
  • BACKGROUND: Previous studies have reported shorter survival of black women compared with white women who had advanced/recurrent endometrial cancer.
  • METHODS: The authors retrospectively reviewed data from 169 black women and 982 white women with International Federation of Gynecologic Oncology (FIGO) Stage III, Stage IV, or recurrent endometrial carcinoma who were participants in 1 of 4 Gynecologic Oncology Group randomized treatment trials of doxorubicin alone or combined with paclitaxel and/or cisplatin.
  • CONCLUSIONS: The data from a large group of women with advanced/recurrent endometrial cancer suggested that a racial disparity in survival persists, despite the finding that black women and white women received similar treatment.
  • Although the causes of racial disparity in endometrial cancer remain to be elucidated, socioeconomic, biologic, and cultural factors should be investigated to identify the etiologic origins of this multifactorial healthcare problem.
  • [MeSH-major] Adenocarcinoma / ethnology. African Americans. Endometrial Neoplasms / ethnology. European Continental Ancestry Group. Neoplasm Recurrence, Local / ethnology

  • MedlinePlus Health Information. consumer health - African American Health.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17001661.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 27469; United States / NCI NIH HHS / CA / CA 37517
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  •  go-up   go-down


52. Geldenhuys L, Murray ML: Sensitivity and specificity of the Pap smear for glandular lesions of the cervix and endometrium. Acta Cytol; 2007 Jan-Feb;51(1):47-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sensitivity and specificity of the Pap smear for glandular lesions of the cervix and endometrium.
  • OBJECTIVE: To investigate the sensitivity and specificity of the Pap smear for detection of adenocarcinoma in situ of the cervix (AIS), endocervical adenocarcinoma (ECAC) and endometrial adenocarcinoma (EAC) as well as the overall specificity of the smear for detection of glandular lesions in general.
  • Computer records were also searched for patients who had a Pap smear result consisting of suspicious or positive for AIS or adenocarcinoma (AC) with subsequent tissue diagnosis during the same time.
  • RESULTS: One hundred percent of patients with AIS, 80% with ECAC and 22% with EAC on histology had positive findings on a Pap smear performed within a year of the histologic diagnosis.
  • It also confirmed the good sensitivity for glandular lesions of the cervix and the poor sensitivity for glandular lesions of the endometrium.
  • It thus confirmed that the Pap smear is not an effective screening tool for endometrial AC, and that the quest for alternative screening methods should continue.
  • [MeSH-major] Adenocarcinoma / diagnosis. Endometrial Neoplasms / diagnosis. Papanicolaou Test. Uterine Cervical Neoplasms / diagnosis. Vaginal Smears
  • [MeSH-minor] Carcinoma in Situ. Cervical Intraepithelial Neoplasia / diagnosis. Female. Humans. Sensitivity and Specificity. Uterine Hemorrhage / diagnosis


53. Xiong Y, Dowdy SC, Gonzalez Bosquet J, Zhao Y, Eberhardt NL, Podratz KC, Jiang SW: Epigenetic-mediated upregulation of progesterone receptor B gene in endometrial cancer cell lines. Gynecol Oncol; 2005 Oct;99(1):135-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epigenetic-mediated upregulation of progesterone receptor B gene in endometrial cancer cell lines.
  • OBJECTIVES: To determine if epigenetic interference can restore progesterone receptor-B (PR-B) expression in PR-B negative endometrial adenocarcinoma cell lines, and to characterize the kinetics of PR-B induction mediated by DNA methyltransferase and histone deacetylase inhibitors.
  • METHODS: The PR-B negative endometrioid cancer cell lines KLE and HEC-1B were used as study models.
  • CONCLUSION: The epigenetically silenced PR-B gene remains sensitive to changes in DNA demethylation and histone acetylation in uterine adenocarcinoma cell lines.
  • These small molecule epigenetic modifying agents may be used to sensitize poorly differentiated, PR-B negative endometrial cancers to progestational therapy.
  • [MeSH-major] Adenocarcinoma / genetics. Endometrial Neoplasms / genetics. Receptors, Progesterone / genetics

  • Genetic Alliance. consumer health - Endometrial cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. AZACITIDINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16024066.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Enzyme Inhibitors; 0 / Histone Deacetylase Inhibitors; 0 / Hydroxamic Acids; 0 / RNA, Messenger; 0 / Receptors, Progesterone; 0 / progesterone receptor B; 3X2S926L3Z / trichostatin A; 776B62CQ27 / decitabine; EC 3.5.1.98 / Histone Deacetylases; M801H13NRU / Azacitidine
  •  go-up   go-down


54. Vaidya AP, Horowitz NS, Oliva E, Halpern EF, Duska LR: Uterine malignant mixed mullerian tumors should not be included in studies of endometrial carcinoma. Gynecol Oncol; 2006 Nov;103(2):684-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Uterine malignant mixed mullerian tumors should not be included in studies of endometrial carcinoma.
  • OBJECTIVE: Uterine mixed malignant mullerian tumors (MMMT) have traditionally been excluded from clinical trials of endometrial cancer because of a belief that they are more correctly included in the sarcoma category.
  • Recently, investigators have suggested that uterine MMMTs are actually dedifferentiated epithelial tumors and should be treated as such.
  • The current study was undertaken to compare outcomes, stage for stage, of uterine MMMT with poor prognosis endometrial adenocarcinomas.
  • Cases were matched by age, stage, performance status, and surgical procedure to controls consisting of grade 3 endometrioid, papillary serous, and clear cell endometrial carcinomas from the same time period.
  • Of the controls, 31 (69%) had grade 3 endometrioid, 11 (24%) papillary serous, and 3 (7%) clear cell carcinoma.
  • CONCLUSIONS: Patients with uterine MMMT have a poorer prognosis than those patients with high grade epithelial tumors, especially for those with early stage disease.
  • Given the discrepancy in survival, these patients should not be included in studies of endometrial carcinoma.
  • [MeSH-major] Endometrial Neoplasms / pathology. Endometrial Neoplasms / therapy. Mixed Tumor, Mullerian / pathology. Mixed Tumor, Mullerian / therapy. Uterine Neoplasms / pathology. Uterine Neoplasms / therapy
  • [MeSH-minor] Carcinoma, Endometrioid / pathology. Carcinoma, Endometrioid / therapy. Case-Control Studies. Chemotherapy, Adjuvant. Female. Humans. Neoplasm Staging. Radiotherapy, Adjuvant. Retrospective Studies


55. Liao CL, Hsu JD, Lee MY, Kok LF, Li YJ, Wang PH, Yao CC, Han CP: Distinguishing between primary endocervical and endometrial adenocarcinomas: is a 2-marker (Vim/CEA) panel enough? Virchows Arch; 2010 Apr;456(4):377-86
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Distinguishing between primary endocervical and endometrial adenocarcinomas: is a 2-marker (Vim/CEA) panel enough?
  • Gynecological pathologists are used to operating many panels of various markers in combination for the diagnostic distinction between primary endocervical and endometrial adenocarcinomas.
  • A tissue microarray was constructed using paraffin-embedded, formalin-fixed tissues from 35 hysterectomy specimens, including 14 primary endocervical adenocarcinomas and 21 primary endometrial adenocarcinomas.
  • However, one panel of 2-markers (Vim, CEA) exhibited the most efficiency (78.3%) in the diagnostic distinction between primary endocervical and endometrial adenocarcinomas.
  • Based on the analyzed data, we conclude that the 2-marker (Vim/CEA) panel seems adequate to be an appropriate, convenient, and efficient means to distinguish between primary endocervical and endometrial adenocarcinomas.
  • [MeSH-major] Adenocarcinoma / diagnosis. Biomarkers, Tumor / metabolism. Carcinoembryonic Antigen / metabolism. Endometrial Neoplasms / diagnosis. Uterine Cervical Neoplasms / diagnosis. Vimentin / metabolism
  • [MeSH-minor] Cyclin-Dependent Kinase Inhibitor p16 / metabolism. Diagnosis, Differential. Female. Humans. Immunohistochemistry / methods. Protein Array Analysis / methods. Receptors, Estrogen / metabolism. Receptors, Progesterone / metabolism

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 2004 Jul;28(7):974 [15223971.001]
  • [Cites] Int J Gynecol Pathol. 2002 Jul;21(3):217-23 [12068166.001]
  • [Cites] J Exp Clin Cancer Res. 2008 Aug 02;27:25 [18673574.001]
  • [Cites] Int J Gynecol Pathol. 2002 Jan;21(1):11-5 [11781517.001]
  • [Cites] Int J Gynecol Pathol. 2009 Sep;28(5):489-96 [19696622.001]
  • [Cites] Arch Pathol Lab Med. 2008 Mar;132(3):402-23 [18318583.001]
  • [Cites] Arch Gynecol Obstet. 2009 Sep;280(3):405-13 [19153755.001]
  • [Cites] BMC Clin Pathol. 2006 Jan 12;6:1 [16409624.001]
  • [Cites] Mod Pathol. 2009 Jun;22(6):797-806 [19347018.001]
  • [Cites] Radiology. 2002 May;223(2):410-6 [11997546.001]
  • [Cites] Virchows Arch. 2003 Mar;442(3):271-7 [12647218.001]
  • [Cites] Clin Chem. 1993 Apr;39(4):561-77 [8472349.001]
  • [Cites] Int J Gynecol Pathol. 2003 Jul;22(3):231-5 [12819388.001]
  • [Cites] Virchows Arch. 2009 Oct;455(4):353-61 [19763614.001]
  • [Cites] Mod Pathol. 2006 Aug;19(8):1091-100 [16648864.001]
  • [Cites] Semin Nucl Med. 1978 Oct;8(4):283-98 [112681.001]
  • [Cites] Arch Gynecol Obstet. 2010 May;281(5):845-50 [19847454.001]
  • [Cites] Curr Treat Options Oncol. 2004 Apr;5(2):119-27 [14990206.001]
  • [Cites] Int J Gynecol Pathol. 2008 Jul;27(3):431-6 [18580323.001]
  • [Cites] Adv Anat Pathol. 2004 May;11(3):162-71 [15096730.001]
  • [Cites] J Transl Med. 2008 Jun 17;6:31 [18559092.001]
  • [Cites] Am J Surg Pathol. 2004 Feb;28(2):160-7 [15043304.001]
  • [Cites] Hum Pathol. 1996 Feb;27(2):172-7 [8617459.001]
  • [Cites] J Negat Results Biomed. 2007 Apr 25;6:6 [17459164.001]
  • [Cites] Int J Gynecol Pathol. 2002 Jan;21(1):4-10 [11781516.001]
  • (PMID = 20221633.001).
  • [ISSN] 1432-2307
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Carcinoembryonic Antigen; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone; 0 / Vimentin
  •  go-up   go-down


56. Wang HY, Shen L, Sun Z: [Endometrial adenocarcinoma in women 40 years old or younger by treatment with progestins: report of 6 cases and review of the literatures]. Zhonghua Fu Chan Ke Za Zhi; 2006 Apr;41(4):237-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Endometrial adenocarcinoma in women 40 years old or younger by treatment with progestins: report of 6 cases and review of the literatures].
  • OBJECTIVE: To evaluate the effectiveness and safety of fertility-sparing treatment with progestins in patients with well-differentiated endometrial adenocarcinoma in women 40 years old or younger.
  • METHODS: Six patients before the age of 40 diagnosed with grade I endometrial adenocarcinoma, who had undergone primary progestin treatment, were retrospectively studied.
  • Relevant articles describing patients with endometrial adenocarcinoma who were treated with hormonal therapy were searched.
  • RESULTS: Four of six cases responded to treatment with normal pathology on follow-up endometrial samplings.
  • CONCLUSIONS: Progestin treatment is proved a safe and feasible therapy in well-differentiated endometrial adenocarcinoma in women 40 years old or younger.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Agents, Hormonal / therapeutic use. Endometrial Neoplasms / drug therapy. Progestins / therapeutic use

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16759457.001).
  • [ISSN] 0529-567X
  • [Journal-full-title] Zhonghua fu chan ke za zhi
  • [ISO-abbreviation] Zhonghua Fu Chan Ke Za Zhi
  • [Language] chi
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Progestins
  • [Number-of-references] 22
  •  go-up   go-down


57. Qian J, Weber D, Cochran R, Hossain D, Bostwick DG: Detection of chromosomal anomalies in endometrial atypical hyperplasia and carcinoma by using fluorescence in situ hybridization. Cancer Cytopathol; 2010 Apr 25;118(2):97-104
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of chromosomal anomalies in endometrial atypical hyperplasia and carcinoma by using fluorescence in situ hybridization.
  • BACKGROUND: Endometrial cancer is the most common pelvic gynecological malignancy.
  • The diagnosis of well-differentiated endometrial adenocarcinoma, atypical hyperplasia, and hyperplasia is often challenging.
  • The authors sought to investigate the utility of chromosomal anomalies for the detection of endometrial hyperplasia and carcinoma using multitarget fluorescence in situ hybridization (FISH).
  • METHODS: Samples were collected by endometrial Tao brush and processed by liquid-based cytological preparation protocol from consecutive cases to include 50 benign, 50 hyperplasia without atypia, 47 atypical hyperplasia, and 53 endometrial cancers.
  • The FISH signals were enumerated in 100 cells per case, and the chromosomal anomalies were correlated with pathologic findings, including histologic diagnoses on matched endometrial tissue samples.
  • RESULTS: Numeric chromosomal anomalies were found in 0% (0 of 50) of benign, 20% (10 of 50) of hyperplasia, 74% (35 of 47) of atypical hyperplasia, and 87% (46 of 53) of carcinoma specimens.
  • The mean percentage of cells with chromosomal changes was 55% in cancer specimens, which was significantly higher than that in hyperplasia without atypia (13%, P < .0001) and atypical hyperplasia (32%, P = .003).
  • FISH anomalies had an overall sensitivity of 81% and specificity of 90% for the detection of atypical hyperplasia and/or endometrial carcinoma.
  • There was no association with grade of endometrial carcinoma.
  • CONCLUSIONS: Multitarget FISH appears to be useful for the differential diagnosis of hyperplasia, atypical hyperplasia, and endometrial adenocarcinoma, with a high level of sensitivity and specificity.
  • It is also a potential tool for the early detection of neoplastic cells in endometrial cytology specimens.
  • Endometrial hyperplasia with FISH-detected chromosomal anomalies may represent a clinically significant subset of cases that warrant close clinical follow-up.
  • [MeSH-major] Adenocarcinoma / genetics. Chromosome Aberrations. Endometrial Hyperplasia / genetics. Endometrial Neoplasms / genetics. In Situ Hybridization, Fluorescence

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2010 American Cancer Society.
  • (PMID = 20225199.001).
  • [ISSN] 1934-662X
  • [Journal-full-title] Cancer cytopathology
  • [ISO-abbreviation] Cancer Cytopathol
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


58. Czeczuga-Semeniuk E, Wołczyński S: Dietary carotenoids in normal and pathological tissues of corpus uteri. Folia Histochem Cytobiol; 2008;46(3):283-90
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Carotenoids and retinyl esters are the source of vitamin A in the human body and its natural derivatives takes part in the regulation of cell replication and differentiation in the human endometrium, may induce the leiomyoma growth and has a role in differentiation of endometrial adenocarcinoma.
  • The aim of the study was to demonstrate the presence of carotenoids in tissues from the normal uterus and from various tumors of the uterine corpus, as well as to compare the total content, major carotenoids and % of carotenoids belonging to the provitamin A group between the tissues examined.
  • In normal tissues, the mean carotenoid content was the highest in the follicular phase endometrium (9.9 microg/g), while the highest percentage of carotenoids belonging to provitamin A group was found in the luteal phase (18.2%).
  • In the pathological group, the highest mean values were demonstrated for epithelial lesions (8.0 microg/g), and within this group - in endometrioid adenocarcinoma (10.8 microg/g).
  • We have demonstrated that all uterine tissues show a concentration of beta-carotene and beta-cryptoxanthin, being the source of vitamin A.
  • The highest total values of carotenoids obtained in the group of endometrioid adenocarcinoma seem to confirm certain enzymatic defects in carotenoid metabolism in the course of the neoplastic process or some metabolic modifications.

  • MedlinePlus Health Information. consumer health - Antioxidants.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • Hazardous Substances Data Bank. BETA-CAROTENE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19056531.001).
  • [ISSN] 1897-5631
  • [Journal-full-title] Folia histochemica et cytobiologica
  • [ISO-abbreviation] Folia Histochem. Cytobiol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Antioxidants; 0 / Cryptoxanthins; 0 / Xanthophylls; 01YAE03M7J / beta Carotene; 36-88-4 / Carotenoids; 51C926029A / violaxanthin; KK8M5T48AI / neoxanthin; X72A60C9MT / Lutein
  •  go-up   go-down


59. Schnatz PF, Guile M, O'Sullivan DM, Sorosky JI: Clinical significance of atypical glandular cells on cervical cytology. Obstet Gynecol; 2006 Mar;107(3):701-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • These data showed the following rates of pathology: 8.5% low-grade squamous intraepithelial lesions (LSIL), 11.1% high-grade squamous intraepithelial lesions (HSIL), 2.9% adenocarcinoma in situ, 1.4% endometrial hyperplasia, and 5.2% malignancy.
  • The most common malignancies were endometrial adenocarcinoma (57.6%), cervical adenocarcinoma (23.6%), ovarian and fallopian tube carcinoma (6.4%), squamous cell carcinoma of the cervix (5.4%), and other (6.9%).
  • CONCLUSION: Histologic diagnosis showed that 29.0% of these Pap tests had findings requiring follow-up or therapeutic intervention, including a 5.2% rate of malignancy.
  • Based on these findings, 99.6% of the diagnoses are within the region of surveillance when AGUS Pap tests are evaluated with colposcopy and directed biopsy, endocervical curettage, an endometrial biopsy in patients with risk factors for endometrial cancer, and pelvic examination.
  • [MeSH-major] Adenocarcinoma / pathology. Cervical Intraepithelial Neoplasia / pathology. Cervix Uteri / pathology. Endometrial Hyperplasia / pathology. Uterine Cervical Neoplasms / pathology


60. Ioachin E: Immunohistochemical tumour markers in endometrial carcinoma. Eur J Gynaecol Oncol; 2005;26(4):363-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical tumour markers in endometrial carcinoma.
  • Endometrial adenocarcinoma is the most common malignant neoplasm of the female genital tract and, despite its relative frequency, the molecular events that contribute to the development and progression of the lesion remain poorly understood.
  • The normal human endometrium is characterized by hormone-dependent variations during the menstrual cycle.
  • This tightly controlled system is disturbed in endometrial hyperplasia and carcinomas and a series of changes initiate and promote progression towards the malignant phenotype.
  • Immunohistochemical expression of different biomarkers such as hormone receptor status (ER, PR), proliferation associated indices (PCNA, MIB1), oncogene (c-erbB-2), tumour suppressor gene products (pRb, p53 protein), cell cycle related proteins (cyclin D1, cyclin E, p21/WAF1), anti-apoptotic protein (bcl-2), adhesion molecule (CD44s), proteolytic enzyme (cathepsin D), heat shock protein (hsp27) and metallothionein (MT) has shown the contribution of these molecules to endometrial carcinogenesis in a hormone-dependent or independent manner as an early or late event.
  • In addition, these biomarkers seem to be correlated with tumour differentiation or myometrial invasion, and therefore could be considered as indicators of the biological behaviour of endometrial carcinoma.
  • Furthermore, the interrelationships of these molecular markers show that these genetic dysregulations could be implicated in the control of cell proliferation and differentiation, and thereby in the multistep process of endometrial carcinogenesis.
  • [MeSH-major] Adenocarcinoma / diagnosis. Biomarkers, Tumor. Endometrial Neoplasms / diagnosis


61. Vinci A, Bacci B, Benazzi C, Caldin M, Sarli G: Progesterone receptor expression and proliferative activity in uterine tumours of pet rabbits. J Comp Pathol; 2010 May;142(4):323-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Progesterone receptor expression and proliferative activity in uterine tumours of pet rabbits.
  • Endometrial adenocarcinoma is the most common uterine tumour of domestic rabbits.
  • The present immunohistochemical study examined the expression of cytokeratin 19 (CK19), the progesterone receptor (PR), the proliferation-associated antigen Ki-67 and telomerase in normal rabbit uterine tissue and examples of endometrial hyperplasia, adenoma and adenocarcinoma.
  • Tubulopapillary adenomas and adenocarcinomas were the most common histological subtypes in this series.
  • Cytoplasmic expression of CK19 was recorded in two of three samples of normal endometrium and in one of three samples of endometrial hyperplasia, in all adenomas and five of six adenocarcinomas.
  • PR was expressed within the nucleus of normal endometrial cells and in one of three samples of endometrial hyperplasia, each of four adenomas and in four of six adenocarcinomas.
  • This finding suggests that PR expression is not directly involved in neoplastic transformation of the endometrium and that such expression is not a prognostic indicator.
  • Nuclear labelling of telomerase activity was found in one of three normal uteri, all samples of endometrial hyperplasia, two of four adenomas, but none of the adenocarcinomas.
  • The proliferation index as determined by Ki-67 expression was 9.7+/-2.75% (mean+/- standard-deviation (SD)) for normal endometrium, 11.29+/-2.5% for hyperplastic endometrium, 19.40+/-3.01% for benign tumours and 19.41+/-7.9% for malignant tumours.
  • These findings may be interpreted to suggest that hormonal and anti-proliferative treatment may be more appropriate for the management of uterine carcinomas in rabbits than anti-telomerase treatment.
  • [MeSH-major] Endometrial Hyperplasia / metabolism. Endometrial Neoplasms / metabolism. Endometrial Neoplasms / pathology. Receptors, Progesterone / metabolism
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Adenoma / metabolism. Adenoma / pathology. Animals. Cell Nucleus / metabolism. Cell Nucleus / pathology. Cell Transformation, Neoplastic / metabolism. Cell Transformation, Neoplastic / pathology. Endometrium / metabolism. Endometrium / pathology. Female. Ki-67 Antigen / metabolism. Mitotic Index. Progesterone / metabolism. Prognosis. Rabbits. Telomerase / metabolism. Uterine Neoplasms / metabolism. Uterine Neoplasms / pathology

  • Hazardous Substances Data Bank. PROGESTERONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Elsevier Ltd. All rights reserved.
  • (PMID = 20096851.001).
  • [ISSN] 1532-3129
  • [Journal-full-title] Journal of comparative pathology
  • [ISO-abbreviation] J. Comp. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Ki-67 Antigen; 0 / Receptors, Progesterone; 4G7DS2Q64Y / Progesterone; EC 2.7.7.49 / Telomerase
  •  go-up   go-down


62. Golbar H, Izawa T, Kuwamura M, Ito S, Yamate J: Uterine adenocarcinoma with prominent desmoplasia in a geriatric miniature pig. J Vet Med Sci; 2010 Feb;72(2):253-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Uterine adenocarcinoma with prominent desmoplasia in a geriatric miniature pig.
  • Grossly, neoplastic enlargement of the uterus was found.
  • Based on these findings, a diagnosis of uterine adenocarcinoma with marked desmoplasia was made.
  • This case is the second report of uterine adenocarcinoma in the miniature pig.

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19942805.001).
  • [ISSN] 0916-7250
  • [Journal-full-title] The Journal of veterinary medical science
  • [ISO-abbreviation] J. Vet. Med. Sci.
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


63. Huang YD, Hung YC, Yeh LS, Chiang IP, Zeng GC, Chang WC: Synchronous ovarian endometrioid adenocarcinoma and endocervical mucinous adenocarcinoma. Taiwan J Obstet Gynecol; 2006 Sep;45(3):264-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Synchronous ovarian endometrioid adenocarcinoma and endocervical mucinous adenocarcinoma.
  • OBJECTIVE: We report a rare case of synchronous cancer consisting of ovarian endometrioid adenocarcinoma and endocervical mucinous adenocarcinoma.
  • Cytology of the pleural effusion showed no malignant cells.
  • Histology showed moderately to poorly differentiated endometrioid adenocarcinoma of the right ovary with extensive lymphovascular permeation, as well as paraaortic and bilateral pelvic lymph node metastases.
  • Extensive tumor thrombi were observed in the lymphovascular channels of the left ovary, bilateral tubes and uterus.
  • Endocervical adenocarcinoma, < 3 mm in depth, was also identified on the cervix.
  • The final surgical-pathologic stage of ovarian endometrioid adenocarcinoma was stage IIIc and of endocervical mucinous adenocarcinoma was stage IA1.
  • Diagnosis should be based on histologic examination and requires appropriate treatment for both tumors.
  • [MeSH-major] Adenocarcinoma, Mucinous / epidemiology. Carcinoma, Endometrioid / epidemiology. Neoplasms, Multiple Primary / pathology. Ovarian Neoplasms / epidemiology. Uterine Cervical Neoplasms / epidemiology


64. Ackerman I: Adjuvant pelvic radiation therapy in endometrial cancer: The pro argument. Int J Gynecol Cancer; 2010 Oct;20(11 Suppl 2):S67-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant pelvic radiation therapy in endometrial cancer: The pro argument.
  • Adjuvant external beam pelvic radiation therapy for stage I endometrial cancer has become increasingly confusing and controversial.
  • By using evidence from the literature, including the most recent randomized data, an argument is made for the use of external beam pelvic radiotherapy for a 63-year-old woman who has undergone a total abdominal hysterectomy and bilateral salpingo-oophorectomy for a grade 2 endometrioid adenocarcinoma of the uterus with 9 of 12 mm of invasion and the presence of lymphovascular space involvement.
  • [MeSH-major] Carcinoma, Endometrioid / prevention & control. Carcinoma, Endometrioid / radiotherapy. Endometrial Neoplasms / prevention & control. Endometrial Neoplasms / radiotherapy. Neoplasm Recurrence, Local / prevention & control

  • Genetic Alliance. consumer health - Endometrial cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21053530.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  •  go-up   go-down


65. Uchida H, Maruyama T, Nagashima T, Asada H, Yoshimura Y: Histone deacetylase inhibitors induce differentiation of human endometrial adenocarcinoma cells through up-regulation of glycodelin. Endocrinology; 2005 Dec;146(12):5365-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histone deacetylase inhibitors induce differentiation of human endometrial adenocarcinoma cells through up-regulation of glycodelin.
  • In human endometrium, postovulatory production of progesterone directs estrogen-primed endometrial glandular cells to differentiate and thereby produce a number of unique bioactive substances, including glycodelin, that are critical for implantation at the secretory phase of the menstrual cycle.
  • In this study, we show that TSA and SAHA, belonging to the hydroxamic acid group of HDACIs, can induce the phenotype of a human endometrial adenocarcinoma cell line, Ishikawa (originally derived from the glandular component of the endometrium), to differentiate to closely resemble normal endometrial epithelium in a time- and dose-dependent manner, as determined by morphological changes, synthesis of glycogen, and expression of secretory phase-specific proteins, including glycodelin.
  • Furthermore, the gene silencing of glycodelin by small interference RNA resulted in the blockade of HDACI-induced differentiation in Ishikawa cells, suggesting the requirement for glycodelin for endometrial epithelial differentiation.
  • Our results collectively indicate that TSA and SAHA are potent differentiation inducers for endometrial glandular cells, providing a clue for a possible therapeutic strategy to modulate endometrial function by targeting glycodelin.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Endometrial Neoplasms / metabolism. Endometrial Neoplasms / pathology. Enzyme Inhibitors / pharmacology. Glycoproteins / metabolism. Histone Deacetylase Inhibitors. Pregnancy Proteins / metabolism

  • Hazardous Substances Data Bank. Vorinostat .
  • Hazardous Substances Data Bank. ESTRADIOL .
  • Hazardous Substances Data Bank. PROGESTERONE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16123169.001).
  • [ISSN] 0013-7227
  • [Journal-full-title] Endocrinology
  • [ISO-abbreviation] Endocrinology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Enzyme Inhibitors; 0 / Glycoproteins; 0 / Histone Deacetylase Inhibitors; 0 / Hydroxamic Acids; 0 / Interleukin-6; 0 / LIF protein, human; 0 / Leukemia Inhibitory Factor; 0 / PAEP protein, human; 0 / Pregnancy Proteins; 0 / RNA, Messenger; 0 / RNA, Small Interfering; 3X2S926L3Z / trichostatin A; 4G7DS2Q64Y / Progesterone; 4TI98Z838E / Estradiol; 58IFB293JI / vorinostat; 9005-79-2 / Glycogen
  •  go-up   go-down


66. Zhang SQ, Cai B, Liu L, He YY, Yang YX, Wan XP: Kallikrein 4 overexpression in endometrial carcinoma and upregulation by estrogen via mitogen-activated protein kinase signal pathway. Int J Gynecol Cancer; 2009 Nov;19(8):1377-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Kallikrein 4 overexpression in endometrial carcinoma and upregulation by estrogen via mitogen-activated protein kinase signal pathway.
  • OBJECTIVE: The aim of this study was to investigate the expression of kallikrein 4 (KLK4) and the potential signal pathway through which estrogen up-regulates KLK4 in endometrial cancer.
  • METHODS: The expression of KLK4 was analyzed in 15 human normal endometrium, 13 hyperplasia endometrium, and 68 endometrioid adenocarcinoma by immunohistochemistry.
  • After exposure to 17beta-estradiol and/or to the mitogen-activated protein kinase (MAPK) inhibitor U0126 and to the PI3K inhibitor LY294002, the expression of KLK4 in the endometrial cancer cell lines KLE and RL95-2 was detected with quantitative reverse transcriptase polymerase chain reaction (qRT-PCR) and Western blot.
  • RESULTS: The expression of KLK4 protein was higher in endometroid endometrial cancer than in hyperplasia or normal endometrium (P < 0.001).
  • Immunohistochemical staining revealed that 92.6% (63/68) of endometrial adenocarcinoma, 61.5% (8/13) of hyperplasia endometrium, and 26.7% (4/15) of normal endometrium were positive for KLK4 protein.
  • Quantitative reverse transcriptase PCR and Western blot analysis showed that estrogen can up-regulate the expression of KLK4 in endometrial cancer cell lines KLE and RL95-2, and the up-regulation effect of 17beta-estradiol on KLK4 can be inhibited by U0126 in the 2 endometrial cancer cell lines but not by LY294002.
  • CONCLUSIONS: Kallikrein 4 is a new nuclear protein, and estrogen up-regulates the expression of KLK4 by activating the MAPK pathway in endometrial cancer cell lines, which may play an important role in the development of endometrial cancer.
  • [MeSH-major] Carcinoma, Endometrioid / metabolism. Endometrial Hyperplasia / metabolism. Endometrial Neoplasms / metabolism. Endometrium / metabolism. Estradiol / pharmacology. Kallikreins / metabolism. Mitogen-Activated Protein Kinases / metabolism

  • Hazardous Substances Data Bank. ESTRADIOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20009893.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Messenger; 4TI98Z838E / Estradiol; EC 2.7.11.24 / Mitogen-Activated Protein Kinases; EC 3.4.21.- / Kallikreins; EC 3.4.21.- / kallikrein 4
  •  go-up   go-down


67. Hahn HS, Yoon SG, Hong JS, Hong SR, Park SJ, Lim JY, Kwon YS, Lee IH, Lim KT, Lee KH, Shim JU, Mok JE, Kim TJ: Conservative treatment with progestin and pregnancy outcomes in endometrial cancer. Int J Gynecol Cancer; 2009 Aug;19(6):1068-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Conservative treatment with progestin and pregnancy outcomes in endometrial cancer.
  • INTRODUCTION: The purpose of this study was to evaluate the efficacy of conservative treatment with progestin and pregnancy outcomes in women with early-stage endometrial cancer.
  • METHODS: We retrospectively analyzed the medical records of 35 patients with endometrial adenocarcinoma, who were treated with progestin from January 1996 to December 2006.
  • Women with early-stage grade 1 endometrioid endometrial adenocarcinoma, who wanted to receive conservative treatment or preserve fertility, were included.
  • Complete remission (CR) was defined as no evidence of endometrial adenocarcinoma or hyperplasia.
  • Partial remission was diagnosed when the patient developed endometrial hyperplasia, and persistent disease was defined as residual endometrial adenocarcinoma by pathologic confirmation.
  • CONCLUSIONS: Conservative treatment with progestin can be considered a good therapeutic option in patients with well-differentiated early-stage endometrioid endometrial adenocarcinoma who wish to preserve their uteri or become pregnant.
  • [MeSH-major] Carcinoma, Endometrioid / drug therapy. Carcinoma, Endometrioid / rehabilitation. Endometrial Neoplasms / drug therapy. Endometrial Neoplasms / rehabilitation. Pregnancy Outcome. Progestins / therapeutic use

  • Genetic Alliance. consumer health - Pregnancy.
  • Genetic Alliance. consumer health - Endometrial cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19820370.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Progestins; C2QI4IOI2G / Medroxyprogesterone Acetate; TJ2M0FR8ES / Megestrol Acetate
  •  go-up   go-down


68. Papanas N, Giatromanolaki A, Galazios G, Maltezos E, Sivridis E: Endometrial carcinoma and diabetes revisited. Eur J Gynaecol Oncol; 2006;27(5):505-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endometrial carcinoma and diabetes revisited.
  • OBJECTIVE: To investigate whether endometrial adenocarcinomas are intrinsically different in diabetic as compared to non-diabetic patients.
  • METHODS: A series of 208 patients with histologically confirmed endometrial adenocarcinomas were divided into groups of diabetic (n = 63) and non-diabetic (n = 145) patients.
  • RESULTS: A history of a second neoplasia was significantly more frequent in diabetic than in non-diabetic patients (p = 0.001), but other endometrial cancer associated characteristics, such as tumor morphology, FIGO stage, obesity, hypertension, nulliparity, estrogen use and menopausal status did not differ between the groups.
  • CONCLUSIONS: A second neoplasia occurred significantly more frequently in diabetic than in non-diabetic patients with endometrial carcinoma, but long-term survival and other clinical and histological features were the same in the two groups.
  • These results indicate that endometrial adenocarcinoma is not intrinsically different in diabetic patients.
  • [MeSH-major] Adenocarcinoma / complications. Diabetes Complications. Endometrial Neoplasms / complications. Neoplasms, Second Primary / epidemiology

  • Genetic Alliance. consumer health - Diabetes.
  • MedlinePlus Health Information. consumer health - Diabetes Complications.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17139988.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


69. Bellone S, Shah HR, McKenney JK, Stone PJ, Santin AD: Recurrent endometrial carcinoma regression with the use of the aromatase inhibitor anastrozole. Am J Obstet Gynecol; 2008 Sep;199(3):e7-e10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrent endometrial carcinoma regression with the use of the aromatase inhibitor anastrozole.
  • Recurrent/metastatic endometrial adenocarcinoma that is not amenable to cure with local or regional therapy and/or chemotherapy represents a discouraging clinical entity for the clinician.
  • We report the case of 58-year-old woman with recurrent endometrial carcinoma that was resistant to chemotherapy that was treated successfully with the aromatase inhibitor anastrozole.
  • [MeSH-major] Adenocarcinoma / drug therapy. Aromatase Inhibitors / therapeutic use. Endometrial Neoplasms / drug therapy. Neoplasm Recurrence, Local / drug therapy. Nitriles / therapeutic use. Triazoles / therapeutic use

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ANASTROZOLE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18550023.001).
  • [ISSN] 1097-6868
  • [Journal-full-title] American journal of obstetrics and gynecology
  • [ISO-abbreviation] Am. J. Obstet. Gynecol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Aromatase Inhibitors; 0 / Nitriles; 0 / Receptors, Estrogen; 0 / Triazoles; 2Z07MYW1AZ / anastrozole
  •  go-up   go-down


70. Karlsson S, Olsson B, Klinga-Levan K: Gene expression profiling predicts a three-gene expression signature of endometrial adenocarcinoma in a rat model. Cancer Cell Int; 2009;9:12
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gene expression profiling predicts a three-gene expression signature of endometrial adenocarcinoma in a rat model.
  • BACKGROUND: In the Western world, endometrial cancers are the most common gynaecological neoplastic disorders among women.
  • The objective of this work was to identify a gene expression signature specific for endometrial adenocarcinomas to be used for testing potential endometrial biomarkers.
  • RESULTS: Changes in expression between endometrial adenocarcinomas and non-/pre-malignant endometrium from the BDII EAC rat model were compared in cDNA microarray assays.
  • CONCLUSION: Taken together, we present a unique data set of genes with different expression patterns between EACs and non-/pre-malignant endometrium, and specifically we found three genes that were confirmed in two independent analyses.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Respir Cell Mol Biol. 2008 Jan;38(1):95-104 [17673689.001]
  • [Cites] Gastroenterology. 2001 Sep;121(3):657-67 [11522750.001]
  • [Cites] Cancer Genet Cytogenet. 2007 Aug;177(1):43-50 [17693190.001]
  • [Cites] J Biol Chem. 2007 Feb 16;282(7):4794-802 [17150964.001]
  • [Cites] Neoplasia. 2005 Sep;7(9):854-61 [16229808.001]
  • [Cites] Gynecol Oncol. 2005 Sep;98(3):427-33 [15993480.001]
  • [Cites] Cancer Res. 2005 May 15;65(10):4218-27 [15899813.001]
  • [Cites] Cancer Genet Cytogenet. 2005 Apr 15;158(2):137-41 [15796960.001]
  • [Cites] Semin Reprod Endocrinol. 1999;17(1):73-92 [10406078.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1996 Jun;5(6):411-7 [8781735.001]
  • [Cites] J Natl Cancer Inst. 1987 Jun;78(6):1245-51 [3473261.001]
  • [Cites] Z Versuchstierkd. 1987;30(5-6):209-16 [3445711.001]
  • [Cites] Gynecol Oncol. 1983 Feb;15(1):10-7 [6822361.001]
  • [Cites] Bioinformatics. 2004 Oct 12;20(15):2479-81 [15073010.001]
  • [Cites] Hum Pathol. 2004 Jun;35(6):649-62 [15188130.001]
  • [Cites] Genome Biol. 2003;4(5):P3 [12734009.001]
  • [Cites] Endocr Relat Cancer. 2003 Mar;10(1):23-42 [12653669.001]
  • [Cites] Genome Biol. 2002 Jul 15;3(8):SOFTWARE0003 [12186655.001]
  • [Cites] Cancer Res. 2002 May 15;62(10):2778-90 [12019154.001]
  • [Cites] Int J Cancer. 2001 Dec 15;94(6):795-9 [11745480.001]
  • [Cites] Cancer Res. 2007 Sep 1;67(17):8043-50 [17804715.001]
  • (PMID = 19426485.001).
  • [ISSN] 1475-2867
  • [Journal-full-title] Cancer cell international
  • [ISO-abbreviation] Cancer Cell Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2687412
  •  go-up   go-down


71. Yoshida M, Watanabe G, Shirota M, Maekawa A, Taya K: Reduction of primordial follicles caused by maternal treatment with busulfan promotes endometrial adenocarcinoma development in donryu rats. J Reprod Dev; 2005 Dec;51(6):707-14
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reduction of primordial follicles caused by maternal treatment with busulfan promotes endometrial adenocarcinoma development in donryu rats.
  • Ovarian dysfunction leading to hormonal imbalance plays a crucial role in uterine carcinogenesis in rats as well as women.
  • However, the effects of a reduction in primordial follicles at birth on uterine adenocarcinoma development have hitherto not been determined.
  • The present study was therefore conducted using female Donryu rats, a high incidence rat strain of uterine adenocarcinoma.
  • The incidence of uterine adenocarcinomas and multiplicity of uterine neoplastic lesions were significantly increased by the 5.0 mg/kg, but not the 2.5 mg/kg busulfan treatment.
  • These results provide evidence that the reduction of primordial follicles promotes uterine adenocarcinoma development in rats in association with an earlier occurrence of the persistent estrus status.
  • [MeSH-major] Adenocarcinoma / etiology. Antineoplastic Agents, Alkylating / pharmacology. Busulfan / pharmacology. Endometrial Neoplasms / etiology. Ovarian Diseases / chemically induced. Ovarian Follicle / drug effects

  • MedlinePlus Health Information. consumer health - Ovarian Disorders.
  • Hazardous Substances Data Bank. BUSULFAN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16177545.001).
  • [ISSN] 0916-8818
  • [Journal-full-title] The Journal of reproduction and development
  • [ISO-abbreviation] J. Reprod. Dev.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Gonadal Steroid Hormones; G1LN9045DK / Busulfan
  •  go-up   go-down


72. Işin Doğan Ekici A, Küçükali T, Coşkun Salman M, Ayhan A: Triple simultaneous primary gynecological malignancies in a 56-year-old patient. Int J Gynecol Cancer; 2006 Sep-Oct;16(5):1947-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this report, the clinical and pathologic findings of a 56-year-old female patient with synchronous triple primary gynecological cancers including well-differentiated ovarian mucinous cystadenocarcinoma, well-differentiated endometrial endometrioid adenocarcinoma, and uterine leiomyosarcoma were presented.
  • Synchronous primary, well-differentiated endometrial endometrioid adenocarcinoma and leiomyosarcoma of uterus without any ovarian neoplasm has only been once described in the English literature.
  • To our knowledge, the presented patient is the first case in aspect of accompanying ovarian mucinous adenocarcinoma to endometrial endometrioid adenocarcinoma and leiomyosarcoma of uterus.
  • [MeSH-major] Carcinoma, Endometrioid / pathology. Cystadenocarcinoma, Mucinous / pathology. Leiomyosarcoma / pathology. Neoplasms, Multiple Primary / pathology. Ovarian Neoplasms / pathology. Uterine Neoplasms / pathology
  • [MeSH-minor] Endometrium / pathology. Female. Humans. Middle Aged. Myometrium / pathology. Ovary / pathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17009998.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


73. Mao TL, Kurman RJ, Jeng YM, Huang W, Shih IeM: HSD3B1 as a novel trophoblast-associated marker that assists in the differential diagnosis of trophoblastic tumors and tumorlike lesions. Am J Surg Pathol; 2008 Feb;32(2):236-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HSD3B1 as a novel trophoblast-associated marker that assists in the differential diagnosis of trophoblastic tumors and tumorlike lesions.
  • Trophoblastic tumors and tumorlike lesions can be confused with a variety of nontrophoblastic tumors; therefore, a trophoblast-associated marker that is expressed in all types of trophoblastic lesions is useful in differential diagnosis.
  • First, the gene expression profile of HSD3B1 was analyzed in silica using serial analysis of gene expression in the database deposited in the public domain and found that HSD3B1 was not expressed in 159 libraries of breast, lung, colorectal, pancreatic, ovarian carcinomas, and a wide variety of normal adult and fetal tissues.
  • In contrast, only 3 (<1%) of 319 nontrophoblastic carcinomas from the uterus, lung, and breast reacted with the HSD3B1 antibody.
  • In conclusion, as compared with other trophoblastic markers, HSD3B1 is highly specific and sensitive, being expressed in all types of trophoblastic lesions but not in a variety of nontrophoblastic tumors of the uterus, lung, and breast.
  • [MeSH-major] 3-Hydroxysteroid Dehydrogenases / metabolism. Biomarkers, Tumor / metabolism. Placenta Diseases / diagnosis. Trophoblastic Neoplasms / diagnosis. Trophoblasts / pathology. Uterine Neoplasms / diagnosis
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adult. Blotting, Western. Diagnosis, Differential. Female. Gene Expression. Humans. Male. Pregnancy

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • COS Scholar Universe. author profiles.
  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18223326.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 1.1.- / 3-Hydroxysteroid Dehydrogenases
  •  go-up   go-down


74. Temkin SM, Pezzullo JC, Hellmann M, Lee YC, Abulafia O: Is body mass index an independent risk factor of survival among patients with endometrial cancer? Am J Clin Oncol; 2007 Feb;30(1):8-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is body mass index an independent risk factor of survival among patients with endometrial cancer?
  • OBJECTIVE: To evaluate whether body mass index (BMI) is an independent risk factor for survival in patients with endometrial adenocarcinoma.
  • METHODS: Women treated for endometrial cancer at the State University of New York (SUNY), Downstate and Kings County Hospital between January 1982 and September 2003 were eligible.
  • Patients were divided into groups based upon their histology at the time of diagnosis.
  • The first included patients with low-grade endometrioid adenocarcinoma (FIGO grades 1 and 2); the second included grade 3 endometrioid adenocarcinoma; and the third contained papillary serous and clear cell carcinomas.
  • There were 312 patients (70%) treated for low-grade endometrial adenocarcinoma; 64 patients (14%) for grade 3 endometrioid adenocarcinoma; and 71 patients (16%) for papillary serous and clear cell adenocarcinoma.
  • BMI was also correlated to tumor grade, stage at diagnosis, age, and race.
  • Statistical analyses revealed the majority of the association between BMI and survival can be attributed to the association between BMI and these other risk factors for survival in endometrial cancer.
  • CONCLUSIONS: Increased BMI is associated with survival advantage among patients with endometrial cancer.
  • [MeSH-major] Adenocarcinoma / physiopathology. Body Mass Index. Endometrial Neoplasms / physiopathology

  • Genetic Alliance. consumer health - Endometrial cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17278888.001).
  • [ISSN] 1537-453X
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


75. Contreras CM, Gurumurthy S, Haynie JM, Shirley LJ, Akbay EA, Wingo SN, Schorge JO, Broaddus RR, Wong KK, Bardeesy N, Castrillon DH: Loss of Lkb1 provokes highly invasive endometrial adenocarcinomas. Cancer Res; 2008 Feb 1;68(3):759-66
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Loss of Lkb1 provokes highly invasive endometrial adenocarcinomas.
  • Mutations in the LKB1 tumor suppressor gene result in the Peutz-Jeghers syndrome, an autosomal dominant condition characterized by hamartomatous polyps of the gastrointestinal tract and a dramatically increased risk of epithelial malignancies at other sites, including the female reproductive tract.
  • Here we show that female mice heterozygous for a null Lkb1 allele spontaneously develop highly invasive endometrial adenocarcinomas.
  • To prove that these lesions were indeed due to Lkb1 inactivation, we introduced an adenoviral Cre vector into the uterine lumen of mice harboring a conditional allele of Lkb1.
  • This endometrial-specific deletion of the Lkb1 gene provoked highly invasive and sometimes metastatic endometrial adenocarcinomas closely resembling those observed in Lkb1 heterozygotes.
  • Although Lkb1 has been implicated in the establishment of cell polarity, and loss of polarity defines most endometrial cancers, Lkb1-driven endometrial cancers paradoxically exhibit (given their highly invasive phenotype) normal cell polarity and apical differentiation.
  • In human endometrial cancers, Lkb1 expression was inversely correlated with tumor grade and stage, arguing that Lkb1 inactivation or down-regulation also contributes to endometrial cancer progression in women.
  • This study shows that Lkb1 plays an important role in the malignant transformation of endometrium and that Lkb1 loss promotes a highly invasive phenotype.
  • [MeSH-major] Adenocarcinoma / genetics. Cell Transformation, Neoplastic / genetics. Endometrial Neoplasms / genetics. Protein-Serine-Threonine Kinases / deficiency

  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18245476.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 1P50CA098258-01; United States / NCRR NIH HHS / RR / K26RR024196
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Multienzyme Complexes; EC 2.7.1.- / STK11 protein, human; EC 2.7.11.1 / AMP-Activated Protein Kinases; EC 2.7.11.1 / Protein-Serine-Threonine Kinases
  •  go-up   go-down


76. Ai Z, Yin L, Zhou X, Zhu Y, Zhu D, Yu Y, Feng Y: Inhibition of survivin reduces cell proliferation and induces apoptosis in human endometrial cancer. Cancer; 2006 Aug 15;107(4):746-56
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inhibition of survivin reduces cell proliferation and induces apoptosis in human endometrial cancer.
  • BACKGROUND: Endometrial cancer is a common gynecologic malignancy among women.
  • The molecular mechanisms involved in the progression of endometrial cancer are unclear, which has hampered the development of an effective treatment.
  • METHODS: Survivin mRNA and protein expression levels were analyzed in human normal cycling endometrium, atypical endometrium, and endometrial adenocarcinoma by immunohistochemical, reverse-transcriptase polymerase chain reaction (RT-PCR), and Western blot analyses.
  • To study the biological function of survivin in endometrial cancer, RNA interference was applied to knock down survivin expression in the Ishikawa endometrial cancer cell line by recombinant plasmids producing survivin small hairpin RNA.
  • RESULTS: Higher levels of survivin mRNA and protein expression were observed in endometrial adenocarcinomas than in atypical or normal endometrium.
  • Immunohistochemical staining revealed that 83.3% (50 of 60) of endometrial adenocarcinoma samples, 55.0% (11 of 20) of atypical endometrium samples, and 25.0% (5 of 20) of normal endometrium samples were positive for survivin protein.
  • Epidermal growth factor (EGF) and transforming growth factor-alpha (TGF-alpha) upregulated survivin protein expression by activating the MAPK pathway in endometrial cancer cells.
  • CONCLUSIONS: Survivin is an attractive target for endometrial cancer treatment.
  • [MeSH-major] Adenocarcinoma / pathology. Apoptosis. Cell Proliferation. Endometrial Neoplasms / pathology. Microtubule-Associated Proteins / antagonists & inhibitors. Neoplasm Proteins / antagonists & inhibitors

  • Genetic Alliance. consumer health - Endometrial cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16826583.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BIRC5 protein, human; 0 / Cysteine Proteinase Inhibitors; 0 / Inhibitor of Apoptosis Proteins; 0 / Microtubule-Associated Proteins; 0 / Neoplasm Proteins; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / RNA, Messenger; 0 / RNA, Neoplasm; 0 / RNA, Small Interfering; EC 2.7.11.24 / Mitogen-Activated Protein Kinase 1; EC 2.7.11.24 / Mitogen-Activated Protein Kinase 3; EC 3.4.22.- / Caspases
  •  go-up   go-down


77. Stewart CJ, Little L: Immunophenotypic features of MELF pattern invasion in endometrial adenocarcinoma: evidence for epithelial-mesenchymal transition. Histopathology; 2009 Jul;55(1):91-101
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunophenotypic features of MELF pattern invasion in endometrial adenocarcinoma: evidence for epithelial-mesenchymal transition.
  • AIMS: Endometrial endometrioid adenocarcinomas (EEC) may show a distinctive morphological alteration characterized by the presence of microcystic, elongated and fragmented ('MELF') glands.
  • These changes share features of epithelial-mesenchymal transition (EMT) in carcinomas arising at other sites.
  • [MeSH-major] Adenocarcinoma / pathology. Cell Differentiation. Endometrial Neoplasms / pathology. Epithelial Cells / pathology. Immunophenotyping. Mesoderm / pathology

  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19614771.001).
  • [ISSN] 1365-2559
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cadherins; 0 / Keratin-7; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone
  •  go-up   go-down


78. Halabalaki M, Alexi X, Aligiannis N, Lambrinidis G, Pratsinis H, Florentin I, Mitakou S, Mikros E, Skaltsounis AL, Alexis MN: Estrogenic activity of isoflavonoids from Onobrychis ebenoides. Planta Med; 2006 May;72(6):488-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Compounds 1 - 4 induced cell proliferation and gene expression in breast and endometrial cancer cells in an ER-dependent manner.
  • While the antiestrogen ICI 182,780 could inhibit the induction of proliferation of ER-positive breast cancer cells by 1-4, it could not prevent 1 from exhibiting significant ER-independent cytotoxicity at 10 microM.
  • By contrast, 1 was much less cytotoxic and only weakly estrogenic for ER-positive endometrial adenocarcinoma cells.

  • MedlinePlus Health Information. consumer health - Herbal Medicine.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16773531.001).
  • [ISSN] 0032-0943
  • [Journal-full-title] Planta medica
  • [ISO-abbreviation] Planta Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Estrogen Receptor alpha; 0 / Isoflavones; 0 / Phytoestrogens; 0 / Plant Extracts
  •  go-up   go-down


79. Obokata A, Watanabe J, Nishimura Y, Arai T, Kawaguchi M, Kuramoto H: Significance of matrix metalloproteinase-7 [correction of matrix metalloproteinase-2], -11 and tissue inhibitor of metalloproteinase-1 expression in normal, hyperplastic and neoplastic endometrium. Anticancer Res; 2007 Jan-Feb;27(1A):95-105
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Significance of matrix metalloproteinase-7 [correction of matrix metalloproteinase-2], -11 and tissue inhibitor of metalloproteinase-1 expression in normal, hyperplastic and neoplastic endometrium.
  • This study aimed to examine the expressions of MMP-7 and -11 and TIMP-1 in normal, hyperplastic and neoplastic endometrium and their correlation to clinicopathologic factors.
  • PATIENTS AND METHODS: Tissue samples of 40 normal endometria, 20 endometrial hyperplasias and 120 endometrial endometrioid adenocarcinomas were used for the study.
  • MMP-7 was expressed at significantly higher levels in endometrial hyperplasia than normal endometrium, whereas MMP-11 was expressed at lower levels.
  • In endometrial adenocarcinoma, MMP-7, MMP-11 and TIMP-1 were expressed at the same levels as in hyperplasia.
  • MMP-7 expression in endometrial carcinoma was correlated with myometrial invasion and estrogen receptor expression.
  • CONCLUSION: MMP-7, MMP-11 and TIMP-1 expression may be regulated by the menstrual cycle, and related to the degradation and remodeling of the normal endometrium.
  • MMP-7 expression might be a prognostic factor in endometrial carcinoma.
  • [MeSH-major] Endometrial Hyperplasia / metabolism. Endometrial Neoplasms / metabolism. Matrix Metalloproteinase 11 / biosynthesis. Matrix Metalloproteinase 7 / biosynthesis. Tissue Inhibitor of Metalloproteinase-1 / biosynthesis
  • [MeSH-minor] Adenocarcinoma / enzymology. Adenocarcinoma / metabolism. Cytoplasm / enzymology. Cytoplasm / metabolism. Endometrium / enzymology. Endometrium / metabolism. Female. Humans. Immunohistochemistry. Neoplasm Staging

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17352221.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Tissue Inhibitor of Metalloproteinase-1; EC 3.4.24.- / Matrix Metalloproteinase 11; EC 3.4.24.23 / Matrix Metalloproteinase 7
  •  go-up   go-down


80. Stone P, Burnett A, Burton B, Roman J: Overcoming extreme obesity with robotic surgery. Int J Med Robot; 2010 Dec;6(4):382-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Obesity is often associated with endometrial cancer and has posed a challenge in surgical management.
  • For the patient with uterine cancer, surgery is necessary for staging, control of symptoms and cure.
  • While surgery is the principal modality for the treatment and management of uterine cancer, the morbidly obese patient faces increased complications and longer postoperative recovery.
  • She was diagnosed with endometrioid adenocarcinoma of the uterus, FIGO grade 1.
  • CONCLUSIONS: Since obesity is a significant risk factor for endometrial cancer and the prevalence of obesity is increasing, developing surgical techniques to appropriately manage these patients is important.
  • With the increasing obesity of our population and the high prevalence of uterine cancer, further advancement of equipment, anaesthesia and surgical techniques to accommodate the larger patient while decreasing complications have yet to be standardized.
  • [MeSH-major] Carcinoma, Endometrioid / surgery. Endometrial Neoplasms / surgery. Laparoscopy / methods. Obesity, Morbid / complications. Robotics / methods

  • Genetic Alliance. consumer health - Obesity.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 John Wiley & Sons, Ltd.
  • (PMID = 20812220.001).
  • [ISSN] 1478-596X
  • [Journal-full-title] The international journal of medical robotics + computer assisted surgery : MRCAS
  • [ISO-abbreviation] Int J Med Robot
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


81. Brown YK, Knowles S, Fiorello CV, Camus MS, Howerth EW: Pathology in practice. Morphologic diagnosis: Uterine adenocarcinoma with metastasis to the lungs, diaphragm, spleen, mesentery, and cecum. J Am Vet Med Assoc; 2010 Dec 1;237(11):1257-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pathology in practice. Morphologic diagnosis: Uterine adenocarcinoma with metastasis to the lungs, diaphragm, spleen, mesentery, and cecum.
  • [MeSH-major] Adenocarcinoma / veterinary. Rabbits. Uterine Neoplasms / veterinary

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21118010.001).
  • [ISSN] 0003-1488
  • [Journal-full-title] Journal of the American Veterinary Medical Association
  • [ISO-abbreviation] J. Am. Vet. Med. Assoc.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


82. Hidaka T, Nakamura T, Shima T, Yuki H, Saito S: Paclitaxel/carboplatin versus cyclophosphamide/adriamycin/cisplatin as postoperative adjuvant chemotherapy for advanced endometrial adenocarcinoma. J Obstet Gynaecol Res; 2006 Jun;32(3):330-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Paclitaxel/carboplatin versus cyclophosphamide/adriamycin/cisplatin as postoperative adjuvant chemotherapy for advanced endometrial adenocarcinoma.
  • AIM: There is no standard chemotherapy regimen for patients with advanced endometrial adenocarcinoma.
  • METHODS: Twenty-eight patients who underwent surgery and had histologically confirmed advanced endometrial adenocarcinoma, International Federation of Gynecology and Obstetrics stage III/IV, received combination chemotherapy.
  • National Cancer Institute Common Toxicity Criteria grade 3-4 thrombocytopenia and gastrointestinal toxicities occurred significantly less frequently in the paclitaxel/carboplatin group (0% and 16.7%) than in the CAP group (31.3% and 68.8%) (P = 0.0389 and P = 0.0062).
  • CONCLUSIONS: We conclude that paclitaxel/carboplatin is a promising regimen which could be substituted for CAP, with major activity and a highly acceptable toxicity profile for the treatment of advanced endometrial adenocarcinomas.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Endometrial Neoplasms / drug therapy

  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16764625.001).
  • [ISSN] 1341-8076
  • [Journal-full-title] The journal of obstetrics and gynaecology research
  • [ISO-abbreviation] J. Obstet. Gynaecol. Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


83. Huang SY, Jung SM, Ng KK, Chang YC, Lai CH: Ovarian metastasis in a nulliparous woman with endometrial adenocarcinoma failing conservative hormonal treatment. Gynecol Oncol; 2005 May;97(2):652-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ovarian metastasis in a nulliparous woman with endometrial adenocarcinoma failing conservative hormonal treatment.
  • BACKGROUND: There have been several reports about successful fertility-preserving treatment of endometrial carcinoma with subsequent pregnancy.
  • However, conservative hormonal treatment for early-stage endometrial cancer still entails some risk.
  • CASE: We present a 36-year-old nulliparous woman, initially diagnosed as clinical stage IA, grade 1 endometrial adenocarcinoma, receiving 6-month conservative treatment with remission achieved at 4 months from diagnosis.
  • Recurrence at the endometrium was documented at the end of treatment.
  • The final pathology revealed well-differentiated endometrioid adenocarcinoma with inner one-third myometrial invasion and right ovarian metastasis.
  • CONCLUSION: This case report signals a warning that negative preoperative imaging studies are not reassuring for a relapsing low-grade, early-stage endometrial carcinoma failing conservative treatment.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / secondary. Endometrial Neoplasms / drug therapy. Endometrial Neoplasms / pathology. Megestrol Acetate / therapeutic use. Ovarian Neoplasms / secondary

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15863173.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] TJ2M0FR8ES / Megestrol Acetate
  •  go-up   go-down


84. Ibáñez Pinto A, Fernández Salgado E, Castro Ortiz E, Baltar Arias R, Vázquez Vázquez S, Ledo Barro L, Vázquez San Luis J, Vázquez Astray E: [Gastrointestinal bleeding of obscure origin caused by a metastatic endometrial adenocarcinoma. Response to hormonal therapy]. Gastroenterol Hepatol; 2007 Nov;30(9):530-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Gastrointestinal bleeding of obscure origin caused by a metastatic endometrial adenocarcinoma. Response to hormonal therapy].
  • [Transliterated title] Hemorragia digestiva de origen incierto por un adenocarcinoma endometrial metastásico. Respuesta al tratamiento hormonal.
  • BACKGROUND: Endometrial cancer (EC) is the most common gynecologic malignancy.
  • A computed tomography scan showed extensive lymphatic, abdominal and pelvic recurrence of the cancer.
  • Control of bleeding and a 22-month survival were obtained after treatment with oral medroxyprogesterone acetate.
  • [MeSH-major] Antineoplastic Agents, Hormonal / therapeutic use. Carcinoma, Endometrioid / secondary. Endometrial Neoplasms / pathology. Gastrointestinal Hemorrhage / etiology. Medroxyprogesterone Acetate / therapeutic use. Pelvic Neoplasms / secondary. Peritoneal Neoplasms / secondary. Retroperitoneal Neoplasms / secondary

  • MedlinePlus Health Information. consumer health - Gastrointestinal Bleeding.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17980130.001).
  • [ISSN] 0210-5705
  • [Journal-full-title] Gastroenterología y hepatología
  • [ISO-abbreviation] Gastroenterol Hepatol
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; C2QI4IOI2G / Medroxyprogesterone Acetate
  • [Number-of-references] 19
  •  go-up   go-down


85. Stilwell G, Peleteiro MC: Uterine adenocarcinoma with pulmonary, liver and mesentery metastasis in a holstein cow. Vet Med Int; 2010;2010:727856
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Uterine adenocarcinoma with pulmonary, liver and mesentery metastasis in a holstein cow.
  • The clinical and pathology features of a cow with uterine adenocarcinoma and multiple metastasis are described.
  • Grossly deformed uterus, enlarged iliac lymph nodes, and rosary arranged nodules in the mesentery were felt by rectal palpation.
  • Necropsy and histopathology exam revealed a uterine adenocarcinoma with multiple pulmonary, liver and mesentery metastasis.
  • Uterine adenocarcinoma with metastasis should be included in the differential diagnosis of cows showing weight loss and mild respiratory distress and palpation of numerous firm nodules in the mesentery should be suggestive of neoplasias' metastasis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Am Vet Med Assoc. 1970 Dec 1;157(11):1577-84 [4098649.001]
  • [Cites] J Am Vet Med Assoc. 1966 Apr 15;148(8):913-5 [5950882.001]
  • [Cites] J Comp Pathol. 1969 Jan;79(1):53-63 [5813284.001]
  • (PMID = 20445789.001).
  • [ISSN] 2042-0048
  • [Journal-full-title] Veterinary medicine international
  • [ISO-abbreviation] Vet Med Int
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Egypt
  • [Other-IDs] NLM/ PMC2860195
  •  go-up   go-down


86. Shimazaki K, Lepin EJ, Wei B, Nagy AK, Coulam CP, Mareninov S, Fu M, Wu AM, Marks JD, Braun J, Gordon LK, Wadehra M: Diabodies targeting epithelial membrane protein 2 reduce tumorigenicity of human endometrial cancer cell lines. Clin Cancer Res; 2008 Nov 15;14(22):7367-77
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diabodies targeting epithelial membrane protein 2 reduce tumorigenicity of human endometrial cancer cell lines.
  • PURPOSE: Endometrial cancer is the most common gynecologic malignancy.
  • In addition, the efficacy of EMP2 diabodies on endometrial cancer tumors was determined using mouse xenograft models.
  • RESULTS: Treatment of human endometrial adenocarcinoma cell lines with anti-EMP2 diabodies induced significant cell death and caspase-3 cleavage in vitro.
  • CONCLUSIONS: These findings suggest that EMP2 may be a potential pharmacologic target for human endometrial cancer.

  • Genetic Alliance. consumer health - Endometrial cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cell. 2001 Aug 24;106(4):403-11 [11525727.001]
  • [Cites] Dev Biol. 2006 Apr 15;292(2):430-41 [16487956.001]
  • [Cites] J Cell Biol. 2002 May 27;157(5):865-72 [12021258.001]
  • [Cites] J Biol Chem. 2002 Oct 25;277(43):41094-100 [12189152.001]
  • [Cites] Clin Immunol. 2003 May;107(2):129-36 [12763482.001]
  • [Cites] Semin Oncol. 2003 Aug;30(4 Suppl 9):80-94 [12908139.001]
  • [Cites] J Virol Methods. 2004 Jan;115(1):83-92 [14656464.001]
  • [Cites] Int J Gynecol Cancer. 2004 Jan-Feb;14(1):145-51 [14764043.001]
  • [Cites] Methods Mol Biol. 2004;248:161-76 [14970495.001]
  • [Cites] Protein Eng Des Sel. 2004 Jan;17(1):21-7 [14985534.001]
  • [Cites] Mol Biol Cell. 2004 May;15(5):2073-83 [14978215.001]
  • [Cites] Curr Opin Cell Biol. 2004 Oct;16(5):544-51 [15363805.001]
  • [Cites] Nucleic Acids Res. 1989 May 25;17(10):4000 [2734114.001]
  • [Cites] Cancer Res. 1991 Dec 1;51(23 Pt 1):6363-71 [1933899.001]
  • [Cites] J Mol Biol. 1991 Dec 5;222(3):581-97 [1748994.001]
  • [Cites] Cancer Res. 1992 Jun 15;52(12):3402-8 [1596900.001]
  • [Cites] Cancer Res. 1993 Apr 15;53(8):1883-8 [8385572.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Jul 15;90(14):6444-8 [8341653.001]
  • [Cites] Cancer Res. 1993 Sep 1;53(17):4026-34 [7689421.001]
  • [Cites] Diagn Mol Pathol. 1994 Dec;3(4):292-7 [7866641.001]
  • [Cites] Curr Opin Cell Biol. 1995 Aug;7(4):552-63 [7495576.001]
  • [Cites] Semin Oncol. 2006 Apr;33(2 Suppl 6):S33-8 [16716801.001]
  • [Cites] Clin Cancer Res. 2006 Jun 15;12(12):3661-97 [16778094.001]
  • [Cites] Cancer. 2006 Jul 1;107(1):90-8 [16736513.001]
  • [Cites] J Clin Oncol. 2006 Oct 10;24(29):4783-91 [17028294.001]
  • [Cites] Vascul Pharmacol. 2007 Jun;46(6):383-93 [17382599.001]
  • [Cites] Microbes Infect. 2007 Jul;9(8):1003-10 [17544801.001]
  • [Cites] Reprod Biol Endocrinol. 2008;6:15 [18400107.001]
  • [Cites] J Cell Biol. 1999 Nov 1;147(3):611-8 [10545504.001]
  • [Cites] J Biol Chem. 2000 Jan 21;275(3):2191-8 [10636925.001]
  • [Cites] Mod Pathol. 2000 Mar;13(3):295-308 [10757340.001]
  • [Cites] J Immunol. 2000 Jul 15;165(2):888-95 [10878363.001]
  • [Cites] Cancer Res. 2000 Nov 15;60(22):6434-40 [11103810.001]
  • [Cites] J Clin Endocrinol Metab. 2001 May;86(5):2323-6 [11344246.001]
  • [Cites] Blood. 2001 Jun 15;97(12):3890-5 [11389031.001]
  • [Cites] J Biol Chem. 2001 Aug 17;276(33):30729-36 [11406621.001]
  • [Cites] J Mol Biol. 1996 Jan 12;255(1):28-43 [8568873.001]
  • [Cites] Semin Oncol. 1997 Feb;24(1 Suppl 1):S1-140-S1-50 [9045311.001]
  • [Cites] Br J Cancer. 1998 May;77(9):1405-12 [9652755.001]
  • [Cites] J Soc Gynecol Investig. 1998 Nov-Dec;5(6):334-8 [9824816.001]
  • [Cites] J Cell Biol. 1998 Dec 28;143(7):1997-2008 [9864370.001]
  • [Cites] Q J Nucl Med. 1998 Dec;42(4):225-41 [9973838.001]
  • [Cites] Cancer Res. 1999 Oct 1;59(19):4761-4 [10519379.001]
  • [Cites] Nat Biotechnol. 2005 Sep;23(9):1126-36 [16151406.001]
  • [Cites] Nat Biotechnol. 2005 Sep;23(9):1137-46 [16151407.001]
  • [Cites] Dev Biol. 2005 Nov 15;287(2):336-45 [16216233.001]
  • [Cites] J Cell Sci. 2002 Mar 1;115(Pt 5):963-72 [11870215.001]
  • (PMID = 19010852.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] ENG
  • [Grant] United States / NIAID NIH HHS / AI / T32 AI007323; United States / NCI NIH HHS / CA / CA016042; United States / NICHD NIH HHS / HD / R03 HD048540; United States / NCI NIH HHS / CA / R21 CA131756; United States / NCI NIH HHS / CA / P50 CA086306; United States / NCI NIH HHS / CA / P30 CA016042; United States / NIAID NIH HHS / AI / 2-T32-AI-07323; United States / NCI NIH HHS / CA / T32 CA009120; United States / NCI NIH HHS / CA / CA009120; United States / NCI NIH HHS / CA / U54 CA119367; United States / NCI NIH HHS / CA / R21 CA131756-01A1; United States / NICHD NIH HHS / HD / R03 HD048540-02; United States / NCI NIH HHS / CA / CA86306; United States / NCI NIH HHS / CA / CA131756-01A1; United States / NICHD NIH HHS / HD / HD48540
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / EMP2 protein, human; 0 / Immunoglobulin Fragments; 0 / Membrane Glycoproteins
  • [Other-IDs] NLM/ NIHMS290195; NLM/ PMC3109074
  •  go-up   go-down


87. Caquant F, Mas-Calvet M, Turbelin C, Lesoin A, Lefebvre D, Narducci F, Querleu D, Leblanc E: [Endometrial cancer by laparoscopy and vaginal approach in the obese patient]. Bull Cancer; 2006 Apr;93(4):402-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Endometrial cancer by laparoscopy and vaginal approach in the obese patient].
  • [Transliterated title] La voie d'abord chirurgicale coeliovaginale chez les patientes obèses atteintes d'un cancer de l'endomètre.
  • To prove feasibility of laparoscopic and vaginal surgical approach in obese patients with endometrial cancer, 81 patients were included retrospectively in 2 Cancer Centres : 41 obese and 40 non obese.
  • Matching 41 obese patients treated by laparoscopy with 29 obese patients with endometrial cancer treated by laparotomy, hospital stay was shorter in the laparoscopic group (3.8 [2-8] vs 7.4 days [5-10] p < 0.001) and pelvic nodes (16.3 [3-50] vs 11.5 [2-34]), operative time (149.9 [80-300] vs 167.9 minutes [60-390]) and disease-free survival (93 vs 80 %) were similar.
  • For obese patients with stage I endometrial adenocarcinoma, laparoscopic approach should be first choice because of similar operative complications and pelvic nodes, shorter hospital stay and less abdominal wall morbidity associated with lower risk to delay adjuvant radiotherapy.
  • [MeSH-major] Adenocarcinoma / surgery. Endometrial Neoplasms / surgery. Gynecologic Surgical Procedures / methods. Laparoscopy / methods. Obesity / complications

  • Genetic Alliance. consumer health - Vaginal cancer.
  • Genetic Alliance. consumer health - Endometrial cancer.
  • MedlinePlus Health Information. consumer health - Obesity.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16627243.001).
  • [ISSN] 1769-6917
  • [Journal-full-title] Bulletin du cancer
  • [ISO-abbreviation] Bull Cancer
  • [Language] fre
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


88. Stewart CJ, Amanuel B, Grieu F, Carrello A, Iacopetta B: KRAS mutation and microsatellite instability in endometrial adenocarcinomas showing MELF-type myometrial invasion. J Clin Pathol; 2010 Jul;63(7):604-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] KRAS mutation and microsatellite instability in endometrial adenocarcinomas showing MELF-type myometrial invasion.
  • BACKGROUND: Some uterine endometrioid adenocarcinomas exhibit a distinctive morphological phenotype characterised by the formation of microcystic, elongated and fragmented (MELF) glands.
  • AIMS: To investigate the molecular characteristics of endometrial tumours showing MELF, with particular reference to the frequencies of KRAS and BRAF mutations and of microsatellite instability (MSI).
  • METHODS: MSI, and KRAS and BRAF mutation status, were assessed in 33 low-grade endometrial adenocarcinomas showing MELF features and the results compared with 33 control cases exhibiting a 'conventional' pattern of myometrial invasion.
  • CONCLUSIONS: Mutations in KRAS and BRAF genes are not directly implicated in the development of a MELF pattern of invasion in endometrial carcinoma.
  • [MeSH-major] Adenocarcinoma / genetics. Endometrial Neoplasms / genetics. Microsatellite Instability. Mutation. Proto-Oncogene Proteins / genetics. ras Proteins / genetics

  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20591910.001).
  • [ISSN] 1472-4146
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / KRAS protein, human; 0 / Proto-Oncogene Proteins; EC 2.7.11.1 / BRAF protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins B-raf; EC 3.6.5.2 / ras Proteins
  •  go-up   go-down


89. Michener CM, Peterson G, Kulp B, Webster KD, Markman M: Carboplatin plus paclitaxel in the treatment of advanced or recurrent endometrial carcinoma. J Cancer Res Clin Oncol; 2005 Sep;131(9):581-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Carboplatin plus paclitaxel in the treatment of advanced or recurrent endometrial carcinoma.
  • PURPOSE: To evaluate the efficacy and safety of the combination of carboplatin plus paclitaxel in patients with advanced, metastatic and recurrent endometrial cancer.
  • METHODS: Medical records were retrospectively reviewed to identify endometrial cancer patients treated in the Gynecologic Cancer Program of the Cleveland Clinic with carboplatin/paclitaxel who had both a histologic diagnosis of endometrial adenocarcinoma and either measurable (CT scan, physical examination) or evaluable (CA-125 criteria) disease.
  • With a median follow-up of 42 months, 13 patients have died of progressive cancer, while four currently have no evidence of disease at the time of last follow-up.
  • CONCLUSIONS: The combination of carboplatin plus paclitaxel demonstrates substantial biological activity in endometrial adenocarcinoma.
  • The safety and efficacy of this regimen makes it an attractive option for first-line chemotherapy in patients with advanced or recurrent endometrial carcinoma.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Endometrial Neoplasms / drug therapy. Neoplasm Metastasis / drug therapy. Neoplasm Recurrence, Local / drug therapy

  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2001 Oct 15;19(20):4048-53 [11600606.001]
  • [Cites] Semin Oncol. 1997 Oct;24(5 Suppl 15):S15-57-S15-61 [9346224.001]
  • [Cites] Semin Oncol. 1999 Feb;26(1 Suppl 2):78-83 [10190786.001]
  • [Cites] Gynecol Oncol. 1993 Dec;51(3):397-400 [8112651.001]
  • [Cites] Gynecol Oncol. 1996 Aug;62(2):278-81 [8751561.001]
  • [Cites] Anticancer Drugs. 1998 Mar;9(3):283-5 [9625439.001]
  • [Cites] J Clin Oncol. 1994 Jul;12(7):1408-14 [8021731.001]
  • [Cites] J Clin Oncol. 2001 Feb 15;19(4):1021-9 [11181665.001]
  • [Cites] Gynecol Oncol. 2000 Sep;78(3 Pt 1):369-72 [10985896.001]
  • [Cites] Am J Clin Oncol. 1993 Dec;16(6):494-6 [8256764.001]
  • [Cites] Gynecol Oncol. 1991 Mar;40(3):264-7 [2013451.001]
  • [Cites] Gynecol Oncol. 2000 Jul;78(1):52-7 [10873410.001]
  • [Cites] Am J Obstet Gynecol. 1986 Nov;155(5):1097-102 [3465243.001]
  • [Cites] Gynecol Oncol. 1999 Jun;73(3):461-3 [10366480.001]
  • [Cites] Semin Oncol. 1997 Oct;24(5 Suppl 15):S15-78-S15-82 [9346228.001]
  • [Cites] J Natl Cancer Inst. 2003 Sep 3;95(17):1320-9 [12953086.001]
  • [Cites] Gynecol Oncol. 2003 Mar;88(3):277-81 [12648575.001]
  • (PMID = 15959825.001).
  • [ISSN] 0171-5216
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


90. Kogan EA, Niziaeva NV, Demura TA, Ezhova LS, Unanian AL: [The morphological and immunohiochemical features of foci of adenomyosis: in its concurrence with endometrial adenocarcinoma]. Arkh Patol; 2010 Jul-Aug;72(4):7-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The morphological and immunohiochemical features of foci of adenomyosis: in its concurrence with endometrial adenocarcinoma].
  • The purpose of the investigation was to study the morphological variants and molecular changes of the endothelial component of adenomyosis (AM) concurrent with endometrial adenocarcinoma (EAC).
  • The foci of AM, which corresponded to epithelial hyperplasia with atypia, were characterized by the oncomarker changes supporting its malignant potential: elevated Ki-67 and EGRF, reduced E-cadherin, changes in MMP-2, MMP-9, TIMP-1, and claudins-2, -3, and -5.
  • [MeSH-major] Adenocarcinoma. Endometrial Neoplasms. Endometriosis. Gene Expression Regulation, Neoplastic. Neoplasm Proteins / biosynthesis


91. Scudder SA, Liu PY, Wilczynski SP, Smith HO, Jiang C, Hallum AV 3rd, Smith GB, Hannigan EV, Markman M, Alberts DS, Southwest Oncology Group: Paclitaxel and carboplatin with amifostine in advanced, recurrent, or refractory endometrial adenocarcinoma: a phase II study of the Southwest Oncology Group. Gynecol Oncol; 2005 Mar;96(3):610-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Paclitaxel and carboplatin with amifostine in advanced, recurrent, or refractory endometrial adenocarcinoma: a phase II study of the Southwest Oncology Group.
  • OBJECTIVES: To evaluate the response rate and progression free and overall survival of patients with advanced endometrial cancer treated with paclitaxel, carboplatin and amifostine.
  • METHODS: Forty-seven eligible patients (median age: 66; range 45-82) with bidimensionally measurable advanced, recurrent, or refractory endometrial cancer were treated with carboplatin (AUC = 6), paclitaxel (175 mg/M2) and amifostine (740 mg/M2) every 4 weeks for 6 cycles or until disease progression or unacceptable toxicity.
  • The median progression-free survival (PFS) was 7 months (95% CI, 6-9 months) and a 6-month PFS rate of 64% (95% CI, 50% to 78%).
  • The regimen demonstrated significant activity in endometrial cancer, comparable to other multi-agent chemotherapy programs in terms of response rate and survival, and with a favorable toxicity profile.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Endometrial Neoplasms / drug therapy. Neoplasm Recurrence, Local / drug therapy

  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. AMIFOSTINE .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15721401.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA03096; United States / NCI NIH HHS / CA / CA04919; United States / NCI NIH HHS / CA / CA12213; United States / NCI NIH HHS / CA / CA12644; United States / NCI NIH HHS / CA / CA13612; United States / NCI NIH HHS / CA / CA14028; United States / NCI NIH HHS / CA / CA20319; United States / NCI NIH HHS / CA / CA22433; United States / NCI NIH HHS / CA / CA32102; United States / NCI NIH HHS / CA / CA35090; United States / NCI NIH HHS / CA / CA35119; United States / NCI NIH HHS / CA / CA35178; United States / NCI NIH HHS / CA / CA35261; United States / NCI NIH HHS / CA / CA35431; United States / NCI NIH HHS / CA / CA35996; United States / NCI NIH HHS / CA / CA37981; United States / NCI NIH HHS / CA / CA38926; United States / NCI NIH HHS / CA / CA42777; United States / NCI NIH HHS / CA / CA45450; United States / NCI NIH HHS / CA / CA45461; United States / NCI NIH HHS / CA / CA45560; United States / NCI NIH HHS / CA / CA46113; United States / NCI NIH HHS / CA / CA46282; United States / NCI NIH HHS / CA / CA46368; United States / NCI NIH HHS / CA / CA46441; United States / NCI NIH HHS / CA / CA58861; United States / NCI NIH HHS / CA / CA63844; United States / NCI NIH HHS / CA / CA63850; United States / NCI NIH HHS / CA / CA67575; United States / NCI NIH HHS / CA / CA68183; United States / NCI NIH HHS / CA / CA76132; United States / NCI NIH HHS / CA / CA76462
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] BG3F62OND5 / Carboplatin; M487QF2F4V / Amifostine; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


92. Mulligan AM, Plotkin A, Rouzbahman M, Soslow RA, Gilks CB, Clarke BA: Endometrial giant cell carcinoma: a case series and review of the spectrum of endometrial neoplasms containing giant cells. Am J Surg Pathol; 2010 Aug;34(8):1132-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endometrial giant cell carcinoma: a case series and review of the spectrum of endometrial neoplasms containing giant cells.
  • Poorly differentiated endometrial carcinomas of specific type include the rarely reported endometrial carcinoma with a malignant giant cell component [endometrial giant cell carcinoma (GCC)].
  • The patients ranged in age from 53 to 83 years, presenting with vaginal bleeding, anemia, or a pelvic mass.
  • Four of the 5 tumors contained areas of endometrial adenocarcinoma of usual type, with a variable giant cell component.
  • The conventional cell types present included 1 case with clear cell carcinoma (30% of tumor volume), 2 with high-grade endometrioid carcinoma (50% and 70% of tumor volume, respectively) and 1 with serous histology (10% of tumor volume).
  • One was composed exclusively of giant cell carcinoma.
  • One patient in whom the tumor was exclusively of the giant cell type, developed lung metastasis 4 years after diagnosis and 1 patient is disease free after 14 years.
  • As histotype supplemented by staging information is critical in selection of treatment modalities and in prognostication in uterine malignancies, accurate classification is mandated.
  • Here, we present a series of endometrial carcinomas containing a component of GCC and discuss the spectrum of giant cell-containing uterine neoplasms.
  • At this time, however, the cumulative data on endometrial GCC are limited and the prognostic significance of the presence and the extent of a giant cell component in endometrial carcinoma remains uncertain.
  • [MeSH-major] Adenocarcinoma, Clear Cell / pathology. Carcinoma, Endometrioid / pathology. Carcinoma, Giant Cell / pathology. Endometrial Neoplasms / pathology. Giant Cells / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20588176.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 25
  •  go-up   go-down


93. García-Cao I, Duran A, Collado M, Carrascosa MJ, Martín-Caballero J, Flores JM, Diaz-Meco MT, Moscat J, Serrano M: Tumour-suppression activity of the proapoptotic regulator Par4. EMBO Rep; 2005 Jun;6(6):577-83
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The endometrium and prostate of Par4-null mice were particularly sensitive to the development of proliferative lesions.
  • Most (80%) Par4-null females presented endometrial hyperplasia by 9 months of age, and a significant proportion (36%) developed endometrial adenocarcinomas after 1 year of age.
  • Finally, the uterus and prostate of young Par4-null mice have increased levels of the apoptosis inhibitor XIAP (X-chromosome-linked inhibitor of apoptosis), supporting the previously proposed function of Par4 as an inhibitor of the (zeta)PKC (atypical protein kinase)-NF-(kappa)B (nuclear factor-(kappa)B)-XIAP pathway.
  • These data show that Par4 has an important role in tumour suppression, with a particular relevance in the endometrium and prostate.
  • [MeSH-major] Apoptosis / physiology. Endometrial Neoplasms / metabolism. Phenotype. Prostatic Neoplasms / metabolism. Proteins / metabolism. Receptors, Thrombin / metabolism. Urinary Bladder Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • Hazardous Substances Data Bank. ESTRADIOL .
  • Hazardous Substances Data Bank. TESTOSTERONE .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] EMBO J. 1999 Nov 15;18(22):6362-9 [10562548.001]
  • [Cites] J Biol Chem. 1999 Oct 15;274(42):29976-83 [10514481.001]
  • [Cites] J Mol Neurosci. 1999 Aug-Oct;13(1-2):17-30 [10691289.001]
  • [Cites] Gastroenterology. 2000 Jun;118(6):1012-7 [10833474.001]
  • [Cites] Cancer Res. 2000 Nov 1;60(21):6008-17 [11085521.001]
  • [Cites] Genes Dev. 2001 Feb 1;15(3):328-39 [11159913.001]
  • [Cites] J Cancer Res Clin Oncol. 2001 Jul;127(7):411-7 [11469677.001]
  • [Cites] Mol Cell. 2001 Oct;8(4):771-80 [11684013.001]
  • [Cites] Br J Cancer. 2001 Nov 30;85(11):1801-8 [11742505.001]
  • [Cites] Cancer Res. 2002 Mar 15;62(6):1768-75 [11912153.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Apr 2;99(7):4465-70 [11904358.001]
  • [Cites] EMBO J. 2002 Aug 1;21(15):4049-57 [12145205.001]
  • [Cites] EMBO J. 2002 Nov 15;21(22):6225-35 [12426394.001]
  • [Cites] EMBO Rep. 2003 Jan;4(1):31-6 [12524517.001]
  • [Cites] Exp Cell Res. 2003 Feb 1;283(1):51-66 [12565819.001]
  • [Cites] EMBO Rep. 2003 Mar;4(3):307-12 [12634851.001]
  • [Cites] Cell Cycle. 2003 Mar-Apr;2(2):71-2 [12695647.001]
  • [Cites] J Biol Chem. 2003 May 30;278(22):19995-20005 [12644474.001]
  • [Cites] EMBO J. 2003 Sep 15;22(18):4689-98 [12970181.001]
  • [Cites] J Cell Biochem. 2004 Feb 15;91(3):504-12 [14755681.001]
  • [Cites] Cell Growth Differ. 1994 Apr;5(4):457-66 [8043520.001]
  • [Cites] Cell. 1996 Sep 6;86(5):777-86 [8797824.001]
  • [Cites] Mol Cell Biol. 1996 Dec;16(12):6945-56 [8943350.001]
  • [Cites] Mol Cell Biol. 1997 Jul;17(7):3823-32 [9199316.001]
  • [Cites] Cancer Res. 1998 Sep 1;58(17):3806-11 [9731488.001]
  • [Cites] Oncogene. 1999 Feb 4;18(5):1205-8 [10022126.001]
  • [Cites] Oncogene. 1999 Nov 25;18(50):7115-23 [10597313.001]
  • (PMID = 15877079.001).
  • [ISSN] 1469-221X
  • [Journal-full-title] EMBO reports
  • [ISO-abbreviation] EMBO Rep.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Proteins; 0 / Receptors, Thrombin; 0 / X-Linked Inhibitor of Apoptosis Protein; 0 / protease-activated receptor 4; 3817-11-6 / Butylhydroxybutylnitrosamine; 3XMK78S47O / Testosterone; 4TI98Z838E / Estradiol
  • [Other-IDs] NLM/ PMC1369092
  •  go-up   go-down


94. Pan H, Sun CC, Zhou CY, Huang HF: Expression of aquaporin-1 in normal, hyperplasic, and carcinomatous endometria. Int J Gynaecol Obstet; 2008 Jun;101(3):239-44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To explore the relationship between aquaporin-1 (AQP1) and endometrial adenocarcinoma.
  • METHOD: Intratumoral microvessel density (IMD) was assessed as well as AQP1 and vascular endothelial growth factor expression in samples from 117 women, 75 with endometrioid adenocarcinoma, 17 with endometrial hyperplasia, and 25 with normal proliferative endometria.
  • In samples from endometrioid adenocarcinoma, the AQP1/IMD ratio was significantly correlated with histologic grade, surgical stage, myometrial invasion, and extrauterine metastasis.
  • CONCLUSION: AQP1 may be involved in the tumorigenesis and progression of endometrioid adenocarcinoma by promoting angiogenesis, and AQP1 level may be both a tumor indicator and a new therapeutic target.
  • [MeSH-major] Aquaporin 1 / metabolism. Carcinoma, Endometrioid / blood supply. Endometrial Neoplasms / blood supply
  • [MeSH-minor] Adenocarcinoma / blood supply. Adenocarcinoma / metabolism. Adult. Antigens, CD34 / analysis. Antigens, CD34 / immunology. Endometrial Hyperplasia / immunology. Female. Humans. Immunohistochemistry. Medical Records. Microcirculation / pathology. Middle Aged. Neovascularization, Pathologic / metabolism. Vascular Endothelial Growth Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18313673.001).
  • [ISSN] 0020-7292
  • [Journal-full-title] International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics
  • [ISO-abbreviation] Int J Gynaecol Obstet
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / Vascular Endothelial Growth Factors; 146410-94-8 / Aquaporin 1
  •  go-up   go-down


95. Keightley MC, Brown P, Jabbour HN, Sales KJ: F-Prostaglandin receptor regulates endothelial cell function via fibroblast growth factor-2. BMC Cell Biol; 2010 Jan 21;11:8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Prostaglandin (PG) F(2alpha) is a key regulator of endometrial function and exerts its biological action after coupling with its heptahelical G protein-coupled receptor (FP receptor).
  • In endometrial adenocarcinoma the FP receptor expression is elevated.
  • We have shown previously that PGF(2alpha)-FP receptor signalling in endometrial adenocarcinoma cells can upregulate several angiogenic factors including fibroblast growth factor-2 (FGF2).
  • In the present study, we investigated the paracrine effect of conditioned medium produced via PGF(2alpha)-FP receptor signalling in endometrial adenocarcinoma cells stably expressing the FP receptor (Ishikawa FPS cells), on endothelial cell function.
  • These findings have relevance for pathologies where the FP receptor is aberrantly expressed, such as endometrial adenocarcinoma, and provide in vitro evidence to suggest that targeting the FP receptor could provide an anti-angiogenic approach to reducing tumour vasculature and growth.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Lett. 2008 May 8;263(1):114-21 [18243528.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Chin Med J (Engl). 2008 Dec 20;121(24):2599-603 [19187602.001]
  • [Cites] J Cell Sci. 2009 Jun 1;122(Pt 11):1812-22 [19435802.001]
  • [Cites] J Biol Chem. 2000 Feb 18;275(7):5096-103 [10671553.001]
  • [Cites] Br J Pharmacol. 2000 Jun;130(3):641-9 [10821793.001]
  • [Cites] Cancer Res. 2000 Sep 1;60(17):4932-8 [10987309.001]
  • [Cites] Neoplasia. 2000 Nov-Dec;2(6):483-90 [11228540.001]
  • [Cites] Cancer Res. 2002 Jan 15;62(2):424-32 [11809691.001]
  • [Cites] Blood. 2002 Nov 1;100(9):3087-94 [12384403.001]
  • [Cites] Nat Rev Cancer. 2003 Jun;3(6):401-10 [12778130.001]
  • [Cites] Exp Cell Res. 2003 Nov 15;291(1):70-82 [14597409.001]
  • [Cites] Cell Tissue Res. 2003 Oct;314(1):157-66 [12851809.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Feb;89(2):986-93 [14764825.001]
  • [Cites] Trends Endocrinol Metab. 2004 Oct;15(8):398-404 [15380812.001]
  • [Cites] N Engl J Med. 1971 Nov 18;285(21):1182-6 [4938153.001]
  • [Cites] Microvasc Res. 1977 Jul;14(1):53-65 [895546.001]
  • [Cites] Nature. 1980 Dec 11;288(5791):551-6 [6160403.001]
  • [Cites] Atherosclerosis. 1987 Jun;65(3):227-36 [3113442.001]
  • [Cites] Cell. 1995 Nov 3;83(3):493-501 [8521479.001]
  • [Cites] Cell. 1996 Aug 9;86(3):353-64 [8756718.001]
  • [Cites] Prostaglandins Leukot Essent Fatty Acids. 1996 Sep;55(3):179-83 [8931116.001]
  • [Cites] Nat Med. 1997 Aug;3(8):887-93 [9256280.001]
  • [Cites] J Biol Chem. 1997 Sep 12;272(37):23347-53 [9287347.001]
  • [Cites] Annu Rev Cell Dev Biol. 1997;13:513-609 [9442882.001]
  • [Cites] J Cell Biol. 1998 Mar 9;140(5):1255-63 [9490736.001]
  • [Cites] Adv Cancer Res. 1998;74:49-139 [9561267.001]
  • [Cites] Am J Pathol. 1998 Jun;152(6):1607-16 [9626064.001]
  • [Cites] Int J Cancer. 1998 Jun 10;76(6):836-41 [9626350.001]
  • [Cites] Cell. 1998 May 29;93(5):705-16 [9630216.001]
  • [Cites] Am J Obstet Gynecol. 1999 Mar;180(3 Pt 1):614-20 [10076137.001]
  • [Cites] Mol Hum Reprod. 1999 Oct;5(10):973-82 [10508227.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Dec;89(12):6112-8 [15579767.001]
  • [Cites] Cancer Res. 2005 Sep 1;65(17):7707-16 [16140938.001]
  • [Cites] J Exp Med. 2006 Apr 17;203(4):941-51 [16567391.001]
  • [Cites] Vascul Pharmacol. 2006 Jun;44(6):411-6 [16651031.001]
  • [Cites] Mol Cell Endocrinol. 2006 Jun 27;252(1-2):191-200 [16701939.001]
  • [Cites] Hum Reprod. 2007 Jan;22(1):36-44 [16905765.001]
  • [Cites] Nat Rev Mol Cell Biol. 2007 Jun;8(6):464-78 [17522591.001]
  • [Cites] J Biol Chem. 2007 Jun 8;282(23):16959-68 [17401137.001]
  • [Cites] Cancer Cell. 2007 Jul;12(1):9-22 [17613433.001]
  • [Cites] Endocrinology. 2007 Aug;148(8):3635-44 [17478553.001]
  • [Cites] Cancer Lett. 2008 Feb 8;259(2):146-55 [18006148.001]
  • [Cites] Cell Cycle. 2007 Dec 15;6(24):3011-4 [18073529.001]
  • [Cites] J Biol Chem. 2008 Jan 25;283(4):2139-46 [18042549.001]
  • [Cites] Expert Rev Mol Med. 2008;10:e4 [18241520.001]
  • [Cites] J Steroid Biochem Mol Biol. 2008 Feb;108(3-5):221-9 [18061438.001]
  • [Cites] Health Stat Q. 2008 Summer;(38):33-46 [18595386.001]
  • (PMID = 20092633.001).
  • [ISSN] 1471-2121
  • [Journal-full-title] BMC cell biology
  • [ISO-abbreviation] BMC Cell Biol.
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / MC/ U127684438; United Kingdom / Medical Research Council / / U.1276.00.004.00002.01
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Intracellular Signaling Peptides and Proteins; 0 / Receptors, Prostaglandin; 0 / prostaglandin F2alpha receptor; 103107-01-3 / Fibroblast Growth Factor 2; EC 1.14.99.1 / Cyclooxygenase 2; EC 1.14.99.1 / PTGS2 protein, human; EC 2.7.1.1 / MTOR protein, human; EC 2.7.1.1 / TOR Serine-Threonine Kinases; EC 2.7.10.1 / FGFR1 protein, human; EC 2.7.10.1 / Receptor, Fibroblast Growth Factor, Type 1; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 2.7.11.24 / Mitogen-Activated Protein Kinase 1; EC 2.7.11.24 / Mitogen-Activated Protein Kinase 3
  • [Other-IDs] NLM/ PMC2824741
  •  go-up   go-down


96. Watanabe J, Watanabe K, Jobo T, Kamata Y, Kawaguchi M, Imai M, Okayasu I, Kuramoto H: Significance of p27 as a predicting marker for medroxyprogesterone acetate therapy against endometrial endometrioid adenocarcinoma. Int J Gynecol Cancer; 2006 Jan-Feb;16 Suppl 1:452-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Significance of p27 as a predicting marker for medroxyprogesterone acetate therapy against endometrial endometrioid adenocarcinoma.
  • We reported that p27 induced by medroxyprogesterone acetate (MPA) may be involved in the progestin-induced growth suppression of human endometrial adenocarcinoma cells.
  • The clinical responses of 15 patients with endometrial carcinoma treated with MPA were examined. p27 expression was evaluated by immunohistochemical staining.
  • The former was significantly higher than the latter. p27 expression could predict the effectiveness of MPA treatment for endometrial carcinoma at an early stage of the 4-month period in MPA therapy and could be a useful predicting marker for MPA.
  • [MeSH-major] Biomarkers, Tumor / analysis. Carcinoma, Endometrioid / drug therapy. Endometrial Neoplasms / drug therapy. Proliferating Cell Nuclear Antigen / analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16515645.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Biomarkers, Tumor; 0 / Proliferating Cell Nuclear Antigen; 0 / p27 antigen; C2QI4IOI2G / Medroxyprogesterone Acetate
  •  go-up   go-down


97. Mihalcea D, Aursulesei D: [Myometrial invasion as a prognostic factor in endometrial adenocarcinoma]. Rev Med Chir Soc Med Nat Iasi; 2009 Jan-Mar;113(1):136-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Myometrial invasion as a prognostic factor in endometrial adenocarcinoma].
  • [Transliterated title] Invazia miometrială-factor de prognostic în adenocarcinomul endometrial.
  • Myometrial invasion is one of the most important prognostic factors in endometrial cancer.
  • MATERIAL AND METHOD: We have studied a cohort of 62 patients with endometrial cancer who underwent surgery in 4-th Gynecology Clinic of "Cuza Vodă" Hospital, Iaşi between 1997-2008.
  • [MeSH-major] Adenocarcinoma / pathology. Endometrial Neoplasms / pathology. Myometrium / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21495308.001).
  • [ISSN] 0048-7848
  • [Journal-full-title] Revista medico-chirurgicală̆ a Societă̆ţ̜ii de Medici ş̧i Naturaliş̧ti din Iaş̧i
  • [ISO-abbreviation] Rev Med Chir Soc Med Nat Iasi
  • [Language] rum
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Romania
  •  go-up   go-down


98. Fanghong Li, Szallasi A, Young RH: Wolffian tumor of the ovary with a prominent spindle cell component: report of a case with brief discussion of unusual problems in differential diagnosis, and literature review. Int J Surg Pathol; 2008 Apr;16(2):222-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Wolffian tumor of the ovary with a prominent spindle cell component: report of a case with brief discussion of unusual problems in differential diagnosis, and literature review.
  • An 87-year-old woman underwent total abdominal hysterectomy and bilateral salpingo-oophorectomy for endometrioid adenocarcinoma.
  • The uterus showed well-differentiated, superficially invasive endometrioid adenocarcinoma arising in a background of atypical complex hyperplasia.
  • This case demonstrates the heterogeneity of Wolffian tumor of the ovary and shows how crucial sampling is in arriving at the correct diagnosis.
  • [MeSH-major] Carcinoma, Endometrioid / pathology. Fibroma / pathology. Ovarian Neoplasms / pathology. Uterine Neoplasms / pathology
  • [MeSH-minor] Aged, 80 and over. Biomarkers, Tumor / analysis. Diagnosis, Differential. Disease-Free Survival. Female. Humans. Immunohistochemistry. Neoplasms, Multiple Primary / pathology. Treatment Outcome

  • Genetic Alliance. consumer health - Wolffian tumor.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18417686.001).
  • [ISSN] 1066-8969
  • [Journal-full-title] International journal of surgical pathology
  • [ISO-abbreviation] Int. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


99. Li A, Felix JC, Minoo P, Amezcua CA, Jain JK: Effect of mifepristone on proliferation and apoptosis of Ishikawa endometrial adenocarcinoma cells. Fertil Steril; 2005 Jul;84(1):202-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of mifepristone on proliferation and apoptosis of Ishikawa endometrial adenocarcinoma cells.
  • OBJECTIVE: To determine the mechanism by which mifepristone improves breakthrough bleeding, the effects of mifepristone on proliferation and apoptosis of Ishikawa endometrial carcinoma cells were evaluated in the presence and absence of progestin.
  • Together, these data imply that the improvement in breakthrough bleeding observed with mifepristone might be due to diminished volume of endometrial tissue similar to that seen with endometrial atrophy.
  • [MeSH-major] Adenocarcinoma / metabolism. Apoptosis / drug effects. Cell Proliferation / drug effects. Endometrial Neoplasms / metabolism. Mifepristone / pharmacology

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. MIFEPRISTONE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16009178.001).
  • [ISSN] 1556-5653
  • [Journal-full-title] Fertility and sterility
  • [ISO-abbreviation] Fertil. Steril.
  • [Language] eng
  • [Grant] United States / NICHD NIH HHS / HD / R0-1 HD 43189
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 320T6RNW1F / Mifepristone
  •  go-up   go-down


100. Wong YF, Cheung TH, Lo KW, Yim SF, Siu NS, Chan SC, Ho TW, Wong KW, Yu MY, Wang VW, Li C, Gardner GJ, Bonome T, Johnson WB, Smith DI, Chung TK, Birrer MJ: Identification of molecular markers and signaling pathway in endometrial cancer in Hong Kong Chinese women by genome-wide gene expression profiling. Oncogene; 2007 Mar 22;26(13):1971-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of molecular markers and signaling pathway in endometrial cancer in Hong Kong Chinese women by genome-wide gene expression profiling.
  • Endometrial cancer is the third most common gynecologic malignancy and the ninth most common malignancy for females overall in Hong Kong.
  • Approximately 80% or more of these cancers are endometrioid endometrial adenocarcinomas.
  • The aim of this study was to reveal genes contributing to the development of endometrioid endometrial cancer, which may impact diagnosis, prognosis and treatment of the disease.
  • Whole-genome gene expression analysis was completed for a set of 55 microdissected sporadic endometrioid endometrial adenocarcinomas and 29 microdissected normal endometrium specimens using the Affymetrix Human U133 Plus 2.0 oligonucleotide microarray.
  • Pathway analysis was performed to reveal gene interactions involved in endometrial tumorigenesis.
  • Unsupervised hierarchical clustering displayed a distinct separation between the endometrioid adenocarcinomas and normal endometrium samples.
  • Supervised analysis identified 117 highly differentially regulated genes (>or=4.0-fold change), which distinguished the endometrial cancer specimens from normal endometrium.
  • Twelve novel genes including DKK4, ZIC1, KIF1A, SAA2, LOC16378, ALPP2, CCL20, CXCL5, BST2, OLFM1, KLRC1 and MBC45780 were deregulated in the endometrial cancer, and further validated in an independent set of 56 cancer and 29 normal samples using qRT-PCR.
  • In addition, 10 genes were differentially regulated in late-stage cancer, as compared to early-stage disease, and may be involved in tumor progression.
  • The results of this study highlight the molecular features of endometrioid endometrial cancer and provide insight into the events underlying the development and progression of endometrioid endometrial cancer.
  • [MeSH-major] Endometrial Neoplasms / metabolism. Gene Expression Profiling. Genome. Signal Transduction

  • Genetic Alliance. consumer health - Endometrial cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17043662.001).
  • [ISSN] 0950-9232
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down






Advertisement